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 Preface 
These documents have been produced by the Swedish Criteria Group for Occupational 
Standards, the members of which are presented on the next page. The Criteria Group is 
responsible for assessing the available data that might be used as a scientific basis for 
the occupational exposure limits set by the Swedish Work Environment Authority. It  
is not the mandate of the Criteria Group to propose exposure limits, but to provide  
the best possible assessments of dose-effect and dose-response relationships and to 
determine the critical effect of occupational exposure. 
 The work of the Criteria Group is documented in consensus reports, which  
are brief critical summaries of scientific studies on chemically defined substances  
or complex mixtures. The consensus reports are often based on more comprehensive 
criteria documents (see below), and usually concentrate on studies judged to be of 
particular relevance to determining occupational exposure limits. More comprehensive 
critical reviews of the scientific literature are available in other documents. 
 Literature searches are made in various databases, including Arbline, Chemical 
abstracts, Cheminfo, Medline, Nioshtic, RTECS and Toxline. Information is also drawn 
from existing criteria documents, such as those from the Nordic Expert Group (NEG), 
WHO, EU, NIOSH in the U.S., and DECOS in the Netherlands. In some cases the 
Criteria Group produces its own criteria document with a comprehensive review of  
the literature on a particular substance. 
 As a rule, the consensus reports make reference only to studies published in 
scientific journals with a peer review system. This rule may be set aside in exceptional 
cases, provided the original data is available and fully reported. Exceptions may also  
be made for chemical-physical data and information on occurrence and exposure levels, 
and for information from handbooks or documents such as reports from NIOSH and the 
Environmental Protection Agency (EPA) in the U.S. 
 A draft of the consensus report is written in the secretariat of the Criteria Group 
or by scientists appointed by the secretariat (the authors of the drafts are listed in the 
Table of Contents). After the draft has been reviewed at the Criteria Group meetings 
and accepted by the group, the consensus report is published in Swedish and English  
as the Criteria Group’s scientific basis for Swedish occupational standards. 
 This publication is the 30th in the series, and contains consensus reports approved 
by the Criteria Group from July, 2008 through June, 2009. The consensus reports in this 
and previous publications in the series are listed in the Appendix (page 116). 
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1 
Consensus Report for Molybdenum and 
Molybdenum Compounds 
February 4, 2009 
Information for this report was obtained from literature searches of Arbline, 
Cheminfo, Cisdoc, HSDB, Hseline, Medline, Mhidas, Nioshtic, Oshline, Rilosh, 
Riskline and Toxline in March of 2007. Supplementary searches of the Toxline 
(including Pubmed) and SPIN databases were made in January and July of 2008. 
The Criteria Group published a previous Consensus Report on molybdenum in 
1983 (65). 
Chemical and physical data 
 
Substance  
formula 
CAS No. Mol 
weight 
Melting  
point (°C) 
Boiling 
point (°C) 
Solubility 
in water 
 
Molybdenum 
   Mo 
7439-98-7 95.95 2629 4612 Insoluble 
Molybdenum disulfide 
   MoS2 
1317-33-5 160.08 1185 450a 
in airb 
Insoluble 
Molybdenum dioxide 
   MoO2 
18868-43-4 127.94   —   — Insoluble 
Molybdenum trioxide 
   MoO3 
1313-27-5 143.95 795 1155a 1.07 g/l (18°C)c 
0.49 g/l (28°C)c 
Ammonium molybdate 
   (NH4)2MoO4 
13106-76-8 196.03   —b   — 400 g/l (20°C) 
Hot waterb 
Ammonium heptamolybdate 
(ammonium paramolybdate) 
   (NH4)6Mo7O24 
12027-67-7 1163.79   —b 
tetrahydr.d: 
-H2O, 90 
  — 
tetrahydr.: 
190b 
  — 
tetrahydr.: 430 g/l 
Hot waterb 
Sodium molybdate 
   Na2MoO4 
7631-95-0 205.92 687   — 443 g/l (20°C) 
Sodium molybdate, dihydrate 
   Na2MoO4·2H2O 
10102-40-6 241.95 -2H2O, 
100 
  — 562 g/l  
Cold water 
Calcium molybdate 
   CaMoO4 
7789-82-4 200.01 965   — Insoluble 
Hot waterb 
Molybdenum pentachloride 
   MoCl5 
10241-05-1 273.21 194 268   —b 
Ammonium 
tetrathiomolybdate 
   (NH4)2MoS4 
15060-55-6 260.26   —   —   — 
 
asublimates    bdisintegrates    cinformation differs    dCAS No. 12054-85-2 
Data in the table are from References 13, 14, 36, 67. 
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Molybdenum is either a silver-white metal (crystalline form) or a dark gray 
powder. It occurs in nature in various minerals, the most important of which  
is molybdenite (molybdenum disulfide). The most important oxidation states  
for molybdenum in compounds are +II, +III, +IV and +VI. Most molybdenum 
compounds are either insoluble or disintegrate on contact with water, but some 
molybdates, notably ammonium and sodium molybdate, dissolve readily (14, 28, 
36, 67). Molybdenum pentachloride can react with water and damp air to form 
chlorine gas, and is reported to be caustic (http://nj.gov/health/eoh/rtkweb/ 
documents/fs/1311.pdf). The molybdenum compounds most prevalent in work 
environments are molybdenum trioxide and molybdates (65). A total of 932 tons 
of molybdenum trioxide was used in Sweden in 2005. The substance was a 
registered ingredient in 44 products (SPIN database, http://195.215.251.229/ 
DotNetNuke/default.aspx). 
Occurrence, use  
Molybdenum is produced from molybdenum trioxide. Most molybdenum is used 
in production of various types of steel and heat-resistant alloys for use in high-
temperature environments. It occurs, for example, in the automobile and airplane 
industries, in machine manufacture, in the electrical industry and in welding. 
Molybdenum levels (total dust) of ≤2.3 µg/m3 (personal monitors) and ≤4 µg/m3 
(stationary monitors) were measured around arc furnaces during production of 
stainless steel in 1999 (27). Molybdenum levels around 100 – 300 µg/m3 (total 
dust) were measured during a workshift of welding in stainless steel (personal 
monitor, 13 samples, 30 minutes each; 1 subject) (50). Molybdenum levels  
of 0.2 – 18 µg/m3 (total dust, 18 samples) were measured in the breathing  
zones of welders using coated electrodes for gas arc welding in mild steel and 
stainless steel during the 1970s (69, 70, 71). Much higher air concentrations of 
molybdenum have been measured in other contexts, however: 1.5 – 7.9 mg Mo/m3 
(total dust) was reported in the breathing zone of a worker grinding, cutting and 
heating metallic molybdenum (70 – 200 minute samples); the background level 
recorded by a stationary monitor (about 5 hours) was 0.7 mg Mo/m3 (61). In a 
plant producing molybdenum oxides from molybdenum disulfide, air levels of 
molybdenum recorded by stationary monitors were in the range 3 – 33 mg/m3 
(total dust), with an 8-hour time-weighted average (TWA) of 9.5 mg Mo/m3.  
The monitors indicated a respirable dust content of 1 – 4.5 mg Mo/m3 (75). 
Molybdenum is also used in production of glass and ceramics – in electrodes, 
stirrers, kiln components, pigments, enamelwork etc. Molybdenum trioxide  
and soluble molybdates (e.g. sodium molybdate, sodium molybdate dihydrate)  
are used as corrosion inhibitors. Molybdenum and molybdenum compounds 
(including molybdenum disulfide, molybdenum trioxide, molybdenum dioxide) 
are also important as catalysts in numerous industrial processes, especially in  
the oil and gas industries. Molybdenum oxides and molybdates may be added to 
plastics as flame retardants. Sodium molybdate is a reported ingredient in some 
de-icers. Other areas of use include leather preparation and chemical fertilizers. 
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Molybdenum disulfide has a special use as a lubricant (2, 14, 36, 65, 67; SPIN 
database, http://195.215.251.229/DotNetNuke/default.aspx). 
Ammonium tetrathiomolybdate has been used therapeutically to counteract 
accumulation of copper in the body, e.g. with Wilson’s disease. In recent years, 
tetrathiomolybdate (the ammonium salt and analogues) has also been proposed, 
and to some extent tried, for treating cancers and inflammatory diseases. Am-
monium tetrathiomolybdate in oral doses (induction doses) of about 120 –  
240 mg/day has been used in cancer therapy, for example (10, 12, 37, 67). 
Molybdenum is an essential trace element for humans, animals and plants  
(2, 65). It is a component of several enzymes, including sulfite oxidase, which 
oxidates sulfite to sulfate and is necessary for the metabolism of amino acids 
containing sulfur, and xanthine oxidase (xanthine dehydrogenase), which is active 
in purine metabolism and oxidates hypoxanthine and xanthine to uric acid (44,  
67, 75). The major dietary sources of molybdenum are grains, dairy products and 
vegetables, and estimated daily intake is on average about 0.1 – 0.2 mg. Plasma 
concentrations of molybdenum are usually in the range 0.3 – 1.1 µg/l, but can be 
as high as 2 – 4 µg/l if intake in food is extremely high (0.5 – 1.5 mg/day) (67). 
Uptake, biotransformation, excretion 
Molybdenum and its compounds can be absorbed in the digestive tract. Data on 
some of the insoluble compounds (e.g. molybdenum disulfide) indicate extremely 
low uptake, but the soluble molybdenum compounds are absorbed quite well. 
Animal data record uptakes of 40 – 85% for single doses of hexavalent molyb-
denum compounds (17, 67). Uptake via inhalation depends on solubility and 
particle size. Quantitative data are scarce, but experiments with guinea pigs, mice 
and rats indicate that hexavalent molybdenum compounds such as molybdenum 
trioxide are readily absorbed via inhalation (14, 17, 49, 67). An inhalation study 
with exposures to 6.7, 20 and 67 mg Mo/m3 as trioxide reports that average blood 
concentrations of molybdenum were respectively about 800, 1800 and 6000 µg/l 
for male rats, 350, 650 and 2400 µg/l for female rats, 100, 210 and 770 µg/l for 
male mice, and 70, 200 and 520 µg/l for female mice (49). No noteworthy mol-
ybdenum uptake was seen in an older study in which guinea pigs were exposed  
to molybdenum as disulfide (dust) at levels around 285 mg Mo/m3 (17). Plasma 
levels up to 365 µg Mo/l were reported in a study of workers exposed to molybde-
num trioxide (and other substances), but it is not clear whether uptake was via 
lungs or via both lungs and digestive tract. The air level of molybdenum was  
9.5 mg/m3 (8-hour TWA, total dust) (75). 
In the blood, molybdenum is bound as molybdate to red blood cells and  
plasma proteins. It is distributed rapidly to most tissues, including liver, kidneys 
and bones, although levels in fat tissue are low. Molybdenum can also pass the 
placental barrier (14, 67). The literature contains very little data on molybdenum 
metabolism, but it is known that molybdenum passes through the cell membrane 
as molybdate, and in the cell, in a copper-dependent process, forms a cofactor 
(Moco) that is subsequently incorporated into various enzymes, including xanthine 
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oxidase and sulfite oxidase. Inability to form this cofactor results in death. Sulfite 
oxidase is activated by addition of the cofactor, whereas activation of xanthine 
oxidase requires a further step (addition of sulfur) (44). The biological half time  
of molybdenum in humans has been reported to be on the order of weeks, and the 
substance is excreted as molybdates, mostly in urine (14). Molybdenum can also 
be excreted in breast milk (14). Studies in which sheep were given intravenous 
injections of radioactively labeled di-, tri- and tetrathiomolybdate indicate that  
the substances undergo a hydrolysis process of several steps leading to formation 
of molybdate, which is then excreted primarily in urine (41).  
Tetrathiomolybdate given orally together with food forms complexes with  
the copper and proteins in the food in the digestive tract, thus severely impeding 
copper absorption. With oral intake between meals, tetrathiomolybdate is taken up 
into the blood and forms a complex with albumin and free copper in serum. This 
complex-bound copper is unavailable for cellular uptake (56). In a comparative 
study, oral doses of radioactively labeled copper (64Cu) were given to rats that also 
received 12 ppm Mo in feed as either ammonium tetrathiomolybdate or sodium 
molybdate: copper uptake was greatly reduced by the tetrathiomolybdate but un-
affected by the sodium molybdate. Distribution of the absorbed copper was also 
affected by the tetrathiomolybdate (45). 
Toxicity 
Human data 
Molybdenum, copper and sulfate have complex interrelationships in the body. 
Exposure to molybdenum may disrupt the normal balance between molybdenum 
and copper, leading to copper deficiency – especially when sulfate intake is in-
sufficient. The serum level of the copper-containing enzyme ceruloplasmin can  
be used as a measure of the body’s copper status. The most prominent symptoms 
of severe copper deficiency are anemia, neutropenia and osteoporosis, and the  
first clinical indication of copper deficiency is a low blood count (usually anemia). 
High uric acid levels in serum due to increased activity of the enzyme xanthine 
oxidase have also been reported with elevated levels of molybdenum (10, 14, 53, 
56, 65, 67, 75). 
Therapeutic use of tetrathiomolybdate in cases of cancer (it inhibits vascu-
larization) has side effects such as bone marrow suppression, anemia and/or 
leukopenia (10, 12, 53). Side effects of this type (as well as effects on the liver) 
have also been seen in treatment of Wilson’s disease with tetrathiomolybdate 
(Table 1). In one study it is also reported that none of the patients had abnormal 
uric acid levels in serum (average doses of ammonium tetrathiomolybdate were 
100 – 300 mg/day) (11). 
There is a case report of acute poisoning due to intake of ammonium hepta-
molybdate (Table 1). The victim had drunk about half a spoonful of the substance 
stirred into her coffee, and immediately thereafter she had stomach cramps 
accompanied by violent, bloody vomiting and severe diarrhea. On arrival at  
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the hospital she was found to have severe gastritis. After a day or so, kidney 
effects (especially on renal tubuli) and moderate anemia were also seen. Two 
months later the monitored parameters (kidney damage, anemia) were completely 
normal. The authors suggest that the loss of blood may have contributed to the 
anemia (6). 
An elevated prevalence of a gout-like condition has been reported in people 
living in a part of Armenia where the earth and vegetation contain high levels of 
molybdenum. Calculated daily molybdenum intake for the population in this area 
was 10 – 15 mg, compared to 1 – 2 mg Mo/day in a control area. Daily intake of 
copper was also somewhat lower in those with higher molybdenum exposure (5 – 
10 mg vs. 10 – 15 mg). Elevated uric acid levels in serum correlated to elevated 
levels of molybdenum and to elevated activity of xanthine oxidase. Uric acid in 
serum from the sick subjects (n = 17) was on average 81 mg/l, compared to 53 
mg/l in healthy subjects (n = 35) living in the same area and 38 mg/l in controls  
(n = 5) living in another area. The average level of copper in blood was somewhat 
(significantly) lower in subjects with symptoms. Enlarged livers, digestive 
disturbances and renal disease were also reported in the sick subjects, but no 
further details were given (Kovalskii et al. 1961, cited in References 14 and 75). 
Acute inflammation in a metatarsal joint and moderately elevated serum urate 
(564 µmol/l; 95 mg/l) were seen in a 36-year-old industrial electrician exposed  
to molybdenum. He later developed pain in the shoulders, wrists and ankles (not 
rheumatic in origin). Serum urate gradually dropped to 482 µmol/l (81 mg/l) over 
the next two years, and during this period the patient’s exposure to molybdenum 
also stopped. He had formerly been exposed while grinding, cutting and heating 
metallic molybdenum. Total dust measurements (70 – 200 minute samples)  
made during a reconstruction of his working conditions showed levels of 1.6 –  
10 mg/m3 (1.5 –7.9 mg Mo/m3) in the breathing zone, and stationary monitoring 
(about 5 hours) showed a background dust level of 0.9 mg/m3 (0.7 mg Mo/m3). 
Three weeks after the reconstruction, the patient had another attack of acute 
arthritis in his ankle. Serum urate was at that time 484 µmol/l (81 mg/l) and he 
received a definite diagnosis of gout. According to the authors, a connection to 
occupational exposure to molybdenum can be suspected but not established (61). 
In a study of 25 workers exposed to molybdenum, 18 reported on a ques-
tionnaire that they had experienced some type of health problem – joint pain, 
backache, unspecified changes in skin or hair, diarrhea etc. (see Table 1). It was 
reported that, although no evidence of molybdenum-induced gout could be seen  
in the responses, turnover among the workers was high. Blood profiles (“complete 
blood counts”) were reported to be normal, and 20 of the 25 workers had normal 
results on lung function tests. Results for the control group (24 students) were  
not given in this part of the study. Elevated levels (sic!) of ceruloplasmin were 
reported in serum of the workers (average values: 50.5 mg/dl vs. 30.5 mg/dl  
in controls), and average levels of uric acid were 59 mg/l for the workers and  
50 mg/l for the controls. Plasma levels of molybdenum were 9 – 365 µg/l in the 
workers and up to 34 µg/l in controls. No direct correlations were seen between 
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molybdenum, uric acid and ceruloplasmin in plasma/serum. The factory produced 
molybdenum oxides from molybdenum disulfide (ammonium dimolybdate, am-
monium heptamolybdate, sodium molybdate and calcium molybdate were also 
reported to occur). Stationary monitors indicated air levels of molybdenum (in 
total dust) in the range 3 – 33 mg/m3, and average exposure was calculated to  
be 9.5 mg Mo/m3 (8-hour TWA). The molybdenum content in respirable dust  
(≤10 µm) from the stationary monitors was in the range 1 – 4.5 mg/m3 (mostly 
soluble molybdenum oxides). A calculation based on a level of 1.02 mg Mo/m3  
in respirable dust indicated a daily body burden of 10.2 mg molybdenum from 
soluble molybdenum particles (75). The data reported in the study provide no 
indication of whether there was a correlation between molybdenum exposure  
and symptoms for any single subject, but normal levels of uric acid in serum  
and normal blood profiles argue in general against such a correlation. 
Of 19 workers exposed to levels of 1 to 25 mg/m3 metallic molybdenum and 
molybdenum trioxide for 4 to 7 years, 3 were reported to suffer from symptoms 
such as breathing difficulty and frequent coughing. Pneumoconiosis (early stages) 
was verified by lung x-rays (14). In a subsequent study, 43 workers with in-
halation exposure to molybdenum trioxide were compared with 23 unexposed 
workers. Exposure was reported to consist of fine to ultra-fine (diameter <250 nm) 
dust, but no air levels were given. Respiratory symptoms (chest pains, breath-
lessness, coughing) lasting more than 6 weeks were reported by 33 of the exposed 
workers; the other 10 reported no symptoms. No clear indications of interstitial 
lung disease were seen on lung x-rays, but “discrete abnormalities” were observed 
in 29/33 (with symptoms) and 5/10 (symptom-free) exposed workers. Lung x-rays 
of controls were normal. Results on lung function tests were better for the exposed 
group than for controls. Cytologic examination of bronchoalveolar lavage fluid 
(BAL) indicated possible sub-clinical alveolitis in exposed workers with 
respiratory symptoms (54). 
In a large study in which patch tests with several metal salts were administered, 
2% molybdenum pentachloride yielded a positive result in 6/211 persons and 2% 
ammonium molybdate in 3/208 persons. One person tested positive for both 
substances. Three of the eight patients worked with metal (14). In a study with 80 
volunteers, 2 showed sensitization when given a patch test with 1% molybdenum 
pentachloride in water (20). Allergic reactions were observed in 1/128 patients 
with hip replacements containing metal when they were patch tested with 1% 
ammonium molybdate in water, and in 4/131 patients with stainless steel stents 
when they were patch tested with 0.5% molybdenum pentachloride in vaseline 
(35, 68). Critical review of the data collected by German dermatology clinics in 
the 1992 – 1999 period shows positive results to patch tests with 1% ammonium 
heptamolybdate in water for 3/787 patients and also 7 uncertain/irritation reactions 
(14, 23). 
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Animal data 
There are large inter-species differences in the toxic effects of molybdenum,  
and intakes of copper, molybdenum and sulfate have a complex interrelationship. 
Ruminants are regarded as particularly sensitive to high levels of molybdenum  
in diet, probably due to the formation of thiomolybdate in the sulfide-rich envi-
ronment of the rumen (14, 36, 65, 75). Molybdenum poisoning can present the 
same symptoms as copper deficiency: anemia, diarrhea, weight loss, joint abnor-
malities, osteoporosis, reproductive problems, kidney damage etc. (4, 33, 48, 57, 
67, 75). 
Insoluble and soluble molybdenum compounds were compared in an older 
toxicity study with rats. There were no deaths or visible indications of toxicity  
in the rats given ≤500 mg Mo/day as molybdenum disulfide in feed for 44 days,  
but animals were clearly affected by repeated exposure to high doses of calcium 
molybdate, molybdenum trioxide and ammonium heptamolybdate tetrahydrate. 
With repeated exposures, the lethal doses for 50% of animals were calculated to 
be about 100 mg Mo/kg b.w./day for calcium molybdate, 125 mg Mo/kg b.w./day 
for molybdenum trioxide, and 333 mg Mo/kg b.w./day for ammonium hepta-
molybdate tetrahydrate (17). In another rat study, 4 weeks of exposure to equi-
molar concentrations (0.8 mmol/100 g feed; about 77 mg Mo/100 g feed)  
of sodium molybdate, molybdenum trioxide and molybdenum pentachloride 
resulted in greatly reduced weight gain and increased activity of alkalic phos-
phatases. The molybdate and trioxide were about equally toxic in these respects, 
the pentachloride somewhat less so. Potassium tetrathiomolybdate was much more 
toxic – all the animals were dead after 4 weeks (73). Thiomolybdate also yielded 
more obvious effects (diarrhea, deaths) than molybdate in a study in which guinea 
pigs were given either ammonium molybdate or thiomolybdate (mostly tetrathio-
molybdate) in drinking water (260 µmol Mo/l; 25 mg Mo/l) before and during 
gestation (25). In a comparative study, rats were given 12 mg Mo/kg feed for 11 
days: with administration as ammonium tetrathiomolybdate, weight gain was 
much poorer and there was total inhibition of ceruloplasmin activity in plasma, 
whereas the sodium molybdate had no such effects (46). 
When feed containing 6 mg Mo/kg as ammonium tetrathiomolybdate was given 
to male rats for 5 weeks (about 0.6 mg Mo/kg b.w./day, assuming a feed intake  
of 100 g/kg b.w./day), the exposure resulted in anemia, diarrhea, skeletal damage, 
growth retardation and fur discoloration. The skeletal damage was also seen in  
1/6 animals at a dose level of 4 mg Mo/kg feed (about 0.4 mg Mo/kg b.w./day). 
Copper content in the feed was relatively low in this study, however (3 mg/kg) 
(46). Poor growth was also observed in another rat study, in which sodium 
molybdate dihydrate was given in feed for several months. This effect was seen  
in males at 20 mg Mo/kg feed (about 2 mg Mo/kg b.w./day) and in females at  
80 mg/kg feed (about 8 mg Mo/kg b.w./day). No anemia was seen in either dose 
group (both sexes) (29, 74). In a recent study in which 1, 4, or 12 mg ammonium 
tetrathiomolybdate/kg b.w./day (0.4, 1.5 or 4.5 mg Mo/kg b.w./day) was given by 
gavage to female rats for about a month (prior to and during early gestation) and to 
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male rats for 2 months, no clinical indications of toxicity are reported at any dose 
level. Significantly lower body weights and feed consumption, as well as mild 
anemia, were seen in male rats in the high-dose group, however (40). Effects on 
kidneys were given particular emphasis in another study in which male rats were 
given ammonium heptamolybdate tetrahydrate (40 or 80 mg Mo/kg b.w./day)  
by gavage for 8 weeks. Poorer growth with lower body weights (p<0.001) and 
somewhat lower kidney weights was observed at the high-dose level. Measure-
ments of various parameters of kidney function indicated mild chronic renal 
failure in the high-dose group, with poor glomerular filtration and effects on  
distal tubuli (8). 
In inhalation studies, guinea pigs were exposed to various molybdenum 
compounds 1 hour/day, 5 days/week for 5 weeks (17). At an average exposure  
of 286 mg Mo/m3 as molybdenum disulfide dust, respiratory rate was increased 
during the exposure but there were no other reported indications of toxicity (1/25 
animals died after 3 exposures). Analysis data showed no uptake of molybdenum 
disulfide. Exposure to 159 mg Mo/m3 in the form of neutralized calcium molyb-
date yielded no clinical indications of toxicity, but 5/24 animals died during the 
experiment (pneumonia occurred, but it is not clear whether it was related to the 
exposure). Elevated molybdenum levels were found especially in the lungs, but 
also in bones and kidneys. Exposure to 205 mg Mo/m3 in the form of molyb-
denum trioxide dust was extremely irritating (eyes, nostrils). Diarrhea, weight 
loss, ataxia and hair loss were also reported, as were changes in liver, spleen  
and lungs. Half of the animals died. There were elevated molybdenum levels in 
kidneys, bones, spleen and liver, and small amounts of molybdenum were also 
found in the lungs. With exposure to molybdenum trioxide in the form of smoke 
(53 or 191 mg Mo/m3), however, only 1/25 animals died at the high exposure and 
no other indications of toxicity were observed. Analyses revealed low levels of 
molybdenum in all examined tissues, including lungs (2, 17). 
In a modern inhalation study, rats and mice were exposed to molybdenum 
trioxide in air concentrations of 3 to 300 mg/m3, 6 hours/day, 5 days/week for 14 
days. Significantly lower weights were noted at 100 mg/m3 (male rats only) and 
300 mg/m3 (both species, both sexes), but there were no clinical indications of 
toxicity (49). Mice and rats were exposed for 13 weeks to molybdenum trioxide 
dust in air concentrations of 1 to 100 mg/m3. There were no significant effects  
on body weights or organ weights and no clinical indications of toxicity, and no 
significant exposure-related differences were seen in histopathologic, hematologic 
and clinical-chemical examinations. There were, however, significantly elevated 
copper levels in livers of the mice (females at 30 mg/m3, both sexes at 100 
mg/m3). Rats and mice exposed to 10, 30 or 100 mg molybdenum trioxide/m3 
(about 6.7, 20 or 67 mg Mo/m3) for 2 years showed no symptoms typical of 
molybdenum poisoning (diarrhea, anemia) or toxicologically significant 
differences in bone density or “bending” of the femur, but histopathologic 
examination revealed exposure-related changes in respiratory passages. The  
rats had elevated incidences of chronic alveolar inflammation at the two higher 
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exposure levels (very mild to moderate; both severity and incidence increased  
with dose). Higher incidences of hyaline degeneration of respiratory and olfactory 
epithelium and squamous cell metaplasias in epiglottal epithelium were also  
seen at all exposure levels (see Table 2), but these changes were regarded as non-
specific defense mechanisms/adaptations. The mice showed similar slight changes 
in nose and larynx (non-specific or indications of defense/adaptation), but had no 
chronic inflammation in alveoli (49). 
No immunotoxic effects were observed in mice after 14 days of exposure to  
1 – 100 ppm (primary antibody response) or 1 – 25 ppm (phagocyte activity and 
sub-populations of lymphocytes in spleen, lymph nodes and peripheral blood) 
molybdenum pentachloride in feed. The sensitization potential of molybdenum 
pentachloride as a contact allergen was also tested in a modified Local Lymph 
Node Assay (LLNA) (1). Although the authors report that the assay showed 
molybdenum pentachloride to be a weak, non-specific contact irritant, the only 
definite conclusion that can be drawn from this experiment is that, under these 
experimental conditions, molybdenum pentachloride has a weaker sensitizing 
potential than the strong experimental contact allergen oxazolone (positive 
control). Molybdenum pentachloride was ranked a potent contact allergen in  
the Guinea Pig Maximization Test (GPMT) (17/20 positive animals vs. 3/20 
controls), whereas sodium molybdate pentahydrate was not (7). Sodium molyb-
date has been reported to cause primary irritation. A 20% solution caused red-
dening of conjunctiva. Calcium molybdate produced no skin irritation and no 
significant eye irritatation when tested on rabbits. No further details on these 
studies are given (36). 
Tetrathiomolybdate has been shown in animal models to have an anti-inflam-
matory effect – it provides protection against doxorubicin-induced heart damage, 
for example. Strong inhibition of the inflammatory cytokines TNFα and IL-1β and 
inhibition of IL-2, an immune-regulatory cytokine, have been reported. Tetrathio-
molybdate has also been reported to provide protection against bleomycin-induced 
pulmonary fibrosis and against liver damage from certain substances, including 
carbon tetrachloride (24). 
A study in which rat liver cells were exposed in vitro to nanoparticles (30 nm  
or 150 nm) of molybdenum trioxide (24 hours) yielded evidence of cytotoxicity, 
expressed as leakage of lactate dehydrogenase and decline in mitochondrial 
function, at 250 µg/ml but not at ≤100 µg/ml (both particle sizes) (26). 
Mutagenicity, genotoxicity 
Molybdenum trioxide was not mutagenic to Salmonella typhimurium strains 
TA97, TA98, TA100, TA1535 or TA1537, either with or without metabolic 
activation (49, 76). Negative results with molybdenum trioxide are also reported 
in in vitro rec assays with B. subtilis (31, 32). Nor was there any increase in 
incidence of sister chromatid exchange (SCE) or chromosome aberrations in 
Chinese hamster ovary (CHO) cells in vitro, either with or without metabolic 
activation (49). In a micronuclei test (250 – 750 µg/ml) and in a cell trans-
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formation test (50 – 200 µg/ml) on Syrian hamster embryo (SHE) cells in vitro, 
however, molybdenum trioxide yielded positive results at the higher dose levels 
(19, 34). Matthews et al. (42) report molybdenum trioxide to be inactive in a cell 
transformation test on BALB/c-3T3 cells (2.3 – 11 mM). 
Ammonium heptamolybdate was mutagenic to E. coli (2 – 10 mM) and slightly 
to moderately genotoxic to B. subtilis (rec assay) in in vitro tests (31, 32, 47). 
There is, however, a briefly described study reporting that ammonium hepta-
molybdate hexahydrate is not mutagenic in bacteria tests (S. typhimurium and E. 
coli) (3). In another type of bacteria test (prophage induction in the microscreen 
assay), which measures DNA damage, sodium molybdate was weakly positive 
without metabolic activation (59), and a co-mutagenic effect was reported in an  
in vitro study with E. coli (elevated numbers of mutants induced by UV light at 
concentrations ≥100 µM) (58). However, sodium molybdate was not genotoxic in 
SOS-response chromotests with E. coli when tested without metabolic activation 
(52). Further, sodium molybdate dihydrate was judged to be inactive in a bacte- 
rial bioluminescence test (72). In a test on Saccharomyces cerevisiae, sodium 
molybdate (40 – 150 mM) had effects on cell division (meiosis), expressed as  
a dose-dependent increase of diploid spores (63). In another study on yeast, no 
mutations or other genetic changes (gene conversions) were observed in tests  
with sodium molybdate and ammonium molybdate (62). In tests for micronuclei 
induction in human lymphocytes in vitro, both ammonium heptamolybdate 
tetrahydrate (0.1 – 2 mM) and sodium molybdate monohydrate (0.1 – 5 mM)  
were positive (66). 
Molybdenum pentachloride was reported to be negative in in vitro bacterial 
tests for genotoxicity (B. subtilis, rec assay; E. coli, SOS-response chromotest) 
(47, 52). 
Molybdenum disulfide was reported to be negative in rec assays with B. subtilis 
(31, 32) and positive in an in vitro cell transformation test (SA7/SHE) (62 – 1000 
µg/ml) (22). 
There are few in vivo studies. Mutagenic effect on gametes was studied in a 
dominant lethal test. Sodium molybdate monohydrate was given to male mice 
(200 or 400 mg/kg b.w./day, 2 days, intraperitoneal injection) that were then 
mated with untreated females over a two-month period. Dose-dependent increases 
of post-implantation losses (10.6%, 16.3%, vs. 6.7% in controls) were observed, 
and the effect was most pronounced the first week after the injections (66). In the 
same study, sodium molybdate monohydrate was judged to be weakly genotoxic 
in the micronuclei test on mice after intraperitoneal injection for two days (200 or 
400 mg/kg b.w.) (66). Molybdenum trichloride was found to be genotoxic in an  
in vivo test with Drosophila (10 – 50 mM per os during the larval stage) (51). 
In summary, molybdenum compounds at high concentrations have been re-
ported to be weakly mutagenic in some, but not all, bacteria tests. Some results 
from in vitro tests with mammalian cells were negative, but micronuclei tests 
with, for example, hamster cells and human lymphocytes, yielded positive results 
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at high concentrations. Weakly positive results were also seen in an in vivo 
micronuclei test and a dominant-lethal test with mice. 
An English summary of an older Russian study (5) states that significantly 
higher frequencies of chromosome changes (“rearrangements”) in peripheral 
lymphocytes were observed in cytogenetic examinations of workers exposed  
to molybdenum and molybdenum compounds, when compared with controls. A 
closer examination of the Russian text reveals that cells from 47 persons exposed 
to molybdenum, molybdenite or ammonium paramolybdate, or to ammonium 
paramolybdate and molybdenum trioxide, and 23 controls were analyzed and that 
the deviations noted in the exposed subjects were usually of the chromatid type 
(not numerical or structural chromosome changes). The study reports that air 
levels (monitoring times not given) were 1.5 –10.2 mg/m3 for molybdenum, 0,9 – 
8.4 mg/m3 (usually 3.6 – 6.2 mg/m3) for ammonium paramolybdate, <23.5 mg/m3 
for molybdenum trioxide, and <54 mg/m3 for molybdenite. 
Carcinogenicity 
In a hospital-based case-control study (15) with 478 cases of lung cancer and  
536 controls, cases and controls were interviewed on occupation, job duties and 
exposures (self-estimated), smoking habits and hobbies. Exposures to 16 different 
proven or suspected lung carcinogens were classified using a job/exposure matrix 
(yes/no, duration), but the study contains no data on air concentrations or blood 
levels. It was found that for those who, according to this classification, had at 
some time been occupationally exposed to molybdenum, the risk of lung cancer 
was doubled (Odds Ratio: 2.1; 95% Confidence Interval: 1.2 – 3.7, based on 52 
exposed cases and 34 exposed controls). The analyses were adjusted for smoking 
habits, socioeconomic factors and education. When the cancer cases were divided 
into thirds according to length of employment and compared with unexposed, the 
greatest risk increase was seen in the highest third (>21 years; OR: 3.3; 95% CI: 
1.3 – 8.3). For the middle and lower thirds the odds ratios were moderately but  
not significantly elevated (1.8 and 1.6 respectively). It is rather remarkable that, 
despite the relatively high exposure prevalences, no risk increases were seen for 
exposure to established lung carcinogens such as asbestos (161 exposed cases,  
169 exposed controls) or PAH (235 exposed cases, 233 exposed controls). This 
may be due to low exposure levels, but no assessment can be made since intensity 
of exposure was not classified in the study. This study is difficult to evaluate, 
since the participation rate is not reported and no effects are reported for estab-
lished lung carcinogens despite the fact that such exposures were relatively 
common. Further, the proportion of subjects classified as occupationally exposed 
to molybdenum was remarkably high (86 of a total of 1014 study participants). 
In an NTP cancer study (49), F344/N rats and B6C3F1 mice were exposed to 
molybdenum trioxide levels of 10, 30, or 100 mg/m3 (corresponding to 6.7, 20  
or 67 mg Mo/m3), 6 hours/day, 5 days/week for 2 years (Table 2). The incidences 
of alveolar/bronchiolar adenoma or carcinoma increased in the male rats with a 
marginally significant positive trend, but was on the same order of magnitude as  
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in historic controls. For male mice, there were significantly elevated incidences  
of alveolar/bronchiolar carcinoma at all dose levels (16/50 at 10 mg/m3, 14/49  
at 30 mg/m3, 10/50 at 100 mg/m3 vs. 2/50 in controls). The combined incidences 
of alveolar/bronchiolar adenoma and carcinoma were significantly elevated at  
the two lower dose levels (27/50, 21/49 vs. 11/50 in controls). Female mice  
had significantly higher incidences of alveolar/bronchiolar adenoma at 30 and  
100 mg/m3 (8/49, 9/49 vs. 1/50 in controls) and adenoma/carcinoma combined at 
100 mg/m3 (15/49 vs. 3/50 in controls). According to the NTP, the study provides 
“some evidence” that molybdenum trioxide is carcinogenic to male and female 
mice, “equivocal evidence” of carcinogenic activity in male rats, and “no evi-
dence” of carcinogenic activity in female rats. 
A significant increase of lung adenomas was reported in mice after intraperi-
toneal injections (3 times/week) of the maximum tolerable dose of molybdenum 
trioxide in a sodium chloride solution (19 injections; total dose 4.75 g/kg b.w.) 
and the substance was judged to be weakly carcinogenic. At lower total doses 
(0.95 and 2.74 g/kg b.w.) the substance did not induce a significant elevation in 
lung tumor incidence (64). The value of this type of experimental study, however, 
has been questioned (65). 
Reduced tumor incidence has been reported in laboratory animals receiving 
various carcinogenic nitroso compounds in drinking water/feed along with sodium 
molybdate. The protective effect of molybdenum is attributed mostly to increased 
detoxification by denitrosation. There may also be some anti-carcinogenic effect 
due to the increased urinary excretion of copper caused by molybdenum, which 
reduces copper levels in serum (49). Experiments with tetrathiomolybdate (which 
binds copper) indicate, however, that the enzyme superoxide dismutase 1 (SOD1), 
which contains copper, may be inhibited within endothelial cells: vascularization 
and cell proliferation may thus be inhibited before a systemic reduction of copper 
levels can be detected. In tumor cells, intracellular inhibition of SOD1 can result 
in inhibited cell proliferation as well as cell death (30). 
The International Agency for Research on Cancer (IARC) has published no 
carcinogenicity classifications for molybdenum or molybdenum compounds. 
Effects on reproduction 
Human studies 
Correlations between semen quality and levels of various metals in blood are 
examined in a recently published study (43). The subjects were 219 men who, 
together with their partners, had sought treatment at two infertility clinics. Among 
the men there were both normal and deviant semen findings, since fertility 
problems can be due to either partner or both. The semen parameters measured 
were volume, number, concentration, proportion of motile sperm, and mor-
phology. Reference values, e.g. a sperm concentration of 20 million/ml, were  
used for classification (greater than/less than). Blood samples were analyzed for 
molybdenum, arsenic, cadmium, chromium, copper, lead, manganese, mercury, 
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selenium, thallium and zinc, and on the basis of blood levels the subjects  
were divided into at least 3 groups for each metal in order to investigate dose-
dependent relationships with the studied semen parameters. The detection limit for 
molybdenum in blood was 1.0 µg/l, and only 30% of the samples had levels above 
this. Persons with molybdenum levels below the detection limit constituted the 
low-exposure group (reference group), and persons with detectable levels of 
molybdenum were divided into two groups of equal size: medium exposure (70 – 
85th percentile) and high exposure (>85th percentile). The highest blood level  
of molybdenum measured in the study was 5.4 µg/l. Several different statistical 
strategies were used, and the analyses included smoking habits, age and presence 
of other metals in blood. The study reports significant or suggestive associations 
and dose-dependent trends for elevated molybdenum levels in blood and elevated 
risk of sub-normal sperm concentration and sperm morphology, whereas the 
relationships between other metals and semen quality were less consistent. For 
example, for molybdenum the adjusted odds ratios for sperm concentration were 
1.4 (95% CI: 0.5 – 3.7) for the medium-exposure group and 3.5 (95% CI: 1.1 – 
11) for the high-exposure group, and for morphology were 0.8 (95% CI: 0.3 – 1.9) 
and 2.6 (95% CI: 1.0 – 7.0) respectively. Interaction between molybdenum and 
low blood levels of copper or zinc were also indicated in the study, but with broad 
confidence intervals. The authors state in conclusion that more and larger epi-
demiologic studies, as well as mechanistic studies, are needed to confirm their 
results, and point out some weaknesses in their study, e.g. that only one blood 
sample and one semen sample was taken from each participant and that only a 
small proportion of the blood samples contained detectable amounts of molyb-
denum. They also point out that blood molybdenum levels in the general popula-
tion may show considerable geographic variation (43). No analyses of exposure 
conditions were made, although dietary factors were discussed. The possibility 
that, for example, copper deficiency or endogenous metabolic changes might  
be able to explain the variation in molybdenum levels was not discussed. The 
relevance of this study to assessment of molybdenum is unclear. 
Animal studies 
Rats and mice were exposed to 10, 30 or 100 mg molybdenum trioxide/m3 (6.7, 
20 or 67 mg Mo/m3) 6.5 hours/day, 5 days/week for 13 weeks: no significant 
effects on sperm count or sperm motility were reported in either species. Exposure 
to molybdenum trioxide for 2 years on the same schedule caused no definite 
exposure-related changes visible in histopathologic examination of reproductive 
organs (e.g. testes, epididymis, prostate, seminal vesicles, uterus, ovaries). The 
blood levels of molybdenum (mean values) in the 2-year study with molybdenum 
trioxide were reported to be about 220, 800, 1800 and 6000 µg/l in male rats  
and 60, 350, 650 and 2,400 µg/l in female rats, at 0, 6.7, 20 and 67 mg Mo/m3 
respectively. Molybdenum levels in the blood of the mice at these exposures  
were much lower (49). 
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Effects on the fertility of male rats were examined in a study in which the 
animals were given 10, 30, or 50 mg sodium molybdate/kg b.w. (about 4.7, 14 or 
23.3 mg Mo/kg b.w.) by gavage 5 days/week for 60 days. Observations at the two 
higher dose levels included degenerative changes in testes, reduced sperm counts, 
lower sperm motility and higher proportions of abnormal sperm. Reduced fertility, 
increases in pre- and post-implantation losses, reduced numbers of living fetuses 
and lower values for weight and length of fetuses were also noted (examined at 14 
mg Mo/kg b.w., mating with untreated females) (55). In an older study, infertility 
was reported in male rats given sodium molybdate dihydrate for several months 
after weaning at a dose level of 80 mg Mo/kg feed, but not at 20 mg Mo/kg feed 
(about 8 or 2 mg Mo/kg b.w./day, assuming a feed intake of 100 g/kg b.w./day). 
Histologic examination of testes from infertile animals revealed degenerative 
changes (29, 74). 
Ammonium tetrathiomolybdate was given to male rats by gavage in doses of  
1, 4 or 12 mg/kg b.w./day (0.4, 1.5 or 4.5 mg Mo/kg b.w./day) for 2 months. The 
NOEL in this study for both systemic effects and reproduction effects was 1.5 mg 
Mo/kg b.w./day (significant reductions of ceruloplasmin in serum were seen at  
all dose levels, however). Effects observed at the high-dose level included mild 
anemia, histopathological changes in testes and epididymis, lower sperm counts, 
greatly reduced sperm motility, and <9% morphologically normal sperm. How-
ever, no effects on reproductive function, expressed as gravid females, were  
noted at any dose after the males had been treated for 4 weeks (40).  
Sodium molybdate dihydrate was given to female rats in drinking water (5,  
10, 50 or 100 mg Mo/l) from weaning until day 21 of gestation (2 to 3 months): 
estrous cycles were prolonged in dose groups receiving ≥10 mg Mo/l (≥1.6 mg 
Mo/kg b.w./day, assuming a weight of 100 g per rat) but fertility was unaffected. 
After mating with untreated males, gravid females in the groups given water 
containing ≥10 mg Mo/l had more resorptions and somewhat less developed 
fetuses (histologic examination). At levels above 10 mg Mo/l there were also 
smaller fetuses and significant reductions in fetal weight. No significant effects 
(estrous cycle, embryotoxicity, fetal development) were seen at the lowest dose 
level (0.9 mg Mo/kg b.w./day, the NOAEL in this study). The feed was reported  
to contain adequate amounts of copper (18, 74). Effects were observed in a three-
generation reproduction study in which mice were maintained on drinking water 
containing soluble molybdate (greatest effects in the F3 generation) at the same 
level (10 mg Mo/l, about 1.5 mg Mo/kg b.w./day, assuming intake of 150 ml 
water/kg b.w./day). There was a higher number of runts in the F3 generation 
(11/123 vs. 0/230 in controls) and several pairs in this generation were sterile. 
Early postnatal deaths were more frequent in both the F1 generation (15/238 vs. 
0/209 in controls) and the F3 generation (34/123 vs. 1/230 in controls), and in  
the F2 generation there were 5 dead litters (0 in controls) (60, 74). 
Guinea pigs given ammonium molybdate in drinking water (260 µmol Mo/l;  
25 mg Mo/l) prior to and during gestation showed no effects on estrous cycle, and 
there were 10/12 live births in exposed animals vs. 21/23 in controls (4/8 females 
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in the exposed group did not become gravid). In the same study, there were only 
3/37 live births to guinea pigs receiving the same amount of molybdenum (260 
µmol Mo/l) in the form of thiomolybdate (mostly tetrathiomolybdate) prior to and 
during gestation or during gestation only. At a dose level of 130 µmol Mo/l (12.5 
mg Mo/l) as thiomolybdate there were 10/21 live births in guinea pigs exposed 
prior to and during gestation, and 18/19 live births in those exposed during 
gestation only. Dose-dependent effects, including diarrhea and deaths, were 
observed in mothers in the thiomolybdate-treated groups, but estrous cycles  
were unaffected (25). 
Ammonium tetrathiomolybdate in doses of 1, 4 or 12 mg/kg b.w./day (0.4, 1.5 
or 4.5 mg Mo/kg b.w./day) was given to female rats by gavage for up to 1 month 
(until day 6 of gestation): there were no clinical indications of toxicity and no 
significant effects on studied parameters (including estrous cycle, mating, fertility, 
implantations, resorptions, number of fetuses) (40). These authors report in an 
abstract that no evidence of embryotoxicity, fetotoxicity or teratogenicity was  
seen in rats after daily oral administration of the substance on days 6 – 17 of 
gestation, at dose levels of 2 or 6 mg/kg b.w./day, whereas 20 mg/kg b.w./day  
(7.4 mg Mo/kg b.w./day) increased the number of resorptions (38). Another 
abstract reports results from an experiment with rabbits: oral administration of 6, 
20 or 60 mg ammonium tetrathiomolybdate (2.2, 7.4 or 22 mg Mo)/kg b.w./day  
on days 7 – 20 of gestation yielded significant reductions in red blood cell counts 
(mothers), more resorptions, and spontaneous abortions in 50% of animals in  
the high-dose group (one animal in the medium-dose group also aborted). Dose-
dependent increases of a “carpal/tarsal flexure” malformation were also seen  
in the two higher dose groups (7.4 and 22 mg Mo/kg b.w./day) (39). 
Sheep given repeated injections of ammonium tetrathiomolybdate (1.7 mg/kg 
b.w. intravenous or 3.4 mg/kg b.w. subcutaneous) after copper poisoning re-
covered their health, but developed endocrine disturbances and fertility problems. 
There were elevated levels of molybdenum especially in pituitary and adrenals, 
where pathological changes were also observed (pituitary atrophy or degeneration 
with depletion of ACTH, LH and FSH; adrenal cortex atrophy). Testicular atrophy 
(reduced spermatogenesis) and ovarian degeneration were also observed. The 
authors suggest that thiomolybdate probably binds to copper in the pituitary/ 
hypothalamus and thus inhibits activity of a copper-dependent enzyme that is 
central to bioactivation of peptide hormones (e.g. pituitary hormones), which can 
lead to pathological changes in reproductive organs and impaired reproductive 
ability (21). 
Nanoparticles (30 nm) of molybdenum trioxide have been tested for 
cytotoxicity on mouse spermatogonia in vitro (5 – 100 µg/ml; 48 hours).  
No distinct effects on cell morphology were observed under a phase-contrast 
microscope, but apoptosis tests indicated increased apoptosis at concentrations 
>25 µg/ml. Reduced mitochondrial function was noted at concentrations ≥50 
µg/ml, and increased leakage of lactate dehydrogenase was observed at levels  
as low as 5 µg/ml. No significant effects on cellular metabolic activity (mito-
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chondrial function) or membrane function (lactate dehydrogenase leakage) were 
observed in a similar test with soluble sodium molybdate (9). 
Dose-effect/dose-response relationships 
Available data on humans support no estimates of dose-response or dose- 
effect relationships for occupational exposure to metallic molybdenum or  
the molybdenum compounds treated in this report. Use of ammonium tetra-
thiomolybdate to treat cases of cancer (induction doses corresponding to about  
0.6 – 1.3 mg Mo/kg b.w./day) has side effects associated with copper deficiency, 
most notably in the form of anemia and/or leukopenia. Side effects of this type,  
as well as effects on the liver, have also been seen in treatment of patients with 
Wilson’s disease (Table 1). 
Molybdenum poisoning in animals has symptoms similar to those of copper 
deficiency: anemia, diarrhea, weight loss, joint abnormalities, osteoporosis, 
reproduction problems and kidney damage (4, 33, 48, 57, 67, 75). Intakes of 
copper, molybdenum and sulfate have a complex interrelationship, however,  
and there are large inter-species differences in sensitivity. Ruminants are regarded 
as particularly sensitive to high levels of molybdenum in diet because of the thio-
molybdate formed in the rumen (14, 36, 65, 75). Some studies in which rats, mice 
and guinea pigs were given relatively low oral doses of tetrathiomolybdate or 
soluble molybdate are summarized below. There are only a few inhalation studies 
with laboratory animals, but available data are summarized below and in Table 2. 
Tetrathiomolybdate – per os 
Anemia, diarrhea, skeletal damage, impaired growth and hair discoloration were 
reported in male rats given ammonium tetrathiomolybdate in diet at dose levels 
equivalent to about 0.4 – 0.6 mg Mo/kg b.w./day (4 – 6 mg Mo/kg feed) (46). In 
this study, however, the copper content in the feed was quite low (3 mg/kg). In a 
more recent study in which ammonium tetrathiomolybdate was given by gavage, 
the NOEL for systemic and reproduction effects in male rats was about 1.5 mg 
Mo/kg b.w./day and the LOEL was about 4.5 mg Mo/kg b.w./day (lower body 
weight, mild anemia, effects on testes and sperm). For the female rats, the NOEL 
for systemic and reproduction toxicity was 4.5 mg Mo/kg b.w./day (40). The 
LOEL for reproduction toxicity (resorptions, developmental defects) in female rats 
and rabbits is reported in two abstracts to correspond to 7.4 mg Mo/kg b.w./day 
(38, 39). In a study with guinea pigs, drinking water containing 130 or 260 µmol 
Mo/l (12.5 or 25 mg Mo/l) as thiomolybdate (mostly tetrathiomolybdate) had 
dose-dependent effects on mothers and on reproduction (25). 
Soluble molybdate – per os 
Lengthened estrous cycles, but no effects on fertility, were seen in female rats 
given drinking water containing sodium molybdate dihydrate in doses corre-
sponding to ≥1.6 mg Mo/kg b.w./day (≥10 mg Mo/l). Increases in resorptions  
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and somewhat less developed fetuses were seen at the same levels. The NOAEL  
in the study can be given as 0.9 mg Mo/kg b.w./day (18, 74). Effects on repro-
duction (early postnatal deaths, unsuccessful reproduction) were also observed in 
mice given about 1.5 mg Mo/kg b.w./day (10 mg Mo/l) as soluble molybdate in 
drinking water for three generations (60, 74). In a study with administration  
of sodium molybdate dihydrate in feed, there was poorer growth in male rats at 
doses of about 2 mg Mo/kg b.w./day (20 mg Mo/kg feed) and in female rats at 
about 8 mg Mo/kg b.w./day (80 mg Mo/kg feed). This concentration also caused 
infertility and degenerative changes in testes in the male rats (29, 74). In a more 
recent study, no significant effects on testes/sperm were observed after sodium 
molybdate was given to male rats by gavage in doses corresponding to 4.7 mg 
Mo/kg b.w./day. Effects of this nature, as well as poor fertility and reproduction, 
were observed at about 14 mg Mo/kg b.w./day (55).  
Molybdenum trioxide – inhalation 
Long-term inhalation exposure to molybdenum trioxide at levels ≥10 mg/m3 (≥6.7 
mg Mo/m3) resulted in elevated incidences of lung tumors in mice, but there was 
no observable dose-response relationship. Dose-dependent, very mild to moderate 
inflammatory changes were seen in lungs of rats after long-term exposure to ≥30 
mg/m3 (≥20 mg Mo/m3) (49). No symptoms indicative of molybdenum poisoning 
(e.g. anemia, hair loss, diarrhea) were observed in either mice or rats at air levels 
≤100 mg/m3 (≤67 mg Mo/m3). Effects on body weight, but no clinical indications 
of toxicity, were seen in mice and rats after short-term exposure to 300 mg/m3 
(200 mg Mo/m3) (49). An older study, however, reports severe irritation, diarrhea, 
weight loss, ataxia, hair loss and death of 50% of animals (guinea pigs) at about 
the same air levels (about 200 mg Mo/m3) (17). 
Molybdenum sulfide – inhalation 
Elevated respiratory rates were observed in guinea pigs during exposure, but  
no other indications of toxicity were reported in an older study with short-term 
exposure to molybdenum sulfide at an air level of about 290 mg Mo/m3 (17).  
Conclusions 
Data are altogether too sparse to allow determination of a critical effect for 
occupational exposure to molybdenum or the molybdenum compounds treated 
here. The most prominent side effects of therapeutic administration of tetra-
thiomolybdate are anemia and/or leukopenia. 
Animal data indicate that the easily soluble molybdenum compounds, includ- 
ing molybdenum trioxide, are more toxic than the less soluble ones. Effects on 
reproduction have been seen in some studies in which mice and rats were given 
soluble molybdate in drinking water at daily doses corresponding to about 1.5 mg 
Mo/kg b.w. In one study, lung tumors were seen in mice after long-term inhalation 
exposure to molybdenum trioxide – in the males at exposures as low as 10 mg/m3 
18 
(6.7 mg Mo/m3). This may be regarded as some evidence that molybdenum 
trioxide is carcinogenic to male and female mice. Evidence of carcinogenic 
activity in male rats was equivocal, and there was no evidence of carcinogenic 
activity in female rats. 
 
 
 
Table 1. Observations in humans in connection to exposure to molybdenium compounds. 
 
Type of exposure 
Substance 
Exposure Calculated dosea Observations Ref. 
 
Occupational:  
molybdenite, 
molybdenum oxides, 
soluble molybdates 
Stationary: 1- 
4.5 mg Mo/m3 
respirable dust; 
9.5 mg Mo/m3 
total dust (8-h 
TWA) 
0.15 mg Mo/kg 
b.w./dayb 
 
Normal blood profiles, 
normal serum urate (various 
symptoms with unclear 
relevance). 
75 
As cancer treatment: 
ammonium  
tetrathiomolybdate 
120-240 mg/dayc 
per os 
0.6-1.3 mg Mo/kg 
b.w./dayc 
Side effectsd: primarily 
anemia and/or leukopenia. 
10, 
12 
As treatment for 
Wilson’s diseasee: 
ammonium 
tetrathiomolybdate 
100-300 mg/dayf 
per os 
 
0.5-1.6 mg 
Mo/kg.b.w./dayf 
Normal serum urate. Side 
effects: anemia, leukopenia, 
thrombocytopenia, elevated 
ASAT, ALAT and alkalic 
phosphatases. 
11 
Poisoning: 
ammonium 
heptamolybdate 
(case report) 
About half a 
spoonful of 
powder (in coffee) 
60-180 mg  
Mo/kg b.w.g 
Stomach pain, bloody vomit, 
severe diarrhea, renal 
effects, anemia. 
 6 
 
a Assuming 100% uptake with both oral administration and inhalation exposure, and body weight 
of 70 kg (unless other information is provided). 
b Based on the body burden calculated by the authors: 10.2 mg Mo/day (1.02 mg Mo/m3 as 
respirable dust, 10 m3 inhaled air). 
c Induction doses 
d Relatively rare when serum ceruloplasmin levels are 10 - 15 mg/dl. 
e The disease is characterized by copper accumulation in the liver, liver damage, brain damage and 
low ceruloplasmin in blood (16, 44). 
f Average doses 
g Assuming that the density of ammonium heptamolybdate is the same as that of ammonium 
heptamolybdate tetrahydrate, 2.5 g/ml (13), half a spoonful is 2.5 – 7.5 ml; and further assuming 
a body weight of 60 kg. 
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Table 2. Exposure-effect correlations observed in laboratory animals exposed by inhalation to 
some inorganic molybdenum compounds. 
 
Exposure mg 
Mo/m3 
Species Effects Ref. 
 
MoO3      
3 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
2 Rat 
Mouse 
No significant effects on body or organ weights  
or in histopathologic, hematologic or clinical-
chemical examination; no clinical indications  
of toxicity; no effect on sperm. 
49 
10 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
6.7 Rat 
Mouse 
Same as above. 49 
10 mg/m3 
(MMAD*  
1.5 µm) 
6 hrs/day, 
5 days/wk, 
2 years 
6.7 Rat Elevated incidence of very mild non-neoplastic 
changes in respiratory passages (squamous cell 
metaplasia in epiglottal epithelium and, only in 
females, hyaline degeneration of nasal respiratory 
and olfactory epithelium). 
49 
10 mg/m3 
(MMAD*  
1.3 µm) 
6 hrs/day, 
5 days/wk, 
2 years 
6.7 Mouse Males only: Elevated incidence of lung tumors: 
alveolar/bronchiolar carcinoma (16/50 vs. 2/50), 
alveolar/bronchiolar adenoma/carcinoma (27/50 
vs. 11/50). 
Both sexes: Elevated incidence of very mild,  
non-neoplastic changes in respiratory passages 
(squamous cell metaplasia in epiglottal 
epithelium, metaplasia in alveolar epithelium). 
49 
30 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
20 Rat No significant effects on body or organ weights  
or in histopathologic, hematologic or clinical-
chemical examination; no clinical indications  
of toxicity, no effects on sperm. 
49 
30 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
20 Mouse Significantly elevated copper levels in liver 
(females). No other significant effects on body or 
organ weights or in histopathologic, hematologic 
or clinical-chemical examination; no clinical 
indications of toxicity, no effect on sperm. 
49 
30 mg/m3 
(MMAD*  
1.6 µm) 
6 hrs/day, 
5 days/wk, 
2 years 
20 Rat Higher incidences of very mild to moderate  
non-neoplastic changes in respiratory passages 
(hyaline degeneration of nasal respiratory 
epithelium, squamous cell metaplasia in epiglottal 
epitheliium, chronic alveolar inflammation and, 
only in females, hyaline degeneration of olfactory 
epithelium). 
49 
30 mg/m3 
(MMAD* 
1.4 µm) 
6 hrs/day, 
5 days/wk, 
2 years 
20 Mouse Elevated incidence of very mild non-neoplastic 
changes in respiratory passages (squamous cell 
metaplasia in epiglottal epithelium, metaplasia  
in alveolar epithelium). 
Higher incidence of lung tumors: males: 
alveolar/bronchiolar carcinoma (14/49 vs. 2/50), 
alveolar/bronchiolar adenoma/carcinoma (21/49 
vs. 11/50); females: alveolar/bronchiolar adenoma 
(8/49 vs. 1/50). 
49 
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Table 2. Cont. 
 
Exposure mg 
Mo/m3 
Species Effects Ref. 
 
As smoke 1 hr/day, 
5 days/wk, 
5 weeks 
53 Guinea 
pig 
No indications of toxicity.  2, 
17 
100 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
67 Rat No significant effects on body or organ weights  
or in histopathologic, hemataologic or clinical-
chemical examination; no clinical indications  
of toxicity. 
49 
100 mg/m3 6.5 hrs/day, 
5 days/wk, 
13 weeks 
67 Mouse Significant elevation of copper content in livers. 
No other significant effects on body or organ 
weights or in histopathologic, hemataologic or 
clinical-chemical examination; no clinical 
indications of toxicity. 
49 
100 mg/m3 
(MMAD* 
1.7 µm) 
6 h/day, 
5 days/wk, 
2 years 
67 Rat Males only: Higher incidence of lung tumors: 
alveolar/bronchiolar adenoma/carcinoma (4/50** 
vs. 0/50). 
Both sexes: Higher incidence of mild to moderate 
non-neoplastic changes in respiratory passages 
(hyaline degeneration of nasal respiratory 
epithelium, squamous cell metaplasia in epiglottal 
epithelium, chronic alveolar inflammation. 
Females only: Hyaline degeneration of olfactory 
epithelium. 
49 
100 mg/m3 
(MMAD* 
1.5 µm) 
6 hrs/day, 
5 days/wk, 
2 years 
67 Mouse Higher incidence of lung tumors: males: 
alveolar/bronchiolar carcinoma (10/50 vs. 2/50); 
females: alveolar/ bronchiolar 
adenoma/carcinoma (15/49 vs. 3/50), 
alveolar/bronchiolar adenoma (9/49 vs. 1/50). 
Both sexes: Higher incidence of very mild to mild 
non-neoplastic changes in respiratory passages 
(hyaline degeneration of nasal respiratory 
epithelium, hyperplasia in laryngeal epithelium, 
squamous cell metaplasia in epiglottal epithelium, 
metaplasia in alveolar epithelium. 
Females only: Hyaline degeneration of olfactory 
epithelium. 
49 
as smoke 1 hr/day, 
5 days/wk, 
5 weeks 
191 Guinea 
pig 
No indications of toxicity. One animal died. 
 
 2, 
17 
 1 hr/day, 
5 days/wk, 
5 weeks 
205 Guinea 
pig 
Extremely irritating to eyes and nostrils; diarrhea, 
weight loss, ataxia and hair loss; changes in liver 
(vacuolization, necrotic foci), spleen and lungs 
(exudate); 26/51 animals died. 
 2, 
17 
21 
Table 2. Cont. 
 
Exposure mg 
Mo/m3 
Species Effects Ref. 
 
CaMoO4 (neutralized)     
 1 hr/day, 
5 days/wk, 
5 weeks 
159 Guinea 
pig 
No clinical indication of toxicity; 5/24 animals 
died (pneumonia was reported, but not clear 
whether it was related to exposure). 
 2, 
17 
MoS2      
 1 hr/day, 
5 days/wk, 
5 weeks 
286 Guinea 
pig 
Elevated respiratory rate during exposure but no 
other indications of toxicity; 1/25 animals died. 
2, 
17 
 
* Mean value for aerodynamic particle diameter. 
** On the same order of magnitude as historic controls. 
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Consensus Report for Grain Dust 
February 4, 2009 
This report is a scientific up-date of the Consensus Report for Grain Dust (46)  
by the Swedish Criteria Group which was based mainly on a document produced 
jointly by the Swedish Criteria Group and NIOSH, U.S.A (10). Relevant studies 
up to the end of year 2008 have been considered for inclusion. 
Composition of grain dust 
Grain dust consists of 60 to 80% organic material and 20 to 40% inorganic 
material. The major components of grain dust are fragments of cereal grain such 
as fractured grain kernels and weed seeds and husks. Other important components 
include micro-organisms (bacteria and moulds), storage mites, insects and insect 
parts, hair, feathers and excrement from rodents and birds, residues of pesticides, 
herbicides, fertilizers, silica and dirt (16). Microbes and components of microbes, 
especially endotoxin, are particularly important in farming (34, 58). The compo-
sition of grain varies depending on several factors. Important factors include type 
of grain, geographic site, wetness of the season, storage temperature of the various 
components. Several constituents of the grain dust, for instance the microbial 
composition, are dependent on growing conditions, season, humidity, temperature, 
storage conditions etc. (16). 
Exposure 
Exposure to grain dust occurs in farming, processing of animal feed, grain mill 
work and in shipment and storage of grain. In Sweden, total dust concentrations 
over 50 mg/m3 have been measured in receiving pits for grain with the hatches 
closed and fans running (63). Personal monitors worn by stevedores unloading 
grain recorded averages of 5.6 to 9.5 mg/m3 total dust over a work-shift, but peaks 
of 66 mg/m3 were noted (68). In 1993-94, studies using parallel measurements of 
total dust and inhalable dust were conducted in 17 industries associated with grain 
exposure by the Swedish National Board of Occupational Safety and Health (2), 
Table 1. Measurements were made in a variety of different tasks in farming, 
animal feed operations, milling and elevator work. Personal samplers were  
used. The previously used sampling method for total dust, the Millipore method 
with cassettes having a filter diameter of 25 mm and 37 mm, respectively, was 
compared with the IOM-sampling method for inhalable dust. In farming, expo- 
sure to grain inhalable dust occurred mostly for short periods with high mean 
exposure concentrations of 9.7 mg/m3 measured typically in threshing and drying 
operations. In work with animal feed, the mean exposures over a working  
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Table 1. Total and inhalable grain dust concentrations in farming, animal feed work, milling 
and grain elevator work in Sweden 1993-1994 and relation between total dust and inhalable 
dust measurements. Modified from ref. (2).  
 
    Total dust (mg/m3)    Inhalable dust (mg/m3) Type of work 
or work place Highest 
value 
Average 
(range) 
 
Highest 
value 
Average  
(range) 
 Total dust/ 
inhalable dust 
(regression 
coefficient) 
 
Farming 6.6 5.5 a  11.6 9.7 a  0.84 g 
        
Animal feed 
work 
11.7 2.7 (1.6-4.3) b  27.9 11.1 (5.5-18.0) b  0.34 h 
        
Mills 20.6 3.3 (0.5-10.7) c  38.2 7.3 (1.2-21.4) e  0.57 h 
       0.42 g 
       0.22 h,i 
        
Grain elevators  5.8 1.9 (0.7-4.8) d  21.7 4.9 (0.9-12.8) f  0.66 g 
 
a Based on one 3-hours measurement, the rest of the day there was no exposure. 
b Based on 6 full day measurements at 3 companies. 
c Based on 17 full day measurements at 6 companies. 
d Based on 6 full day measurements at 5 companies. 
e Based on 16 full day measurements at 6 companies. 
f Based on 7 full day measurements at 6 companies. 
g Total dust measured with 25 mm cassette. 
h Total dust measured with 37 mm cassette. 
i Sweeping and sifting. 
 
 
day ranged from 5.5 to 18.0 mg/m3 (mean 11.1 mg/m3, inhalable dust). High 
concentrations were measured in maintenance tasks. The corresponding exposures 
in mills and grain elevator work were 1.2-21.4 (7.3) and 0.9-12.8 (4.9) mg/m3, 
respectively. However, in grain elevator work, the production on the sampling day 
was low, and the concentrations may underestimate those of a normal production 
day. Tasks performed from a control room were associated with low concentra-
tions. The results are summarised in Table 1. For further details of exposure levels 
for different work tasks within the different work environments with grain dust 
exposure, see ref. (2). Endotoxins were also analysed in 8 grain dust samples from 
4 mills. Endotoxin levels varied between 10 and 971 ng/m3. There was no correla-
tion between dust levels and endotoxin levels (2). 
The studies by the Swedish National Board of Occupational Safety and Health 
(2) revealed that the IOM sampling method (inhalable dust), which conforms with 
the European standard EN 481:1993 and the corresponding Swedish standard SS-
EN 481, measures significantly higher grain concentrations than the Millipore 
method (total dust), the difference being in most cases linear. However, the 
relations depend on the kind of grain dust and the diameter of the Millipore 
cassette used. The Millipore method with a cassette filter diameter of 37 mm 
measured significantly higher dust concentrations than the 25 mm filter diameter. 
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Table 1 shows the relations (regression coefficients) between total dust and 
inhalable dust, obtained in farming, animal feed work, milling and grain eleva- 
tor work. The differences are important when comparing older measurements  
of total dust with the present ones of inhalable dust.  
Uptake, biotransformation, excretion 
There are no data on uptake of grain dust or its deposition in the lungs. 
Toxic effects  
The major health effects of inhaled grain dust are irritant symptoms from the 
respiratory tract, asthma, acute and chronic reduction of lung function that is  
non-asthmatic, and grain fever (16, 24, 27, 28). Apart from grain dust, endotoxins 
have been suggested as the cause of respiratory effects (34, 38, 57, 58). The 
mechanisms of the acute and chronic effects on the respiratory tract are largely 
unknown. Both grain dust and endotoxin can induce inflammatory response as 
shown by release of several interleukins, neutrophil chemotactic factor and as 
increases in neutrophils in association with decreased FEV1 (18, 39, 66). Acid 
stress has been reported to be involved in the acute effects on the lung function, 
whereas oxidative stress is part of the regulation of chronic effects on lung 
function (23). Grain fever and asthma, being separate disorders, have here been 
reviewed under headings of their own. Studies on grain fever having a benign 
prognosis, and asthma, do not contribute to the recommendation of an exposure 
limit. The subdivision causes some overlapping in the text. In addition, there are  
a few historical case reports on pneumoconiosis in dock workers who handled 
mostly grain (30), allergic alveolitis (hypersensitivity pneumonitis, "farmer's 
lung") in farmers (21, 51) and serious dyspnea in grain workers (56). 
Grain fever 
Grain fever is an acute inhalation fever that also has been classified as organic 
dust toxic syndrome (ODTS) (54). The prevalence of grain fever in various studies 
has varied from 6% to 32% of exposed workers (16, 24, 61). Grain fever is charac-
terized by chilliness and fever often accompanied by headache, malaise, myalgia, 
chest tightness, dyspnea, cough and expectoration. During a symptomatic phase 
leucocytosis with more immature white cells in peripheral blood is commonly 
seen. The radiograph is as a rule normal (26). When six grain workers and six 
controls were experimentally exposed to high doses of grain dust, grain fever 
symptoms were experienced by all exposed. Thus, grain fever is not thought to  
be induced by a specific immunological mechanism. It has been suggested that 
grain fever is caused by exposure to endotoxin (26).  
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Asthma 
Sensitization to various constituents of grain dust occurs. In most cases of  
asthma among grain workers, however, the causative agent remains unidentified. 
IgE-mediated asthma has been reported to be caused by sensitization to wheat (25) 
and storage mites such as Glycycophagus destructor (20, 36) and Lepidoglyphus 
destructor (62). Sensitization among asthmatics to this particular storage mite 
occurred in 12% of the subjects and 4% of the asthmatics displayed sensitization 
to another storage mite, Acarus siro, as well. Studies on sensitization to grain dust 
among exposed workers have revealed IgE responses as shown by skin prick 
testing and determinations of serum specific IgE (50). The prevalence of allergic 
asthma among grain workers appears to be rather low. Grain exposure causes also 
non-allergic asthma. Endotoxin has been implicated as a cause of the non-allergic 
asthmatic reactions (3). A prevalence study of asthma among grain workers 
including 669 grain workers and 560 office workers was undertaken in Vancouver 
(14). The prevalence of current asthma was only 2.4% and 2.7%, respectively. As 
the prevalence of atopy was only 17.3% among grain exposed, and 31.3% among 
office workers, respectively, it was postulated that asthmatics are likely to move 
from grain dust exposure, which undoubtedly will cause aggravation of any 
asthma, occupational or non-occupational. Another indication of selection is the 
finding that wheeze, e.g. Senthilselvan et al. (55); Peelen et al. (52), is one of the 
most prevalent respiratory symptom among grain workers and is also significantly 
more prevalent among grain exposed than controls, whereas asthma appears less 
frequent and not in the same way more prevalent among exposed than among 
unexposed. 
Acute and chronic effects on the respiratory system and eyes 
Respiratory and eye symptoms 
Early cross-sectional studies by doPico et al. (24, 27, 28 ) on grain workers in 
Minnesota, USA and by Broder et al. (5, 7, 8, 9) and Corey et al. (19) in Thunder 
Bay, Canada have demonstrated the high prevalence of respiratory symptoms 
among grain workers.  
In the Minnesota studies, exposure levels were very high (range of means 10.3-
253 mg/m3), with 66% of measurements in excess of 15 mg/m3. Consequently, the 
prevalences of symptoms were also high with 88.6% of the exposed grain handlers 
complaining of one ore more respiratory symptoms. Typical symptoms included 
cough, expectoration, wheezing, dyspnea, chest tightness, nasal stuffiness and eye 
irritation (24).  
In a subsequent Minnesota study, grain workers were compared with unexposed 
city service workers (28). Lung function parameters were included (FEV1, FVC, 
FEV25-75, FEV50, diffusion capacity). Respiratory symptoms and airflow ob-
struction (decline in FEV1/FVC, FEV25-75 and FEV50) were significantly more 
prevalent among exposed. It was also reported that the probability of having 
respiratory symptoms, especially chronic bronchitis and wheezing at work, are 
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independent of, and usually greater than, the probability of developing these 
symptoms from smoking. 
Studying symptoms in 283 grain workers and 192 city service workers in 
relation to exposure (27), significantly higher prevalences of cough (48% vs. 
32%), expectoration (38% vs. 19%), wheezing (13% vs. 9%), dyspnea (12 vs 6%), 
nasal stuffiness (38 vs. 26%) and eye irritation (13% vs. 6%) were found among 
grain workers. Of the 209 total dust measurements, 93% were below 10 mg/m3 
and 86% below 5 mg/m3 with mean concentrations of 3.3 ±7.0 mg/m3. At ex-
posures >5 mg/m3, the increases in the prevalences of cough, expectoration  
and dyspnea were highly significant.  
In a follow-up study (9) conducted in 1980 on 441 grain elevator workers  
and 180 civic workers having participated in the original survey in 1977 (5) in 
Thunder Bay, Canada. Still available were 315 grain and 107 civic workers; the 
remainder had retired or left. The results of the 1980 study were compared with 
those of the 1977 study. Spirometry was obtained (FEV1, FVC, FEF50, FEF75). 
Dust exposure was measured using a dust collector for respirable dust with a 
nylon cyclone and a cassette with a filter having a pore size of 0.8 µm. The res-
pirable dust was the fraction collected on the filter, whereas the non-respirable 
fraction was collected in the cyclone (19). In 1977 the exposure was 0.4-1.6 for 
respirable dust and 3.6-36.8 mg/m3 for non respirable dust. In 1980 this had 
dropped to 0.2-1.4 and 0.1-2.0 mg/m3, respectively. Data of those workers who 
had participated in the 1977 study but left before the 1980 study were compared 
with those workers who had remained in work and were re-examined in 1980.  
The workers who had left were significantly younger, had a shorter duration of 
employment, a greater prevalence of reported eye irritation, cough, phlegm and 
shortness of breath than those who had remained in work. Civic workers who  
had left, while being likewise younger and had a shorter duration of employment 
than still employed, displayed no statistically significant differences in symptom 
prevalences. In 1980 there were little differences among currently exposed and 
controls; however, that result should be interpreted with caution due to the 
obvious healthy worker effect (9). In the Thunder Bay studies, exposure was 
measured as the respirable and the non-respirable fraction. The sum of respirable 
and non-respirable may be roughly compared with inhalable dust, although it  
is likely to be lower than inhalable dust. The study revealed a strong selection 
among grain exposed. 
In 1978 and 1979, 47 newly employed grain handlers were studied immediately 
before or soon after starting their employment and re-examined two and a half 
months later. As controls, 21 civic workers were examined in a similar way (8). 
Exposure data were not given. Compared with the civic workers, grain handlers 
showed a remarkable increase in the prevalence of cough, phlegm and eye 
irritation between the two examinations. Consistent small decreases in lung 
function parameters (FEV1, FVC, TLC and flow rates) were recorded, the decline 
in FEV1 being the only statistically significant change. Changes were similar in 
smokers and non-smokers. In another study on Thunder Bay workers temporarily 
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laid off for a few months, the respiratory symptoms were partly reversible, 
whereas symptoms returned after the workers re-entered the former work (6).  
More recent prevalences of respiratory symptoms were presented in a com-
parison between Dutch and Canadian grain handling industries (52). The Dutch 
animal feed studies comprised 315 workers from two animal feed elevators and  
12 production factories (57) and 78 workers from the same factories tested four 
years later (60). The Dutch transfer elevator was represented by 438 workers. The 
exposure in the Dutch animal feed and transfer elevator industries was measured 
as inhalable dust (57, 60). The Canadian grain industry was represented by 339 
workers employed in five terminal elevators (35) and by 67 dock workers (22). 
The exposure of the Canadian terminal elevator and dock workers was measured 
as total dust (35). A comparison between the two sampling methods revealed that 
the Dutch sampling device sampled roughly twice the amount of  
the Canadian device. Cumulative exposures were calculated using exposure data 
in different job categories. When interpreting the high frequency of symptoms 
among Canadian dock workers, despite low current and cumulative exposure 
levels, differences in sampling methods should be taken into account (Table 2). 
Canadian dock workers were not exposed on a daily basis and they were exposed 
to high peak exposures which varied over the day (Table 2). The Dutch workers 
 
 
Table 2. Prevalences of respiratory symptoms among in Dutch and Canadian grain 
workers (52). 
 
Symptoms and 
exposure 
Dutch animal 
feed mills 
N =390 
(%) a 
Dutch transfer 
elevator 
N = 438 
(%) a 
Canadian terminal 
elevator 
N = 339 
(%) b 
Canadian dock 
workers 
N = 67 
(%) c 
 
Chronic cough 8 11 14 15 
Chronic phlegm 4 10 19 24 
Breathlessness 5 10 17 6 
Ever wheeze 15 24 18 30 
Frequent wheeze 5 12 6 9 
     
Current exposure 
mean (SD)  
inhalable* or total** 
dust, mg/m3 
7.9 (9.6)* 44.6 (23.7)* 3.5 (2.0)** 2.0 (0.8)** 
Cumulative exposure 
mean (SD)  
total dust, mg x 
year/m3 
108.5 (127.3) 643.6 (406.9) 157.6 (134.1) 22.3 (26.7) 
 
a
 Smid et al. (57), Tielemans et al. (60). 
b
 Huy et al. (35). 
c
 Dimich-Ward et al. (22). 
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symptoms displayed a dose-response relationship. It can be noted that "ever 
wheeze" was the most common symptom among the Dutch animal feed and 
transfer elevator as well as Canadian dock workers. This comparative study 
demonstrates similar types and frequencies of symptoms related to grain  
exposure in two different countries (52).  
 
Acute effects on lung function 
A proportion of grain exposed workers are known to have a cross-shift decline in 
lung function. The reported cross-shift fall in FEV1 varies in different studies (12, 
27). The decrease has been significantly greater than in unexposed controls (19). 
Six men handling barley were followed for two working days by measuring flow 
volume curves every two hours. All six experienced falls in ventilatory capacity  
of up to 800 ml. A similar decrease in ventilatory capacity was seen in five male 
volunteers not previously exposed to barley dust, when they sat in a silo for  
two hours. Decreases in ventilatory capacity ranging from 200 ml to 800 ml  
were measured with recovery taking up to 72 hours (47). In a study including 
respiratory symptoms and lung function conducted in 283 grain workers and  
192 city service workers exposed to a mean total dust level of 3.3 ±7.0 mg/m3, 
cross-shift decreases in FEV1, FVC, Vmax50 and Vmax75 were reported (27). 
Similar decreases in FEV1 were reported in previously unexposed individuals 
when exposed to high levels of grain dust indicating that the decline in lung 
function is not mediated by a specific immunological mechanism. The decrease  
of FEV1 was unrelated to skin reactivity to grain dust antigens (27, 31, 47).  
Asthmatic subjects appeared to have a greater decrease in lung function 
parameters across the shift than non-asthmatic workers. The authors (33) of  
the study suggested that this may be linked to an increased bronchial reactivity. 
The airflow obstruction seems to be unrelated to atopy (4). However, in another 
study no associations between cross-shift decline in FEV1 and bronchial hyper-
responsiveness or eosinophilia were found (32). 
Endotoxin may be one causative toxic substance as experimental challenges 
tests with corn dust extracts and equivalent concentrations of endotoxin resulted  
in a similar degree of airflow obstruction (17, 37). 
Inhalation challenge tests with grain dust have been accompanied by neutro-
philia in the respiratory tract both in experimental animals (39) and in humans 
(66). Release of neutrophil chemotactic factor and IL-1 from macrophages is 
further indications of a non-allergic inflammatory reaction (44, 66). In experi-
mental studies on the mechanisms of the neutrophil recruitment, grain dust 
extracts of grain sorghum, corn, oats, and soybeans were evaluated for their  
ability to directly attract human neutrophils using a blindwell neutrophil 
chemotaxis assay. Each extract was found to possess significant chemotactic 
activity causing cleavage of the complement proteins C3 and properdin factor B 
(PFB). The extracts also lead to the generation of C5a, a potent neutrophil 
chemoattractant generated by complement activation (65).  
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In an inhalation challenge cross-over study, inhalation challenge tests were 
performed with a buffered saline and aqueous corn dust extract to 15 non-
smoking, non-asthmatic, non-atopic male grain handlers. Compared with buffered 
saline, inhalation of corn dust extract resulted in significant airflow obstruction, 
which was observed within 30 min of exposure and persisted for 5 h. Corn dust 
extract resulted in an acute inflammatory response characterized by higher concen-
trations of neutrophils, IL-1, IL-6, IL-8 , and TNF-alpha in bronchoalveolar lavage 
(BAL) fluid. The interleukin changes were also significantly associated with the 
decrease in FEV1 (18). 
Grain workers in the Port of Vancouver, Canada, were studied in a series of  
five studies (11, 12, 13, 31, 59). Relevant exposure data of the Port of Vancouver 
studies are given in Table 4. In one of the studies (12), no significant differences 
were noted between grain workers (610 subjects) and municipal employees (136 
subjects) with regard to eye, nose and chest symptoms, though FEV1 and FVC 
values were lower in the grain workers. However, in a sub-group of 33 grain 
workers (11), 22 had respiratory symptoms and reduced lung function. Of these, 
11 showed hyper-responsiveness in a metacholine test, while the other 11 had 
symptoms indicating chronic bronchitis. None of them reacted to a skin test  
for grain dust. 
 
Chronic effects  
Enarson et al. (31) reported a 6-year prospective study on a cohort consisting  
of all grain handlers employed in four grain elevators in Canada. The study was 
conducted in 1975-1981 (11, 59). In order to identify the most important factors 
influencing lung function, a nested case-control was formed of 81 workers. Cases 
(27 workers) were defined as 10% of workers having shown the worst trend in 
FEV1 over the study period, whereas referents were those 54 workers with the best 
trend. Each case was matched with two controls for age and smoking. The mean 
decline in FEV1 in the exposed group was greater than 100 ml/year. There was a 
significant relationship between the odds ratio of being a case and the mean level 
of dust exposure at work. Thus, the risk of a decline greater than 100 ml/year was 
associated with a mean total dust level of >5 mg/m3. The risk was not related to 
atopy, history of asthma, or presence of respiratory symptoms (31).  
Another study (29) determined whether chronic bronchitis and pulmonary 
function abnormalities were more common in lifetime non-smoking grain elevator 
workers (n=90) than in lifetime non-smoking unexposed community control 
subjects (n=90). Lung function was assessed by spirometry and flow-volume 
curves. The prevalence of chronic bronchitis, defined as daily production of 
phlegm for 3 months/yr for at least 2 years, was higher in exposed workers 
(23.1%) than in non-smoking controls (3.3%) (p <0.01). Also airflow obstruction 
(maximal mid-expiratory flow rate and maximal expiratory flow at 50% of VC) 
was significantly more prevalent in exposed non-smokers than in controls. No 
data on exposure levels were given. 
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The original health survey conducted in Thunder Bay, Saskatchevan, Canada in 
1977 and reported by Broder et al. (5), compared over 441 grain elevator workers 
with a control group of nearly 179 municipal employees. In a subsequent study by 
Corey et al. (19), ventilatory performance was studied. Information on symptoms 
were acquired by a questionnaire. Spirometry (FEV1, FVC, FEF50, FEF25, TLC, 
RV) was performed daily during a work week to a sub-group consisting of 47 
grain workers and 15 municipal employees (19). On an average, the non-respirable 
dust concentration was 5.7 ±10.9 mg/m3 and the respirable fraction 0.9 ±0.7 
mg/m3. The frequencies of coughing and positive skin reactions to grain dust  
were higher in grain workers than in controls. The FEV1, FVC and FEV1/FVC 
decreased from Monday to Wednesday and the decreases were sustained on 
Friday. Fifty percent of the workers had a daily reduction of at least 923 ml/second 
in FEF50 and 310 ml/sec in FEF25 for each 1 mg/m3 increase in respirable dust 
concentration. The FEV1 and FVC also dropped significantly more in grain 
workers, both over the work day and over the work week (19). 
In the Port of Vancouver studies, elevator workers were surveyed every third 
year from 1975 to 1988. Air sampling using personal samplers was undertaken  
for measurement of exposure to total grain dust between the years 1974 and 1989. 
Altogether 781 personal air samples representing 20 job titles has been analysed as 
total dust over the 16 years. Workers included in the study by Huy et al. (35) were 
tested in the fifth survey in 1988, when detailed individual job histories were 
taken. Complete test results were available for 498 grain workers and 55 civic 
workers serving as an unexposed control group. Longitudinal analyses were 
performed on 385 grain workers and 52 controls for whom test results were 
available from at least one earlier survey. Respiratory symptoms included in the 
questionnaire were chronic cough, chronic phlegm production, wheezing and 
dyspnea. The spirometric parameters used for analysis were forced expiratory 
volumes in one second (FEV1), forced vital capacity (FVC), and maximal mid-
expiratory flow rate (MMEF). Matching exposure data with data on grain ex-
posure, four exposure categories were defined: unexposed, <4, 4-9, >9 mg/m3 
(total dust). Estimated cumulative exposures were calculated for each worker. 
There were no differences between exposure groups with respect to reported use 
of dust masks, frequency of peak exposures or duration since last peak exposure. 
Exposure levels had declined over the years ranging in 1974 from 1.4 to 97.8 
mg/m3 and in 1989 from 0.1 to 79.6 mg/m3.  
Huy et al. (35) reported that phlegm production was statistically significantly 
more prevalent in all exposure groups, also in the low exposure group (<4 mg/m3) 
than in the control group. The medium and high exposure groups had significantly 
higher rates of dyspnea than the controls. The study clearly demonstrated a dose-
response relationship of respiratory symptoms, which was evident for all studied 
respiratory symptoms. The increase in symptoms was more pronounced in non-
smokers and former smokers than among smokers.  
A distinct dose-response between exposure categories and lung function 
parameters was demonstrated by Huy et al. (35). In the cross-sectional analyses  
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of the 1988 survey participants, FEV1 and FVC were lowest in the highest 
exposure group. In the group with intermediate exposure (4-9 mg/m3), a 
significantly reduced FEV1 and lower levels of FVC and MMF were seen 
compared with the low exposure group (<4 mg/m3) as well as the controls. FVC 
was significantly lower (p<0.05) in the low exposure group (<4 mg/m3) compared 
with controls (5.04 l and 5.26 l, respectively) and still lower in the intermediate 
exposure group (4-9 mg/m3), i.e. 4.88 l (p<0.01). In the longitudinal analysis, 
there was also a greater decline in FVC in the low-exposure group than among 
controls. A likewise greater longitudinal decline in FEV1 and MMEF in the 
intermediate exposure group when compared with the low exposure group was 
reported. However, looking at the annual loss of lung function, the low exposure 
group was loosing lung function slower than the controls. The authors have com-
mented this suggesting that this may be due to self-selection out of the exposed 
work by such workers who rapidly loose lung function (35).  
As the results on lung function may be due to the higher exposure levels prior to 
1978, a further comparison between workers in the low and intermediate exposure 
categories were undertaken including only workers employed since 1978, after 
which grain concentrations have been <10 mg/m3. In the analysis using multiple 
linear regression coefficients for grain dust exposure level and duration, the result 
were identical to those seen for the entire population, i.e. lower lung function 
levels cross-sectionally and faster rates of decline in lung function longitudinally. 
Therefore, the authors did not consider the effects to be due to earlier higher levels 
of exposure. Analyzing the relationship between symptoms and lung function, 
dyspnea was found to be related to lower levels of FEV1 and FVC (35). 
Kennedy and co-workers (40) conducted a further study on the Port of 
Vancouver employees to study whether, and to what extent the decrease in lung 
function showed reversibility after retirement, and to assess whether the lung 
function impairment in former grain workers, if not reversible, also caused 
functional disability. The study comprised 82 retired grain workers and 54 retired 
civic workers, all of whom had participated in the Port of Vancouver grain eleva-
tor programme, thus having had lung function measurements every 3 year since 
1975 as reported previously by Huy et al. (35) and Chan-Yeung et al. (15). In 
addition to spirometry, methods included questionnaires on respiratory symptoms 
as well as on the impact of breathing difficulties on the activities of daily life, 
chest radiography, and a 6-min walk test. Grain workers had still more dyspnea 
(44% vs. 11%) and lower FEV1 (78.6 vs. 88.2% of predicted) and FVC (90.0 vs. 
97.7% of predicted) values compared to the civic workers. There had been no 
reversibility of the lung function after retirement. The grain exposed walked a 
shorter distance and scored higher on the impairment of activities scale. Thus,  
the respiratory impairment of grain workers was associated with interference in 
the daily activities.  
The Port of Vancouver studies have also revealed a relationship between cross-
shift decreases in FEV1 and future degree of decline in lung function. The decline 
in lung function at follow-up among highly exposed (>9 mg/m3) workers was 
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greater in workers who had exhibited a cross-shift decrease. In general, the acute 
cross-shift decline in lung function was associated with a greater decline in lung 
function than in workers without an acute response to grain dust (41). 
In a study in Saskatchewan, Canada, grain elevator workers were followed for 
15 years, from 1978 to 1993 (49). Data on respiratory symptoms and spirometry 
(FEV1, FVC) were obtained every three years. The 3-year periods were referred  
to as cycles. To predict the annual decline in FEV1 and FVC, a transitional model 
using the generalized estimating equations (GEE) methodology (45). Exposure 
data were not included in this study. The study showed that previous FEV1 was a 
significant predictor of future FEV1 obtained in cycles II, III and V regardless of 
smoking status. Similarly, previous FVC was a predictor of FVC in cycles II, III 
and IV. The decline in FEV1 and FVC was greater in cycles II and III than in 
cycles IV and V. The smaller decline in FEV1 and FVC in cycles IV and V  
was considered to be due to dust control improvements (49). 
In a cross-sectional study from the Netherlands of 194 male workers exposed  
to organic dust for a mean time of 16.3 years at grain elevators in five animal  
feed mills, Jorna et al. (38) measured lung function in relation to four exposure 
categories representing arithmetic means (unexposed, 0-4, 4-9, >9 mg/m3).  
The controls comprised 55 non-production workers rarely exposed to grain  
dust, although some of them had previously been exposed. The exposure was 
characterized by the 50% cut-off diameter of 30 µm (corresponding fairly well 
with the inspirable, i.e. the inhalable, dust fraction) and endotoxin levels with a 
range of arithmetic means between 0.4-29.1 ng/m3. Present exposure was based  
on 54 measurements of inhalable dust and endotoxin, whereas the cumulative 
exposure was derived from the personal job histories. In addition to spirometric 
flow volume curves, impedance measurement were performed. The analyzed 
impedance parameters were resistance at 8 Hz (R8) and 28 Hz (R28), as well as 
the difference between R28 and R8 (frequency dependence, FD), the reactance  
at 8 Hz (X8) and the resonant frequency (f0). 
The results reported by Jorna et al. (38) included: in multiple linear regression 
analysis, chronic bronchitis and "wheezing ever" were statistically more common 
among all exposure groups, including the low one (0-4 mg/ m3) and displayed  
a clear dose-response relationship. Chronic bronchitis was also associated with 
cumulative dust exposure, whereas shortness of breath was related to present 
endotoxin exposure. Wheezing was related to both cumulative dust exposure  
and endotoxin exposure. Air flow decreased with increasing exposure in a dose-
response manner. The mean FEV1, PEF (peak expiratory flow), MMEF (maximal 
mid-expiratory flow) and FEF75 (forced expiratory flow at 75% of the expired 
vital capacity) decreased statistically significantly with increasing exposure at all 
levels when adjusted for age, height and smoking. Also the impedance parameters 
indicated an obstructive air flow. R8 and f0 increased whereas X8 decreased with 
increasing exposure. In the linear regression analyses, FEV1, PEF, MMEF, FEF75, 
R8, X8, FD and f0 all differed statistically signifycantly between the low exposure 
group (0-4 mg/m3) and the unexposed, Table 3. Symptoms in this study were  
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Table 3. Mean values of lung function in control workers and production workers 
classified into exposure categories with respect to airborne grain dust (38). 
 
Lung function Controls 
n = 54 
Mean (±SEM) 
0-4 mg/m3 §  
n = 97 
Mean (±SEM) 
4-9 mg/m3 
n = 17 
Mean (±SEM) 
9 mg/m3  
n = 25 
Mean (±SEM) 
 
FVC (l) 5.63   (0.12) 5.34   (0.08) 5.37   (0.20) 5.28   (0.21) 
FEV1 (l) 4.51   (0.11) 4.20   (0.08) * 4.10   (0.08) * 3.99   (0.20) *** 
PEF (l/s) 12.3   (0.24) 11.5   (0.18) * 10.7   (0.35) ** 10.4   (0.32) *** 
MMEF (l/s) 4.45   (0.21)   3.80   (0.13) ** 3.52   (0.40) ** 3.30   (0.29) *** 
FEF75 (l/s) 9.54   (0.34) 8.74   (0.22) ** 8.03   (0.61) ** 7.38   (0.49) *** 
R8 2.23   (0.09) 2.52   (0.09) ** 2.54   (0.28) ** 3.50   (0.34) *** 
X8 -0.03   (0.03)   -0.08   (0.04) ** -0.24   (0.17) ** -0.50   (0.16) *** 
FD 0.29    (0.04) 0.16   (0.06) * 0.07   (0.13) ** -0.43   (0.20) *** 
F0 8.46    (0.20) 9.21   (0.35) * 10.9   (1.47) ** 14.1   (1.48) *** 
 
§ Exposure categorization by arithmetic mean. Statistical testing by linear regression adjusted for  
  age, height, weight and smoking. 
* p <0.05 
** p < 0.01 
*** p < 0.001 
 
 
 
shown to be associated with decreased lung function. Thus, symptoms compatible 
with chronic bronchitis were significantly associated with a decrease in FEV1 and 
MMEF. Also shortness of breath was related to changes in FEV1. All changes in 
lung function parameters were more closely associated with endotoxin exposure 
than to inhalable dust exposure
 
(38).  
Post et al. (53) reported from the Netherlands a five-year follow-up study on 
140 grain elevator workers that were included in a previous study by Smid et al. 
(57). Exposure was calculated using eight-hour inhalable dust samples taken in 
eight different facilities. Categories of exposure were >10, 4-10 and <4 mg/m3. 
The corresponding endotoxin exposure categories were >40, 20-40 and <20 
ng/m3, respectively (53). The logistic regression analysis showed that workers 
with a dust exposure >4 mg/m3 (or endotoxin >20 ng/m3) at the survey conducted 
in 1986-88 had at the follow-up examination higher risk of rapid decline in FEV1 
(OR 3.3; 95%CI 1.02-10.3) compared with the low exposure (<4 mg/m3) group. 
Adverse effects were not found in the low exposure group, i.e. exposed to <4 
mg/m3 inhalable dust. The presence of respiratory symptoms at the base-line ex-
amination was a strong predictor of subsequent loss to follow-up, whereas base-
line lung function was not. The authors emphasized the need to take into account 
the obvious selection out of grain dust exposure during the study period when 
interpreting results (53). 
In the comparison between Dutch and Canadian grain handling industries 
(presented in section Respiratory and eye symptoms and Table 2), a distinct dose-
response relationship between cumulative exposures to grain dust and FEV1 was 
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demonstrated (52). The dust exposures varied considerably between industries,  
the highest exposure being found in Dutch transfer elevator work (mean current 
44.6 mg/m3 and cumulative exposure 643 mg x year/m3) and the lowest among 
Canadian dock workers (mean current 2.0 mg/m3 and cumulative exposure 22.3 
mg x year/m3). However, sampling methods differed considerably between Dutch 
and Canadian measurement, the Canadian sampling method arriving at much 
lower concentrations than the Dutch method. A correction factor of two was 
suggested to even out the difference (52).  
Mutagenicity 
No information was available on mutagenic effects of grain dust. 
Carcinogenicity 
A few epidemiological studies on populations exposed to grain dust studies have 
been published. In Finland, all working persons born between 1906 and 1945 were 
followed during 1971-95. The follow-up comprised 30 million person-years. 
Exposures were estimated using the population census. A raised SIR of 3.55 
(95%CI 3.0-7.72) was reported for laryngeal cancer among men, mainly grain 
millers, exposed to plant dusts. No associations between exposure and nasal 
cancer, lung cancer or mesotheliomas were found (43). 
In a study on 1325 deceased members of the American Federation of Grain 
Millers´ life insurance plan, the proportionate mortality ratio (PMR) was raised for 
cancers of the lymphatic and hematopoietic systems (PMR 149, 95%CI 106-209). 
Grain mill workers had the highest risk for lymphatic and hematopoietic cancers 
(PMR = 202), particularly lymphosarcoma and reticulum cell sarcoma (PMR = 
216) and other lymphatic neoplasms (PMR = 272); of the cancers in the latter 
category, three were myelomas (<1 expected) (1). An association between farming 
and multiple myeloma has been proposed in a series of meta-analyses comprising 
32 peer-reviewed studies published between 1981 and 1996. A relative risk of 
1.23 (95%CI 1.14-1.32) was found. The estimator of relative risk of female 
farmers was 1.23 (95%CI = 1.17-1.29). Exposures possibly contributing to the 
occurrence of myelomas include pesticides and infectious microorganisms (42). A 
similar increase in the incident of multiple myeloma was found in a cohort of 140 
208 Swedish farmers; the incidence was increased also in parts of Sweden where 
the use of pesticides have been less frequent (64).  
The studies on carcinogenicity deal with mixed, unspecific exposures. It is, 
therefore, not possible to draw any conclusion about carcinogenicity of grain dust. 
Reproductive effects 
No information was available on reproductive effects of grain dust. 
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Dose-response/dose-effect relationships 
Relevant data on relationships between grain dust concentrations and observed 
effects have been compiled in Table 4. 
Several studies have been consistent in reporting indications of a healthy worker 
effect in elevator work (9, 15, 48, 53, 57, 67). When interpreting data on dose-
effect and dose-response relationships, it should be borne in mind that selection 
out of the exposed environment will lead to an underestimation of the risk of the 
remaining survival population. It will weaken any associations between exposure 
and decline in lung function and other health effects, especially in cross-sectional 
studies. Asthmatics are likely to leave the exposed work. 
In long-term follow-up studies, respiratory symptoms and decline in lung 
function display an exposure-response relationship within exposure categories  
of <4; 4-9, >9 mg/m3 inhalable dust (35, 38). Symptoms such as cough, phlegm, 
"chronic bronchitis" and wheeze were significantly more common among workers 
exposed to levels <4 mg/m3 measured as inhalable dust (38), as well as total dust 
(35). Symptoms from the respiratory tract compatible with chronic bronchitis  
as well as shortness of breath were significantly associated with subsequent 
decreases in lung function (38).  
Dose-response studies indicate that an excessive decline in forced vital capacity 
(FVC) occurs at concentrations <4 mg/m3 measured as total dust (35), and in 
forced expiratory volyme (FEV1) at concentrations <4 mg/m3 measured as 
inhalable dust (38). The decline in lung function increases in an exposure-
response manner within exposure categories of <4; 4-9, >9 mg/m3 inhalable dust 
(38). Exposure to higher concentrations may have influenced the effects on lung 
function decline, although probably not strongly (35). The risk of rapid decline  
of FEV1 occur at exposure levels >4 mg/m3 inhalable dust (53). A significant 
decrease in FEV1 and FVC was seen in grain workers over the work day and  
over the work week at exposure levels of 0.9 ±0.7 mg/m3 respirable dust and  
5.7 ±10.9 mg/m3 non-respirable dust (19). 
Conclusions 
Effects on the respiratory system as symptoms and decline in lung function are the 
critical effects. No NOAEL (no observed adverse effect level) or LOAEL (lowest 
observed adverse effect level) can be assessed, but effects have been found at 
concentrations below 4 mg/m3 inhalable dust.  
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Table 4. Effects at various concentrations of grain dust. 
 
Exposure 
(mg/m3) 
Effects Ref. 
 
10.3-253 
total dust 
Itchy eyes, nasal congestion, wheezing, cough, mucus 
expectorations, chronic bronchitis. 
24 
0.9 ±0.7 
respirable dust 
5.7 ±10.9  
non-respirable dust 
Bronchial obstruction and constriction. 19 
<5 (3.3 ±7.0) 
total dust 
Higher prevalence of cough, expectorations, shortness 
of breath, wheezing, eye irritation, nasal congestion. 
27 
5.4-6.3 
total dust 
Irritation of eyes and nose, coughing, shortness of 
breath. 
13 
>5 
total dust 
Rapid decline in FEV1, in excess of 100 ml/year. 31 
0-4 
inhalable dust  
"Chronic bronchitis" and "wheezing ever" more 
common than in unexposed. 
38 
dose-response 
pattern (0-4, 4-9, >9) 
Decrease in FEV1, PEF, MMEF, FEF75.  
<4 
total dust 
More phlegm production and lower FVC than controls. 35 
4-9 
total dust 
Phlegm, dyspnea, decline in FEV1, FVC, MMF.  
>4 
inhalable dust 
Rapid decline of FEV1. 53 
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Consensus Report for Styrene 
April 1, 2009 
This document is an update of the Consensus Report published in 1980 (143) and 
the revision thereof published in 1991 (102). It incorporates information from a 
monograph published in 2002 by the International Agency for Research on Cancer 
(IARC) (71) and risk estimates made by the Harvard Center for Risk Analysis 
(31). Other sources of information include reports and evaluations by the National 
Toxicology Program (101, 122) and the Agency for Toxic Substances and Disease 
Registry (5) in the USA, the Health Council of the Netherlands (64), and the 
Health and Safety Executive in the U.K. (68). Literature searches have been made 
and updated regularly, and a final search of Medline was made in November of 
2008. Abbreviations used in the text are written out in Appendix 1 at the end of 
the report. 
Chemical and physical data 
CAS No.: 100-42-5 
Synonyms: ethenylbenzene, phenylethene,  
 phenylethylene, vinylbenzene  
Formula: C8H8
 
Structure:  
 
 
 
 
Mol weight: 104.15 
Boiling point: 145 °C 
Melting point: - 31 °C 
Vapor pressure: 867 Pa (25 °C) 
Saturation concentration: 8567 ppm (25 °C) 
Density: 0.91 g/cm3 
Distribution coefficient:  2.95 
   Log Poctanol/water 
Conversion factors: 1 mg/m3 = 0.23 ppm (25 °C) 
 1 ppm = 4.26 mg/m3 (25 °C) 
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Styrene is a clear, viscous liquid with a penetrating odor. It polymerizes readily  
at room temperature in the presence of oxygen, and oxidizes on exposure to air 
and light (2). It does not dissolve easily in water (310 mg/l at 25 °C) (113), but  
is soluble in acetone, diethylether and ethanol (35). 
The reported half time for styrene in air is 7.3 hours (108). The odor threshold 
for styrene has been reported to be 0.32 ppm (2), although an odor threshold of 50 
– 80 ppb is reported by the Institute of Environmental Medicine at the Karolinska 
Institute (72) and 16 ppb is given in the WHO air quality guidelines (158). 
Occurrence, use 
Low levels of styrene occur naturally in some foods (e.g. cinnamon).  
Styrene is commercially available as a 99.6 – 99.9% pure monomer containing 
at most 10 ppm of the polymerized product. 
Styrene is a component of several types of resins used in manufacturing a wide 
range of products. The six most common resins are polystyrene (building material, 
packaging material), styrene-butadiene rubber (tires and other vehicle compo-
nents), unsaturated polyester resins in fiberglass-reinforced plastic (boats, storage 
tanks, bathtubs/shower stalls), styrene-butadiene latex (backings for floor cover-
ings and paper) acrylonitrile-butadiene styrene (household and office equipment), 
and styrene acrylonitrile (household products, battery casings). 
About 190,000 tons of styrene were used in Sweden in 2005 (Product register, 
Swedish Chemicals Agency, http://apps.kemi.se/flodessok/floden/flodessok. 
cfm?lang=eng). 
The Swedish National Board of Occupational Safety and Health (now the 
Swedish Work Environment Authority) mapped styrene use in Sweden in 1997 
(3). It ranged from boat hulls and silos to small products such as hoods and bath-
room sinks. Production methods were spraying, hand laminating and casting. 
Exposure 
Background exposure 
Low environmental levels of styrene (about 1 ppb) are quite common, since 
styrene is used industrially on a large scale and is also formed in combustion,  
and therefore occurs in vehicle exhaust and cigarette smoke (31). The maximum 
exposure from styrene in food and drink kept in polystyrene containers has been 
estimated to be about 9 µg/day (about 3 ppb, or about 3 µg/kg foodstuff) (95). 
Styrene exposure via food – from the food itself and from preparation and storage 
in styrene containers – has been estimated to be less than 0.2 µg/kg b.w./day 
(calculated for a body weight of 70 kg) (31).  
Occupational exposure 
Air levels in workplaces are generally below 10 ppm, but can be higher around 
work with fiberglass-reinforced plastic (31). Most epidemiological and exposure 
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studies have been focused on the handling of unsaturated polyester resins during 
production of fiberglass-reinforced plastic: boats, house trailers, vats, bathtubs  
etc. During the lamination process, when the resin is applied by hand or sprayed 
into open molds, styrene concentrations in the surrounding air can far exceed  
the Swedish exposure limit of 20 ppm (8-hour time-weighted average). A study  
made in 1996–1999 and covering 328 employees in various fiberglass production 
facilities in the northeastern USA reported a median value of 9.14 ppm for all 
examined subjects (135). The highest median value, 45.1 ppm (range 6.74 – 117 
ppm) was reported for 48 persons who made recreational vehicles. In these work-
places the levels of styrene oxide were about 500 times lower than the styrene 
levels (135). 
In a survey of styrene exposure in ester plastics industries in Sweden, 15% of 
measurements exceeded 20 ppm, the occupational exposure limit for styrene (3). 
Uptake, biotransformation, excretion 
With occupational exposure to styrene, the primary path of uptake is via the lungs. 
Pulmonary uptake of styrene has been calculated in several inhalation studies (70, 
154), and reported uptakes in these studies have ranged from 59 to 89%. Concen-
trations of styrene in blood and exhaled air drop rapidly within the first hour after 
exposure stops. Styrene accumulates in fat tissue and is excreted in urine, most of 
it as mandelic acid (MA) and phenylglyoxylic acid (PGA) (71, 154). The half time 
depends largely on the duration and intensity of exposure. Uptake and disposition 
of inhaled 13C styrene were measured in 4 male volunteers who were exposed to 
50 ppm styrene during light exercise (50 W): it was found that the half times for 
excretion in urine were on average 3.1 hours for MA and 9.2 hours for PGA (78). 
The half time for styrene in fat tissue has been calculated to be about 2 to 4 days 
(48).  
The measured rate of skin uptake varies widely from study to study (79). In one 
study with human skin, the rate of uptake was reported to be 0.06 mg/cm2/hour 
(12). Skin uptake was measured by determining styrene in exhaled air and styrene 
metabolites in urine of subjects who had held one hand in liquid styrene for 15 or 
30 minutes. This study was considered to be the best available study of skin 
uptake by humans (79). 
Applying the ECETOC criteria for skin notation (i.e. exposure of 2000 cm2  
skin for 1 hour) (45) to a skin uptake rate of 0.06 mg/cm2/hour (12) yields a dose 
of 120 mg via skin uptake. Assuming inhalation of 10 m3 air in 8 hours and 50% 
uptake, this is equivalent to 26% of the dose absorbed via inhalation at the present 
Swedish exposure limit of 90 mg/m3. Skin exposure to liquid styrene can thus 
result in a significant addition to the body burden. 
Skin uptake of styrene in vapor form is reported to be low: 0.0009 mg/cm2/hour 
with whole-body exposure to 600 ppm (128). In another study, skin uptake with 
exposure to 300 – 735 ppm styrene vapor was calculated to be 5% of inhalation 
uptake (160).  
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In a study that compared urine excretion of styrene metabolites in four workers 
who made fiberglass boat hulls when they wore protective clothing and/or res-
piratory protection or used no protective equipment, it was concluded that per-
cutaneous absorption of styrene vapor is not a significant pathway of exposure 
(97). The average air concentration of styrene during the monitored tasks was  
49 ppm. 
Styrene is transformed via several different cytochrome P450 enzymes to  
R- and S- stereoenantiomers of styrene 7,8-oxide (SO) and to the ring-oxidized 
metabolite 4-vinylphenol (50, 71, 105, 117, 166) (Figure 1). In humans, more than 
95% of absorbed styrene is initially transformed to SO (78), and metabolites of 4-
vinylphenol are estimated to make up about 1% of the total amount of metabolites 
(105). Results from studies with human liver indicate that CYP2E1 is the cyto-
chrome P450 isoform responsible for metabolism of styrene at low substrate 
concentrations (84, 116, 157). Two cytochrome P450 enzymes, CYP2A13 and 
CYP2F1, which are expressed in respiratory passages, may be important in 
metabolism of styrene in the lungs (27, 50, 117). In addition to the cytochrome 
P450-dependent oxidation of styrene, oxyhemoglobin has been shown to catalyze 
the formation of SO from styrene in red blood cells (151). 
Styrene metabolism is saturated in humans at air concentrations of about 100 – 
200 ppm (99). A maximum metabolic capacity of 0.92 µmol/kg b.w./minute, with 
an individual variation of 50% (Coefficient of Variation = 0.5) was derived from 
physiologically based toxicokinetic modeling (parameters based on a total of 24 
volunteers in 3 studies who were exposed to 50 – 386 ppm during rest or light 
exercise) (81). 
Figure 1 shows the main metabolic pathways in humans. SO is effectively 
hydrolyzed via microsomal epoxide hydrolase to styrene glycol, which after 
several further metabolic steps results in MA and PGA, which are excreted  
in urine. After 8 hours of inhalation exposure (100 ppm styrene), 57% of the 
absorbed dose is recovered in urine as MA and 33% as PGA. The relative 
proportion of MA and PGA (the MA/PGA quotient) in urine at the end of the 
exposure was 3 ± 1, and 14 hours later 0.8 ± 0.3 (59). A small amount of the SO 
(about 1% in humans) may be conjugated to glutathione (GSH) and form R- and 
S-diastereoisomeric forms of the specific mercapturic acids N-acetyl-S-(1-phenyl-
2-hydroxyethyl)-L-cysteine (M1) and N-acetyl-S-(2-phenyl-2-hydroxyethyl)-L-
cysteine (M2), which are also excreted in urine (30). The variation in urine levels 
of the metabolites M1 and M2 has been ascribed to differences in the ability to 
conjugate to glutathione via the glutathione transferase enzymes GSTM1 and 
GSTT1 (63). The decisive role of the GSTM1 genotype in excretion of M1 and 
M2 was clearly shown in urine analyses of two workers who had been accidentally 
exposed to styrene (104). Levels of M1 and M2 were about five times lower in 
one of the workers, who lacked GSTM1 activity. The metabolism of 4-vinyl-
phenol is understood in less detail, but it has been suggested that further 
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Figure 1. The main pathways for metabolic breakdown of styrene. The pathways 
accounting for the greater amounts in humans are indicated by the thicker arrows.  
ALD: alcohol dehydrogenase, ALDH: aldehyde dehydrogenase, CYP: cytochrome  
P450, EH: epoxide hydrolase, GSH: glutathione, GST: glutathione transferase, SULT: 
sulfotransferase, UGT: glucuronosyl transferase.
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metabolism via the enzymes CYP2E1 and CYP2F gives rise to toxic metabolites 
(22, 23, 167). Conjugation to glucuronic acid and sulfate is followed by excretion 
of conjugates of 4-vinylphenol in urine. 
Styrene metabolism in humans shows wide individual variation, and seems to 
be induced not only by repeated exposure to styrene but also by exposure to etha-
nol (98, 99, 120, 121). Induction of styrene metabolism by ethanol and by caloric 
restriction has also been shown in studies with rats (30, 132). Styrene induces 
several different cytochrome P450 enzymes in exposed rats (65). mRNA expres-
sion of the enzyme CYP2E1 in lymphocytes, which is a biomarker for CYP2E1 
activity, shows positive correlations to excretion of the mercapturic acids M1 and 
M2 (in individuals with the GSTM1-positive genotype) and to urine levels of MA 
(63). Overall, CYP2E1 stands out as the enzyme most important to both toxicity 
and metabolism of styrene in humans. The greatest difference between rats and 
mice with regard to styrene metabolism seems to be that the amounts of metabo-
lites formed via ring oxidation to 4-vinylphenol and via phenylacetaldehyde are 4 
to 10 times greater in mice. In people, metabolism via SO and further hydrolysis 
to MA and PGA seems to be by far the most dominant path, and metabolism via 
phenylacetaldehyde accounts for much less than it does in rats and mice (38). 
A number of recently published studies focus on metabolism of styrene to 
cytotoxic metabolites in lungs, and results of several of them indicate that local 
metabolism in Clara cells in terminal bronchioles plays a central role (see below 
under “Inter-species differences in sensitivity”). 
Biological exposure monitoring 
Biological exposure monitoring has attractive advantages. It provides an 
integrated dose measure over time, reflects differences in workload as well as 
exposure via both inhalation and skin uptake, and shows the effects of protective 
equipment. Several different markers/methods for biological exposure monitoring 
of styrene have been described, including styrene in blood or urine, metabolites  
in urine (hippuric acid, MA, PGA, or PGA+MA), styrene in exhaled air, styrene 
oxide or styrene glycol in blood, mercapturic acids in urine (M1 and M2, see 
Figure 1), and adducts of hemoglobin and albumin in blood (for a review of 
methods see Reference 1). The latter methods, using protein adducts, yield 
integrated exposure estimates for longer periods (weeks or months) (1, 145). 
Glucuronic acid- and sulfate-conjugated metabolites of 4-vinylphenol have also 
been proposed as biomarkers for styrene exposure (105). Of these markers, MA, 
PGA and MA+PGA in urine are the ones most widely used and best validated (1). 
The American Conference of Governmental Industrial Hygienists (ACGIH) 
bases its biological exposure limit for styrene on the sum of the metabolites  
MA and PGA in urine, and recommends a biological exposure index of 400 mg 
MA+PGA/g creatinine in samples taken within one hour after a workshift, which 
is reported to correspond to occupational exposure to an air concentration of about 
20 ppm. This urine level reflects exposure for the day, and to some extent for  
the previous day. MA and PGA are not specific indicators of styrene exposure, 
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however, since other substances (e.g. ethylbenzene) also produce the same metab-
olites and/or interact (e.g. ethanol, toluene) with the metabolism of styrene. It is 
therefore recommended that, in order to confirm specific styrene exposure, blood 
styrene be measured also, and a (semiquantitative) biological exposure index of 
0.2 mg/l is recommended for styrene in blood taken directly after a workshift (1). 
In this report, where biological markers are used to estimate occupational ex-
posure levels for styrene, the following correlations have been applied: 400 mg 
MA+PGA or 300 mg MA/g creatinine in urine samples taken directly after a 
workshift corresponds to an 8-hour exposure to an air concentration of 20 ppm 
styrene (1). 
Toxic effects 
Effects on the central nervous system and sense organs 
The review below is limited to studies made since 1990, when the previous 
Consensus Report on Styrene was published, and takes up only those studies 
performed in accordance with accepted standards and containing exposure 
information useful in determining occupational exposure limits. 
 
Acute effects 
Table 1 presents the two reports found in the literature search that deal with  
acute central nervous system (CNS) effects on experimentally exposed people 
(133, 140). Both of these studies were made with several exposure schedules and 
exposure levels, but neither of them could demonstrate any effects of styrene at 
the tested levels (up to 6 hours at 50 ppm). 
 
Effects of occupational exposure 
Effects on the sense organs and CNS documented in studies of occupationally 
exposed workers are presented in Tables 2, 3 and 4.  
 
Effects on results of psychological performance tests 
Table 2 summarizes the reported results of psychological performance tests,  
and presents information from three original studies (77, 149, 159) and a report 
containing a meta-analysis (8). All the studies in Table 2 show effects of styrene 
exposure at levels near the present Swedish occupational exposure limit of 20 ppm 
(90 mg/m3). 
In the meta-analysis, the authors review several studies in which the reaction 
time of workers exposed to styrene was tested. The review covers four studies  
of choice reaction time (tests in which the subject has to choose the appropriate 
response to several simple signals) and three in which simple reaction time was 
tested. The authors report significant correlations between choice reaction time 
and a measure of cumulative styrene exposure. Their calculations indicate that 
eight years of exposure to a styrene concentration of 20 ppm yields a 6.5% 
increase in reaction time (8). 
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Table 1. Acute effects registered in human subjects experimentally exposed to styrene  
by inhalation. 
 
Exposure 
level 
Exposure  
time 
Number of 
subjects 
Tests used Effects Ref. 
 
14 ppm 
(varying:  
0.5–40 ppm) 
4 hours 24 Simple and choice 
reaction time 
Attention 
No effects. 133 
20 ppm 3 hours 16 Simple and choice 
reaction time  
Attention 
No effects. 133 
 
5, 25, 50 ppm 
(constant) + 
25, 50 ppm 
(varying) 
6 hours 24 Color vision 
Contrast sensitivity 
Odor threshold 
Simple and complex 
reaction time 
Memory 
Coordination  
No effects. 133, 
140 
 
 
 
Table 2. Occupational exposure to styrene and effects on results of psychological 
performance tests. 
 
Exposure level Years  Type of study Effects Ref. 
 
20 ppm a 8 Meta-analysis b  6.5% increase in choice 
reaction time. 
 8 
21.9 ppm c 
(range 0–181 
ppm) 
8.3 ± 7.9 Cross-sectional: 
41 exposed 
45 controls 
Prolonged reaction 
time. 
Elevated vibration 
thresholds. 
149 
30 ppm d 
(20% of 
measurements  
> 50 ppm) 
5 ± 4.5 Cross-sectional: 
30 exposed 
30 controls 
Prolonged reaction 
time. 
 77 
36 ppm c < 10 e Cross-sectional:  
90 exposed  
64 controls 
Prolonged reaction 
time. Worse results on 
coding test. 
159 
 
a
 20 ppm is the exposure level that has significant effects after 8 years of exposure, as  
  calculated by linear regression. 
b
 Of the studies included, 2 (77, 149) are reviewed in this document. 
c
 Average value. 
d
 Calculated by the authors from metabolites in urine. Average value was 722 mg MA+ 
  PGA/g creatinine (95% CI: 610 – 833).  
e
 Time employed is given in the original paper as number of hours doing lamination work. 
 
 
In a French study, test results of 30 boat builders exposed to styrene levels 
generally below 50 ppm were compared with those of 30 employees at the same 
company who were not exposed to styrene. The groups were matched for ethnic 
background, sex, age, and intellectual and sociocultural levels. Noise levels for  
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the two groups were about the same. All measurements were made on Mondays, 
and the tests were given both before and after the workshift. Three tests of 
attention and memory were given, and on the test days MA and PGA in urine  
were measured and air levels of styrene were measured individually with passive 
sampling and stationary monitors at each workstation. The average air level of 
styrene was 22.7 ppm (range 4 – 55 ppm). Levels of MA+PGA were 37.6 (range  
0 – 165) mg/g creatinine in the morning before exposure, and 574.8 (range 90 – 
2180) mg/g creatinine after the workshift. There was a relatively good correlation 
between styrene in air and metabolites in urine: r = 0.73 (p < 0.001). Metabolites 
were also measured in post-shift urine samples for ten months, and the average 
value was 722 mg/g creatinine (95% CI: 610 – 833). According to the authors, this 
level corresponds to an average exposure of about 30 ppm, although levels above 
50 ppm were indicated by 20% of the samples. The exposed subjects did worse 
than controls on all three tests, both before and after exposure, but when they were 
divided into three exposure groups no clear dose-effect relationship could be seen. 
Since the differences between exposed subjects and controls were independent of 
acute exposure, the authors interpret their results as clear indication of long-term 
effects of styrene exposure (77). 
In a cross-sectional study of a retrospective cohort at a boat building plant  
in Belgium, a group of workers previously exposed to styrene (n = 90) and a  
group with low-level current exposure (n = 27) were tested and their results were 
compared with those of a control group (n = 64). The previously exposed workers 
were tested three to four years after their exposures had stopped. An earlier study 
(published only in Dutch) reports that 4 – 9% of time-weighted averages exceeded 
50 ppm and 4% of short-term values were above 100 ppm. Company records 
contained information that allowed computation of the exact number of exposed 
hours for each worker, as well as the exposure level at the corresponding points  
in time. Average exposure during 1982 – 1989 was 35 ppm for the workers who 
were still employed and 37 ppm for those who were no longer exposed. At the 
time of the study the average exposure level for the employed group was 9.6 (SD 
± 5.6, range 2.7 – 28.2) ppm. The authors refer in their conclusions to an exposure 
level of 155 mg/m3, which is about 36 ppm. Both of the exposed groups did worse 
than controls on the “Symbol digit” (a coding test) and number memory tests. The 
results of a coordination test were worse only for the previously exposed group. 
These differences could be seen even after several confounding variables were 
included in the statistical model. Only the number of years doing exposed work 
correlated with performance: i.e. intensity of exposure was not related to per-
formance (159). 
In a study from Taiwan, published in 1996, 41 exposed workers and 45 controls 
from six companies producing fiberglass-reinforced plastic were examined. Of  
the original group of 177 persons, 25 with less than 6 years of education were 
excluded because they were not able to take the tests. A further 26 persons refused 
to take the tests, and 40 persons were excluded for medical reasons. On the day of 
the study 88 exposure measurements were made with personal monitors and 22 
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with stationary monitors. The subjects were divided into two groups based on 
these readings, and those with the lowest exposures (0 – 6.4 ppm) were put in  
the control group. Time-weighted average exposure for the exposed group was 
21.9 ppm, with a median value of 8.6 ppm (range 0 –181), and number of years  
in exposed work was 8.3 ± 7.9. The subjects filled out questionnaires and were 
given psychological performance tests, and vibration thresholds and temperature 
thresholds were also measured to examine function of the peripheral nervous 
system. Significant differences between the groups could be seen in a test of 
attention and in vibration thresholds in both hands and feet (149). 
 
Effects on color vision 
The color vision test used in most of the studies reviewed here is “Lanthony D15”. 
This test consists of 15 color samples in unsaturated pastel colors, which are to  
be ordered according to color. The test was originally developed to differentiate 
between different types of color vision defects, but because of its sensitivity it has 
been widely used in occupational toxicology examinations for the past 20 years. 
The results are usually reported in the form of a Color Confusion Index (CCI), 
which reflects the severity of errors made in sorting. The mechanism behind the 
observed effects on color vision is not known – that is, it is not known whether 
they result from an effect on the nervous system or from some effect on the eye 
itself. The extent to which the effects are reversible is also unknown, but some 
reversibility is suggested in some studies. 
Twelve reports regarding effects on color vision in styrene-exposed workers are 
reviewed below. Nine of these are original reports (20, 46, 49, 52, 53, 57, 73, 74, 
87, 147), one is a statistical calculation of a critical exposure level based on results 
of two studies (21), and two are meta-analyses (8, 125). The relevant studies are 
summarized in Table 3. 
A study made in Japan includes 87 exposed workers and 87 controls, all of 
whom were men. Stationary monitors showed exposure levels in the range 7 – 36 
ppm. The exposed subjects were divided into three groups on the basis of MA in 
urine: < 0.1 g/l, 0.1 – 0.2 g/l, and > 0.2 g/l. According to the authors, these levels 
correspond to styrene exposures of up to 8 ppm, 8 – 16 ppm and above 16 ppm. 
The average MA values for the three groups indicated exposures of about 4, 10, 
and 46 ppm respectively. Both the medium- and high-exposure groups had poorer 
color vision than their matched controls. There was also a dose-effect relationship 
(r = 0.38; p < 0.001) between MA in urine and performance on the color test (87). 
In 2002 this research group published a further color vision study. The subjects 
were boat builders exposed to styrene. Exposure levels were calculated on the 
basis of metabolites (MA+PGA) in urine, and the subjects were divided into high 
(above 10 ppm) and low (up to 10 ppm) exposure groups of 29 persons each and 
matched for age to a mixed control group of 29 persons. The results for the two 
exposed groups and the controls were analyzed. Both of the exposed groups had 
significantly worse results on the color test than the control group (57). 
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Table 3. Effects on color vision from occupational exposure to styrene. 
 
Exposure level 
(ppm) 
Years of 
exposure 
Type of study Effects   Ref. 
 
< 10 a 
> 10 a 
– Cross-sectional: 
29 high exposure 
29 low exposure 
29 controls 
Significant difference from 
controls for both exposure 
groups. Weak dose-effect 
correlation. 
57 
< 8 a 
8 – 16 a 
> 16 a 
6 Cross-sectional: 
21 low exposure 
24 med. exposure 
42 high exposure 
87 controls 
Medium- and high-exposure 
groups showed effects when 
compared to controls. 
Dose-effect correlation. 
87 
16 – Cross-sectional: 
36 exposed 
36 controls 
Significant difference. 
Dose-effect correlation. 
53 
16.2 
(range 1-129) 
7 Cross-sectional: 
41 exposed 
41 controls 
Poorer color vision in the 
exposed group. 
52 
20 b, c 8 Meta-analysis of 6 
different studies d: 
Calculation of level  
for significant effect. 
2.3% deterioration in color 
vision, equivalent to 1.7 
years of aging. 
8 
9 c (range 1-13) 
23 e (range 14-
30) 
12.9 
17.8 
Cross-sectional: 
55 low exposure 
53 high exposure 
Significant difference 
between groups. Weak dose-
effect correlation (p=0.52). 
73, 
74 
24.3 6.5 Cross-sectional: 
60 exposed 
60 controls 
A significantly higher 
number of persons in the 
exposed group had mistakes 
on a color vision test. 
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< 30 a 
> 30 a 
7 Cross-sectional: 
40 low exposure 
17 high exposure 
57 controls 
Significant difference 
between high-exposure 
group and controls. 
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a
 Calculated from metabolites in urine (see section on “Biological exposure monitoring”). 
b
 Statistical calculation of the level at which significant effects appear.  
c
 Calculated from the different dose measures used in the different studies. 
d
 Of the six studies reviewed in the meta-analysis, five are reviewed in this report.  
e
 Calculated average exposure for entire working life. 
 
 
A Swedish study of styrene-exposed workers, based on data collected during 
1998 – 1999, was published in 2005. At the time of the study, exposure for the 
108 participating workers ranged from 1 to 20 ppm. Results of an individually 
calculated index for average career exposure (Lifetime Weighted Average 
Exposure, LWAE) ranged from 1 to 30 ppm. The workers were divided into two 
groups on the basis of this index: average exposures for the two groups were 9 
(range 1 – 13) and 23 (range 14 – 30) ppm. Comparison of results on the color test 
showed a significant difference between the two groups, and a weak dose-effect 
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relationship with the historical exposure data could be seen. There was, however, 
no correlation between color perception and current exposure (73, 74). 
One of the earliest studies reporting effects on color perception due to expo- 
sure to relatively low levels of styrene was published in 1991 by scientists in Italy. 
In a study of color perception in a group of 41 exposed workers and their matched 
controls, they report a dose-related effect of about 7 years of exposure to an 
average 16.2 ppm (geometric mean; range 1 – 129 ppm) (52). 
Two years later the same research group published a study of color perception 
in 36 exposed workers and their matched controls. This study was published as  
a part of a larger study on levels of styrene metabolites in urine. Here as well, 
exposures were about 16 ppm (geometric mean), and color perception was poorer 
in the exposed group. A dose-effect correlation could also be seen (53). 
Another early study showing effects of low-level styrene exposure on color 
perception was published in 1992. This report covers 60 exposed workers at  
a shipyard, who were compared with a control group matched for age, social  
status and ethnic background. On the day of the test the air level of styrene was 
24.3 ppm, and the post-shift level of MA+PGA in urine was 287 mg/g creatinine. 
Although there was little difference between the groups in total number of errors 
on the color perception test, a significantly larger proportion of the exposed  
group made mistakes suggesting that color vision was affected. There were  
also differences in performance on a coordination test (49). 
Color vision was tested in a group of 57 styrene-exposed workers and their 
matched controls. The average exposure level for the exposed workers, as shown 
by stationary monitors, was 18.5 (range 6.6 – 36.4) ppm. The exposed workers 
performed more poorly than controls. When they were divided into two groups on 
the basis of MA level in urine – up to 30 ppm for the first group, and over 30 ppm 
for the second – and the two groups were compared with age-matched controls, 
there was a group difference only for the group exposed to over 30 ppm (46). 
In 2001 a research group in Germany published what they called an “inter-
vention study” of a small group of 22 styrene-exposed laminators and 11 controls. 
Color perception was tested Monday morning and Thursday afternoon of the same 
week, on a total of 6 occasions: before and immediately after a 4-week vacation, 
and again on the same schedule about 10 months later, after exposure levels had 
been reduced. Styrene exposure was determined by measurements of MA+PGA in 
urine samples taken in conjunction with the Thursday afternoon tests. Color vision 
had improved appreciably after the 4-week vacation. When the subjects were 
examined 10 months later, color vision had improved further on the correspond- 
ing test occasions and test scores had returned to “normal range”. The authors 
concluded that styrene has a dose-dependent effect on color perception (147). 
They assert that the effect is reversible, which their data suggest, but neglect to 
point out that even at the lowered exposure there was a tendency for color vision 
to deteriorate during the workweek. They also assert that “The current BAT value 
(600 mg MA+PGA per gram creatinine) protects employees from this non-adverse 
effect.” 
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Visual acuity, color perception and contrast sensitivity were tested in a study  
of 128 styrene-exposed boat builders at three companies in Canada. Stationary 
monitors indicated an average exposure level of 48 ppm (SD = 61, first quartile  
5 ppm, median 10 ppm, and third quartile 89 ppm). MA in urine was also deter-
mined. After exclusion of 47 persons (most of them for medical reasons), the 
remaining 81 persons, 79 men and 2 women, were included in the statistical 
analyses. Their average age was 29 (SD = 8), and they had been employed for  
an average of 5 years (SD = 4). The results of the analyses showed that both color 
perception and contrast sensitivity are negatively affected by styrene exposure, and 
a dose-effect relationship could be seen (20). 
Data from the studies described above by Gobba et al. (52) and Campagna et al. 
(20) were used by a group of scientists from Canada and Italy (21) in an attempt  
to statistically calculate a lowest observed effect level (LOEL). The basis for  
their analysis consisted of 118 workers, 67 from Canada and 51 from Italy. The 
mathematical model they used indicates a LOEL of 4 ppm, with an upper limit  
of 26 ppm for the 95% confidence interval (21). This model has not won general 
acceptance within risk assessment, however, and the authors themselves seem a 
bit uncertain of their interpretation of the results. 
In a meta-analysis of results from six different studies (21, 46, 52, 54, 57, 87) a 
group of American scientists calculated the effects that can be expected from eight 
years of occupational exposure to 20 ppm styrene (the present exposure limit). 
The meta-analysis yielded significant results: the effect of 8 years of exposure to 
20 ppm styrene is equivalent to the deterioration of color vision associated with  
an age increase of 1.7 years (8).  
One more report will be reviewed here, although it contains no new findings. It 
also is a meta-analysis, and includes seven different groups in six original studies 
(46, 52, 53, 86, 87, 147). It was made by a research group in Dortmund. Although 
each of these studies reports significant findings, the authors of the meta-analysis 
contend that the meta-analysis did not yield significant results. The reason for this 
lack of significance is the large variability in effect sizes over the different studies. 
The authors discuss several possible reasons for this absence of significance, but 
arrive at no definite conclusion (125). 
 
Effects on hearing and balance 
A number of studies throwing light on the connection between styrene exposure 
and effects on hearing and balance have been published in recent years. One prob-
lem in assessing these studies is that the noise exposure of the studied groups is 
often not reported, or is at best incompletely described. Another is that historical 
data are often lacking. Below is a brief review of results from studies showing 
correlations between low-level exposure to styrene and effects on hearing and 
balance (Table 4). 
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Table 4. Effects on hearing and balance observed in cross-sectional studies of workers 
occupationally exposed to styrene. (S = styrene exposure; N = noise exposure; C = controls) 
 
Exposure level 
(ppm styrene) 
Job tenure 
(years) 
Number of 
subjects 
Effects Ref. 
 
7.5 a  7.1 (SD=6.2) 32 S 
60 C 
Hearing thresholds for most tested 
frequencies were significantly higher  
in exposed subjects than in controls. 
 
106 
14.5 ± 12.2 b  290 S 
223 C 
Odds quotient for hearing loss with 
styrene exposure was 3.9 (95% CI: 2.4 
– 6.2) after correction for age, sex, and 
current and previous noise exposure. 
There was a significant positive linear 
correlation between average career 
exposure to styrene and elevated 
hearing thresholds at 6 and 8 kHz. 
 
141 
142 
18 c 
3.8 d 
9.1 e 
17 (1–39) S 
 
 
65 S 
 
 
112 
 12 (1–35) N 
18 (2–38) C 
78 N 
81 C 
Persons exposed to styrene but not high 
noise levels had significantly higher 
hearing thresholds at some frequencies 
than either controls or persons exposed 
to noise only. 
 
15.6 f 
3.2 g 
9.1 c 
 154  
S and S+N 
 
 
  159 
N and C 
In the final multiple logistic regression 
analysis, only current noise level, age 
and MA level in urine significantly 
affected hearing thresholds. An 
increase of 152 mg MA/g creatinine in 
urine was associated with an odds ratio 
of 2.44 for hearing loss (95% CI: 1.01–
5.89). 
 
 
25 ± 28 S 
5 ± 10 C 
 88 S 
88 C 
There were significant effects on 
several variables in the balance test, 
even after relatively brief exposures. 
 
146 
37 
(range 3–98) 
7.6 (2–25) 20 S 
10 C 
Effects on balance test. No effects 
noted in audiometry or auditory 
brainstem response. 
19 
 
a
 Calculated from values of 149 ± 80 mg MA+PGA/g creatinine in urine. 
b
 Calculated career average (range 0.8 – 72.5 ppm). 
c
 Calculated career average. 
d
 Measured air levels (range 0.1 – 22.5 ppm). 
e
 Calculated from an average value of 136.8 mg MA/g creatinine in urine (range from below the  
  detection limit to 30 ppm). The value is an underestimate because of the dilution effect (see text). 
f
 Average career exposures to styrene and styrene+noise were calculated by the Criteria Group.  
g
 Measured air level. Averages for styrene and styrene+noise were calculated by the Criteria Group. 
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A Polish research group (141, 142) examined effects on hearing from occupa-
tional exposure to solvents (styrene alone or in combination with toluene) in  
the plastics and fiberglass boat industries. The studied group consisted of 290 
persons (250 exposed to styrene only) with average career exposures of 14.5 ± 
12.2 ppm (range 0.8 – 72.5 ppm) for styrene and 82.1 ± 4.3 dB (range 71.3 – 93.0 
dB) for noise. The reference group consisted of 223 office and factory workers not 
exposed to solvents. Career exposure to noise was on average 73.2 ± 5.3 dB for 
the office workers (n = 157) and 89.2 ± 3.1 dB for the factory workers (n = 66). 
Audiograms for 63.1% of the exposed group and 41.7% of the reference group 
showed deviations, and the multiple logistic regression analysis yielded an odds 
ratio of 3.9 (95% CI: 2.4 – 6.2) for hearing loss related to styrene exposure, after 
adjustment for age, sex, and current and previous noise exposure. There was also  
a significant positive linear correlation between average career exposure to styrene 
and elevated hearing thresholds at 6 and 8 kHz. 
A research group in Finland published a study of 252 styrene-exposed workers 
who made fiberglass boats (146). They tested balance, measured air levels of 
styrene for 148 workers with passive samplers, and determined MA and PGA in 
urine. Two groups, one consisting of 88 “laminators” and the other of 88 workers 
with lower exposures, were matched for age. The calculated average air level  
of styrene was 108 mg/m3 (SD = 119), or 25 ppm, for the high-exposure group, 
and 21 mg/m3 (SD = 42), or 5 ppm, for the low-exposure group. The group with 
higher exposure showed poorer performance for several parameters on the balance 
test.  
In a cross-sectional study of personnel at 11 Swedish companies, Morata et al. 
(112) examined hearing loss in persons exposed to low levels of styrene and/or 
high noise levels. Four groups were compared: one group exposed to styrene (n = 
65), one exposed to styrene and high noise levels (n = 89), one exposed to high 
noise levels (n = 78), and a control group (n = 81) exposed to neither styrene nor 
high noise levels. For the two groups exposed to noise, the average noise levels 
were respectively 85 dB and 89 dB (range 75 – 116 dB). The average noise level 
was 82 dB (range 75 – 84 dB) for the styrene-exposed group and 77 dB (range 69 
– 86 dB) for the controls. Styrene exposure was measured with personal monitors 
for a day, and was 3.8 ppm (range 0.05 – 22.5 ppm) for the styrene-exposed group 
and 2.8 ppm (range 0.01 – 11.7 ppm) for the group exposed to both styrene and 
noise. On the day the styrene levels were monitored, 24-hour urine samples were 
taken starting at the beginning of the shift. Average MA levels were 137 mg/g 
creatinine (range from below the detection limit to 441) in the styrene-exposed 
group, and 137 mg/g creatinine (range from below the detection limit to 456) in 
the group exposed to both styrene and noise. The correlation between MA levels 
in urine and air levels of styrene was significant but low (p< 0.001, r = 0.27). 
Career exposure to styrene was also estimated, using information in company 
records. Calculated career exposure was 306 ppm x years (average exposure time 
17 years) for the group exposed to styrene, and 208 ppm x years (average exposure 
time 15 years) for the group exposed to both styrene and noise. Persons exposed to 
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styrene (with or without high noise levels) had significantly higher hearing thres-
holds at 2, 3, 4 and 6 kHz than both controls and those exposed to noise alone.  
Of several variables included in the final multiple logistic regression analysis,  
only current noise level, age and MA level in urine significantly affected hearing 
thresholds. An increase of 152 mg MA/g creatinine in urine carried an odds ratio 
of 2.44 (95% CI: 1.01 – 5.89) for hearing loss, i.e. an exposure increase of about 
10 ppm more than doubles the risk of hearing loss. No statistically significant 
interactions between styrene and noise (other than purely additive) could be shown 
(112). Calculating the air levels of styrene from MA levels in urine (see section on 
“Biological exposure monitoring”; a post-shift level of 300 mg MA/g creatinine 
corresponds to an air level of 20 ppm styrene (1)) yields an air level of 9.1 ppm 
(range from below the detection limit to about 30 ppm) for the two groups ex-
posed to styrene. This is an underestimate due to a dilution effect, however,  
since the urine samples were collected over 24 hours.  
A more thorough assessment of data from the study described above was pub-
lished by the same authors in 2006 (80). They report analyses of more detailed 
hearing tests, and conclude that the effects on hearing are probably not in the  
ear alone, but also in the CNS. 
A small group of 20 exposed workers was studied by Calabrese et al. (19), who 
tested hearing and balance and measured electrical activity in the brain. Exposure 
was measured with passive sampling and also estimated from styrene metabolites 
in urine. Average exposure was 37 ppm (SD = 29), with a range of 3 – 98 ppm. 
Urine samples were collected on Friday morning before the day’s exposure. MA+ 
PGA was on average 348 mg/g creatinine (SD = 197). Data for the exposed 
workers were compared with reference data for the tests, and no effects could  
be seen on audiometry or auditory brainstem responses (ABR), although several 
parameters on the balance test were affected. 
A conference proceedings published in 2007, probably without peer review, 
contains a study of a small group of styrene-exposed workers at a large Italian 
boatyard (106). The average noise level at their workplace was 73 dB(A), which 
normally does not damage hearing. These workers were compared with a control 
group. The two groups were also checked for noise exposure away from work, 
family history of hearing loss, previous hearing problems, and use of medications 
with known ototoxic effects. Noise at the workplace was measured. Styrene ex-
posure was determined by post-shift measurements of MA+PGA in urine, and 
hearing thresholds were measured at several frequencies (0.5 – 1 – 2 – 3 – 4 – 6 – 
8 kHz). Measured levels of MA+PGA in urine corresponded to an exposure of 7.5 
ppm styrene in air. The 20 exposed men and 12 exposed women were matched for 
age and sex to a control group of 60 persons. The matching yielded 20 men and 4 
women in each group, and the statistical analysis showed that the exposed subjects 
had somewhat less acute hearing at all tested frequencies except 8 kHz in the right 
ear. The hearing loss was at most 25 dB. 
Hearing thresholds in a group of laminators (n = 127) and other workers (n = 
127) who made fiberglass-reinforced boats were tested on two occasions: during a 
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workweek and in conjunction with time off work. On the latter occasion they had 
been exposure-free for 7 to 23 days. The subjects were divided into three groups 
(low, medium, high exposure) on the basis of metabolites in urine. Average meta-
bolite levels for the three groups were 51, 229 and 970 mg MA+PGA/g creatinine 
(equivalent to 2.5, 11.5 and 48.5 ppm styrene, see section on “Biological exposure 
monitoring”. Effects were seen only at exposure levels of 30 – 50 ppm and after 
many years of exposure (148). 
Ischemic heart disease (IHD) 
In a mortality study, 40,688 persons who worked with reinforced plastic in 
Denmark, Finland, Italy, Norway, Great Britain and Sweden were followed and 
causes of death were compared with rates for the national populations. Mortality 
due to circulatory disease was lower than projected: the Standardized Mortality 
Ratio (SMR) in the exposed groups ranged from 0.91 to 0.97 (88). 
Mortality due to ischemic heart disease was also lower among workers who 
develop and manufacture styrene-based products than among the national popu-
lation in the USA: SMR = 0.81 (95% CI: 0.71 – 0.92) (15). 
These results are in conformity with the assumption that, in general, the 
working population is healthier than the national population as a whole, which 
contains many people unable to work.  
A cohort of 5,204 persons who produced plastic boats in two companies in the 
USA between 1959 and 1978 was followed until 1998. At one of the companies 
the average exposure was 42.5 ppm in the fiberglass department and at the other 
71.7 ppm in the laminating department. These were the high-exposure depart-
ments. Neither of these departments showed a significant elevation in risk for 
IHD. However, mortality due to respiratory diseases was higher among these 
workers than in the populations of the state of Washington (SMR 2.07; 95% CI: 
1.24 – 3.23) and the USA as a whole (SMR 1.92; 95% CI: 1.15 – 3.00) (129). 
A total of 15,826 people worked for at least six months with production of 
reinforced styrene plastic in 30 factories in the USA during the years 1948 –  
1977. Styrene exposure ranged from 1 to 200 ppm. The cohort was followed until 
1989 and causes of death were compared with national mortality rates. A total of 
1,628 people in the cohort died. There was no significant elevation in mortality 
due to IHD (SMR 1.04; 95% CI: 0.94 – 1.14), although there was an elevation  
in mortality due to IHD for persons employed less than one year (SMR 1.29;  
p < 0.05) (168). Persons exposed or employed for less than a year usually have  
a higher mortality rate than persons with longer/steadier employment, but this 
elevation in mortality is generally due more to mental illnesses and external  
causes than to IHD (13). 
In one study, 498 cases of IHD were compared with a random selection of  
997 persons employed during the 1943 – 1984 period in two styrene-butadiene 
rubber plants in the USA. Both styrene and butadiene exposures were estimated, 
and ranked from 0 to 10 on an exposure matrix containing 579 job assignments. 
Mortality due to acute IHD was elevated among those who had been exposed  
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to styrene during the preceding two years (Relative Risk 4.99; 95% CI: 1.7 – 
23.34). There was no significant correlation to chronic IHD, but for acute IHD 
there was a dose-response correlation, with an elevation in risk when styrene 
exposure during the previous two years exceeded 0.2 ppm. For exposures above 
0.3 ppm the risk elevation was 4 (Relative Risk 4.3; 95% CI: 1.6 – 11.8) (108). 
A later study examines mortality due to IHD in a total of 16,579 men who 
worked in styrene-butadiene rubber plants in the USA and Canada. This study  
also includes the two production plants of the Matanoski and Tao study (108).  
No significant correlation between styrene exposure during the previous two  
years and mortality due to acute IHD could be observed in this study. There was, 
however, a correlation between average lifetime styrene exposure and chronic 
IHD for persons below the age of 55 (44). 
There is thus one study that raises suspicions of a connection between IHD and 
exposure to styrene (108), and a larger study with similar design that was unable 
to confirm such a connection (44). One possible explanation for this discrepancy 
may be that the study reporting an elevated risk (108) included all employees, 
whereas the other study (44) included only persons who had been employed  
for at least a year. 
Effects on respiratory passages 
Styrene at air levels of about 20 ppm is reported to cause irritation of eyes, throat 
and respiratory passages (70). Welp et al. investigated the question of whether 
styrene causes non-malignant lung diseases in the cohort of 34,560 men and 6,128 
women who participated in the European lung cancer study reported by Kogevinas 
et al. (88), see below under “Carcinogenicity, Human data”. It was found that 
pneumonia as cause of death had a significant correlation (p for trend 0.01) to 
intensity of styrene exposure (average exposure level) but not to cumulative 
exposure. Mortality due to bronchitis, emphysema and asthma showed no cor-
relation to styrene exposure (156). 
Toxic effects on respiratory passages have also been documented in experi-
ments with rats and mice (Table 5). Mice are more sensitive than rats: hyper-
plasias in nasal epithelium and lungs have been reported with chronic exposure  
to 20 ppm for mice and 50 ppm for rats (36, 37, 38). Cell proliferation in termi- 
nal bronchioles has also been observed in mice after oral doses of 100 mg/kg/day 
for 5 days (58). Reduced levels of Clara cell protein (CC16) and morphological 
damage in the terminal bronchioles of mice exposed to styrene indicate that Clara 
cells are the target cells for cytotoxicity in the lungs (24, 25, 37, 38, 51, 62, 83). 
Styrene’s toxic effects on respiratory passages are assumed to be due primarily  
to its oxidation to SO and to the less common ring-oxidized metabolite 4-vinyl-
phenol, which is more toxic than SO in lungs of mice (22 – 26, 39, 83, 167). 
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Table 5. Toxic effects observed in the respiratory passages of laboratory animals 
exposed to styrene by inhalation. 
 
Exposure  
(ppm) 
Exposure 
schedule 
Species Effects Ref. 
 
20 6 hrs/day, 
5 days/week, 
104 wks (males) 
98 wks (females) 
CD-1 mice Degeneration and atrophy in nasal 
mucosa, and in females also a 
significant increase in bronchial 
adenomas. 
37 
40 6 hrs/day, 
3 days 
CD-1 mice Cell proliferation in lungs. 58 
40 6 hours CD-1 mice 
(females) 
Elevated levels of ALP and LDH and 
reduced level of CC16 in pulmonary 
lavage; reduced serum levels of CC16. 
51 
160 6 hrs/day, 
5 days 
CD-1 mice 
(females) 
Destruction of Clara cells in lungs. 51 
 
50 6 hrs/day, 
5 days/week, 
104 weeks 
Sprague-
Dawley rats 
Low-level but dose-related histopatho- 
logical changes in nasal mucosa of all 
animals killed week 52 and week 104. 
36 
 
 
Other toxic effects 
Hepatotoxicity with exposure to styrene during work with fiberglass-rein- 
forced plastic has been reported in two independent studies (16). Significant  
and exposure-dependent elevations in bilirubin (direct) and elevated transaminase 
activity (ALAT and ASAT) are described. The first study had 47 exposed subjects 
and 14 controls, average exposure was 21.8 ppm and average length of employ-
ment was 3.8 years. The second study had 21 exposed subjects and 26 controls, 
average exposure was 24.1 ppm, and average length of employment was 5.5 years. 
Results of animal experiments indicate that styrene causes severe but reversible 
oxidative stress in the liver (26, 150). A single intraperitoneal dose of 600 mg/kg 
given to mice produced a reversible drop in reduced glutathione (GSH) levels and 
a compensatory activation of γ-glutamylcysteine synthetase (26, 150). Histological 
changes and initally lowered levels of reduced glutathione in the liver were also 
reported in rats exposed to 300 ppm styrene 6 hours/day, 5 days/week for 11 
weeks (153). 
Oxidative damage, including effects on viability, permeability, and levels  
of reduced glutathione and antioxidant enzymes, as well as DNA strand breaks 
(comet assay), have been reported with in vitro exposure of human skin to styrene 
levels of 100 ppm or higher (34). 
There are a few reported cases of allergic contact eczema caused by styrene  
(32, 138, 139). Styrene was classified as a weak (138) or mild/moderate (unclear 
which) (134) contact allergen in the Guinea Pig Maximization Test. Since styrene 
is a widely used substance and skin contact must be quite common, it can be 
concluded that styrene rarely causes contact allergy. 
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Genotoxicity 
In vitro data 
The ability of styrene to damage genetic material has been widely tested in several 
different systems. In its most recent (2002) genotoxicity assessment of styrene, the 
IARC reports that SO (both with and without metabolic activation) causes muta-
tions in Ames’ tests with Salmonella. Styrene, on the other hand, was reported  
to yield mostly negative results in Ames’ tests for mutagenicity. Some positive 
results were reported after metabolic activation (71). 
Styrene does not react with DNA, but SO forms covalent bonds with DNA and 
proteins. SO has been shown in several in vitro studies to form N2 and O6 adducts 
of guanine in DNA in exposed mammalian cells (71, 166). 
Promutagenic damage in the form of DNA strand breaks and fragmentation  
has been observed in human lymphocytes exposed in vitro to relatively high con-
centrations of styrene. This concurs with observations of adducts of DNA and 
proteins (71). Results of five recently published in vitro studies reporting DNA 
damage to human lymphocytes exposed to high doses of styrene and SO are 
presented in Table 6.  
It has been demonstrated that styrene is metabolized in blood to genotoxic 
metabolites (6). Chinese hamster cells (V79 cells), cultivated on slides, were 
exposed to styrene (2.4 and 4.8 mM) for 4 hours in a rat liver perfusion system 
containing red blood cells (hemoglobin) from cows. They were placed directly 
after the liver so that the perfusate washed over the V79 cells. A notable 
 
 
Table 6. Genetic damage observed in human cells exposed in vitro to styrene or styrene oxide.a 
 
System Dose Effect Result      Ref. 
 
Lymphocytes 
 
Styrene  
0.5 and 1.5 mM 
Sister chromatid exchanges. Positive (1.5 mM) 11 
Lymphocytes 
 
Styrene 
5 and 10 mM 
DNA fragmentation (comet assay). Positive (5 mM) 94 
Lymphocytes Styrene oxide 
10, 20, 50, 100  
and 200 µM 
DNA fragmentation (comet assay).  
Micronuclei. 
Sister chromatid exchanges. 
Positive (50 µM) 
Positive (50 µM) 
Positive (50 µM) 
91 
Lymphocytes Styrene oxide 
10, 25, 50, 75  
and 100 µM 
DNA fragmentation (comet assay). Positive (25 µM) 18 
Lymphocytes Styrene oxide 
50 and 200 µM 
DNA fragmentation (comet assay). 
Micronuclei. 
Positive (50 µM) 
Positive (50 µM) 
93 
Human lympho-
blastoid cell line  
GSTM1(-) 
Styrene oxide 
1–2 mM 
Gene mutations (HPRT) b Positive (1 mM) 137 
 
a
 These studies were not included in the IARC evaluation published in 2002. 
b  HPRT = hypoxanthine phosphoribosyltransferase 
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observation was that the presence of red blood cells was necessary for the 
appearance of mutations. The authors eliminated SO as the DNA-reactive 
metabolite formed because SO is very rapidly metabolized by the perfused  
liver and also because it caused no mutations in V79 cells exposed to  
2.08 mM SO for up to four hours.  
Animal data 
In some, but not all, animal experiments, exposure to high concentrations of 
styrene has been reported to increase frequencies of chromomsome aberrations, 
sister chromatid exchanges and micronuclei. In the IARC evaluation published  
in 2002, these results are not considered to be convincing evidence of cytogenetic 
damage in experimentally exposed animals (71). Some studies published since  
the IARC evaluation are summarized in Table 7. 
Mice were exposed to 750 or 1500 mg/m3 (176 or 352 ppm) styrene 6 hours/day 
for 1, 3, 7 or 21 days: a dose-dependent increase of DNA adducts in lungs was 
observed, and there was a significant increase in the number of micronuclei in 
bone marrow on day 7, but not on day 21 (163). The number of micronuclei in 
bone marrow on day 7 had a significant correlation to DNA strand breaks on  
day 7, but not at other times. The study was repeated with addition of a further 
sampling occasion on day 14 (47). The repeated study yielded no evidence of  
an exposure-dependent increase of micronuclei in bone marrow. 
Recently published genotoxicity assessments of styrene have consistently 
concluded that styrene has a weak damaging effect on chromosomes in experi-
mental animals (31, 101, 166). 
 
 
Table 7. Types of genetic damage observed in laboratory animals exposed to styrene by 
inhalation. a 
 
Exposure System Effect Result Ref. 
 
125 or 250 ppm, 
6 hours 
CD-1 mice, 
liver 
Unscheduled DNA synthesis. Negative 29 
0, 40 or 160 ppm, 
6 hours/day,  
1, 5 or 20 days 
CD-1 mice, 
lungs 
8-OH-deoxyguanosine. Negative 51 
0, 160 or 500 ppm, 
6 hours/day,  
1, 5 or 20 days 
Crl:CD rats, 
lungs  
8-OH-deoxyguanosine. Negative 51 
352 ppm, 
7 or 21 days 
NMRI mice, 
bone marrow 
SO-adenine and SO-guanine. 
DNA strand breaks (comet assay). 
Micronuclei. 
Positive 
Weakly positive 
Weakly positive b 
163 
352 ppm, 
1 to 21 days 
NMRI mice, 
bone marrow 
Micronuclei. Negative 47 
 
a These studies were not included in the IARC evaluation published in 2002. 
b Significant after 7 days but not after 21 days. 
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Human data 
N3 and O6 adducts of SO to guanine have been identified in lymphocytes of 
styrene-exposed workers (161, 162, 164, 166). Hemoglobin adducts and O6 and 
N2 deoxyguanosine DNA adducts correlate to external exposure measurements 
and to biomarkers in urine (164). 
Using an alkalic elution method, Walles et al. showed in 1993 that the number 
of DNA single-strand breaks in white blood cells from 17 styrene-exposed work-
ers in a Swedish plastics factory was significantly correlated to the amount of 
styrene in air and to the amount of MA in urine (155). The levels in workplace air 
were below the Swedish exposure limit of 20 ppm, averaging 7 ppm (range 0.4 – 
20 ppm). Blood and urine samples were taken before and after a workshift and  
on the following morning. Only the after-shift measurements showed significant 
correlations between DNA strand breaks and intensity of exposure, measured as 
styrene in blood, styrene in urine and MA in urine. The authors concluded that 
most of the DNA damage was rapidly repaired. 
Use of the comet method has increased sensitivity in detection of single-strand 
breaks in DNA, and in studies of styrene-exposed workers made in the past few 
years strand breaks have been found in DNA from both lymphocytes and sperm 
(18, 55, 92, 109, 110). Significant correlations have been found between DNA 
strand breaks and internal dose measures such as DNA adducts or hemoglobin 
adducts in people occupationally exposed to styrene (164). Along with adducts  
in N-terminal valine in hemoglobin, which is the most sensitive marker of styrene 
exposure, the presence of DNA adducts and strand breaks indicates electrophilic 
activity.  
Further, lymphocytes from workers exposed to styrene have an elevated ability 
to repair DNA damage: this has been observed in vitro in cells treated with 0.1 
mM SO (55) or with x-ray radiation (5 gray) (165). These results can be regarded 
as evidence that ongoing exposure to styrene induces DNA repair enzymes. 
The IARC, on reviewing about 30 studies of occupational exposure to styrene  
in various industries, found some evidence of a quantitative correlation between 
styrene exposure and frequency of chromosome aberrations, but not frequencies  
of sister chromatid exchanges or micronuclei. Elevated occurrence of chromosome 
aberrations was reported in 12 of 25 studies, sister chromatid exchanges in 6 of 
16, and micronuclei in 3 of 14 studies. Similarly, an expert panel at the Harvard 
Center for Risk Analysis judged that there is evidence of exposure-related chro-
mosome aberrations in styrene-exposed persons, but less evidence for the occur-
rence of sister chromatid exchanges and micronuclei (31). Since the IARC review, 
a further 11 studies of genotoxic effects/DNA damage in workers exposed to 
styrene have been published. The results are summarized in Table 8, which also 
contains information from the above-mentioned 1993 study documenting strand 
breaks in DNA at very low styrene levels (155). 
Three of the studies (55, 111, 165) are very well made, reported in detail, and 
based on groups of 44 to 95 exposed subjects. They show positive correlations 
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between micronuclei in lymphocytes and styrene metabolites in urine at low 
exposure levels. 
A study of 86 Czech laminators, which included 16 unexposed workers and  
26 external referents, reports statistically significant correlations between the 
frequency of binuclear lymphocytes with micronuclei and the level of styrene in 
air (p<0.001) and in blood (p<0.001) (165). The average air level for all exposed 
subjects was 19.1 ± 13.2 ppm (mean ± SD). 
A Belgian study of 44 men making fiberglass-laminated products and 44 
matched male referents from two factories producing electric cables reports 
significant differences between exposed subjects (9.5 ± 9.6 ppm) and referents 
with regard to numbers of micronuclei in mononuclear lymphocytes (p<0.001), 
binuclear lymphocytes (p = 0.02), and nasal lavage fluid (p = 0.04) (55). 
For the 95 Italian laminators (76 men and 19 women) examined in one of the 
studies by Migliore et al. (111), post-shift levels of styrene metabolites in urine 
were 300 ± 338.2 mg MA+PGA/g creatinine. Air levels of styrene (8.7 ± 0.9 ppm) 
and urine levels of the glutathione conjugates M1 and M2 and the ring-oxidized 
metabolite 4-vinylphenol were determined for 45 subjects, and showed strongly 
significant correlations. This study also showed clear correlations between 
micronuclei in lymphocytes and the number of chromosome aberrations. Both 
chromosome aberrations and micronuclei showed significant correlations to 
MA+PGA and to 4-vinylphenol. In a figure in the article that charts the correla-
tions between level of 4-vinylphenol and number of binuclear micronuclei per  
103 cells (Figure 2a) and frequency of centromere-positive micronuclei (Figure 
2b), it appeared that two subjects with extremely high exposures might account  
for the significance of the correlations between these effect markers and levels  
of 4-vinylphenol. In the process of compiling this document, Lucia Migliore  
was contacted: she supplied the raw data and could confirm that the correlations 
remained significant if these two subjects were removed from the calculations.  
It was observed that individuals with the GSTT1-null genotype had significantly 
higher levels of micronuclei among the styrene-exposed but not among the unex-
posed. Since GSTT1 is expressed in erythrocytes but not at all in lymphocytes, 
this finding may indicate that metabolism of styrene to electrophilic metabolites 
(which can be conjugated and detoxified by GSTT1) in erythrocytes may play a 
role in the occurrence of DNA damage in lymphocytes.  
In a work published in 2003 (164), Vodicka et al. present a compilation of 
several studies they had published in 1993 – 2001. They review data on chromo-
some aberrations in lymphocytes from 75 styrene-exposed subjects that show 
strong correlations between the level of chromosome aberrations and styrene 
levels in air (R2 = 0.212; p = 0.0001) and in blood (R2 = 0.24; p = 0.001). 
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Table 8. Genetic effects observed in subjects occupationally exposed to styrene a. The studies 
are listed chronologically. 
 
Material Exposure Effect Result Ref. 
 
Lymphocytes 
17 exposed 
Laminators. 7.0 ppm styrene 
(average, n=16; range 0.4–
20); 70 mg MA/g creatinine 
(average, n=17; range nd–
261) post-shift. 
Single strand breaks  
(alkalic elution). 
Positive 155 
Lymphocytes 
14 exposed 
70 controls 
Laminators. 3 monitoring 
occasions: 313.2 ± 90.9, 324.8 
± 71.4, 352.8 ± 153.1 mg 
MA/g creatinine (average  
± SE). Air levels of styrene 
estimated by the authors: 16.8 
± 5.9 ppm, 17.5 ± 4.6 ppm, 
19.3 ± 10 ppm (average ± SE) 
post-shift. 
DNA fragmentation (comet). 
Micronuclei. 
Sister chromatid exchanges. 
Positive 
Positive 
Positive 
92 
Lymphocytes 
26 exposed 
26 controls 
Laminators. 240 mg MA+ 
PGA/g creatinine (median, 
range 98–382) post-shift. 
Single strand breaks  
(DNA unwinding). 
Positive 136 
Sperm 
46 exposed 
27 controls 
Laminators. 28% exposed  
>20 ppm styrene; 173.6 mg 
MA/g creatinine (median, 
range 5.8–1428.7) post-shift. 
DNA fragmentation (comet). Positive 109 
Sperm 
18 exposed 
13 controls 
Laminators. 295.8 mg MA/g 
creatinine (average, range 
20.8–947.8) post-shift. At 
least 2 years of exposure.  
Numerical changes in 
chromosomes. 
Negative 115 
Lymphocytes Combined studies. SO-DNA adducts, n=30. 
Hb adducts, n=76. 
Gene mutations (HPRT), n=72. 
DNA fragmentation (comet), n=58. 
Chromosome aberrations, n=79. 
Positive 
Positive 
Positive b 
Positive 
Positive 
164 
Lymphocytes 
(genotyped) 
48 exposed 
14 controls 
Laminators and polymer 
production workers. 36.8 ± 
0.7 ppm styrene (geometric 
mean ± GSD, range 1.2–
115.7); 205.5 ± 2.4 mg 
MA+PGA/g creatinine 
(geometric mean ± GSD, 
range 31.6–1412.5) post-shift. 
DNA fragmentation (comet). Positive 18 
Lymphocytes 
(genotyped) 
86 exposed 
42 controls 
Laminators. 19.1 ± 13.2 ppm 
styrene (average ± SD). 
DNA fragmentation (comet). 
Micronuclei. 
Chromosome aberrations. 
Elevated DNA repair ability. 
Negative 
Positive c 
Negative 
Positive 
165 
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Table 8. Continued. 
 
Material Exposure Effect Result Ref. 
 
Lymphocytes 
(genotyped) 
44 exposed 
44 controls 
Laminators. 201.6 ± 148.3 mg MA/g 
creatinine (average ± SD, range nd–
618.2) post-shift. Air levels of 
styrene estimated by the authors:  
9.5 ± 9.6 ppm (average ± SD,  
range 0–36.6). 
Hb adducts. 
DNA fragmentation (comet). 
Micronuclei in lymphocytes. 
Micronuclei in nasal lavage. 
Positive d 
Positive e 
Positive 
Positive 
55 
Lymphocytes 
(genotyped) 
28 exposed 
28 controls 
Laminators. 27 ± 5 ppm styrene 
(average ± SE, range 2 – 91); 401  
± 73 mg MA+PGA/g creatinine 
(average ± SE, range 47–1490) 
morning after shift. 
Sister chromatid exchanges. 
Micronuclei. 
Positive 
Negative 
144 
Lymphocytes 
(genotyped) 
95 exposed 
98 controls 
Laminators. 8.7 ± 0.9 ppm styrene 
(average ± SD, range 0.47–125.6), 
n=45; 300 ± 338.2 mg MA+PGA/g 
creatinine (average ± SD, range 
10.2–1856.0), n=95; post-shift. 
Micronuclei. 
Chromosome aberrations. 
Positive 
Positive 
111 
Lymphocytes 
Sperm 
42 exposed 
25 controls 
Laminators. 630 ± 35 mg 
MA+PGA/g creatinine. 
Micronuclei in lymphocytes. 
DNA fragmenation (comet) in 
sperm. 
Positive f 
Positive f 
110 
 
a Not included in the 2002 IARC evaluation. 
b Significant positive correlation to air levels of styrene but not to MA in urine. Significant  
  correlation between HPRT (hypoxanthine phosphoribosyltransferase) mutations and cumulative  
  exposure time. 
c Significant positive correlations to all exposure markers. Average for exposed subjects  
  significantly different from workplace controls but not significantly different from average for  
  external controls. 
d Significant positive correlation to urine levels when blood samples were taken but not to average  
  levels in urine samples taken weekly for 3 months. 
e Significant positive correlation to Hb adducts but not significantly higher than unexposed  
  subjects. 
f Significant correlation between DNA fragmentation in sperm and micronuclei in lymphocytes for  
  67 subjects (both exposed and controls) but no correlation to metabolites in urine. 
 
 
Variations in metabolism and repair probably explain quite a bit of the individ-
ual differences in sensitivity to styrene, and probably also lie behind the difficulty 
in establishing dose-response relationships based on exposure levels in air. In 
many of the studies presented in Table 8, attempts were also made to identify 
sensitive groups by genotyping for biotransformation enzymes or DNA-repair 
enzymes. Because the groups were small, however, most of the presented results, 
which identify bearers of certain polymorphic variants of some biotransformation 
enzymes and DNA repair enzymes, are very tenuous and need to be verified. 
Conclusions on genetically determined sensitivity to styrene are therefore not 
reviewed or further commented here. A study of micronuclei in 644 individuals 
(pooled data from studies of 343 occupationally exposed and 301 unexposed 
subjects), published in 2006, reports that the occurrence of micronuclei is 
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significantly higher in women and also that it increases with age (85). It is likely 
that in some of the early studies a correlation between styrene exposure and 
occurrence of micronuclei went undetected because of age and sex differences 
between exposed groups and controls. 
To sum up, there are data from several studies of styrene-exposed subjects that 
show exposure-related elevations in DNA strand breaks and other cytogenetic 
changes. These findings must be placed in the context of our general knowledge 
about what cytogenetic changes mean in terms of cancer risk. In follow-ups of 
individuals who have been tested for cytogenetic changes in several contexts (not 
only in studies of occupational exposure) it has been observed that elevated levels 
of chromosome aberrations in lymphocytes are an indicator of increased cancer 
risk (60, 61). Further, a recent study in the the Human MicroNucleus project has 
shown that micronuclei in peripheral lymphocytes of healthy persons constitute  
a biomarker predictive of elevated cancer risk (14). The study reports higher total 
cancer incidences in groups with elevated numbers of micronuclei. These groups 
also had significantly lower survival. Bladder cancer and renal cancer, as well as 
stomach and intestinal cancer, were significantly correlated to high frequencies  
of micronuclei. 
Using the rad-equivalence method, the ability of SO to form micronuclei was 
compared to that of gamma radiation (56). Comparison of the doses of SO and 
gamma radiation that yielded similar amounts of micronuclei in human lympho-
cytes exposed in vitro, along with knowledge of the carcinogenic potency of 
styrene oxide, allowed calculation of a lifetime risk of developing fatal lymphatic 
hematopoietic cancer: 0.17 (range 0.037 – 5) per 1000 persons occupationally 
exposed to 20 ppm styrene for 40 years.  
Carcinogenicity 
The IARC has assessed the carcinogenicity of styrene and classified it as “possibly 
carcinogenic to humans” (Class 2B) (70, 71). 
Animal data 
Eight chronic toxicity/cancer studies have been made with rats. Exposures were 
via inhalation, gavage or drinking water (Table 9). In its 2002 evaluation (71),  
the IARC stated that “there was no reliable evidence for an increase in tumour 
incidence in rats”. 
Female rats were exposed by inhalation to 0, 25, 50, 100, 200 or 300 ppm 
styrene for 52 weeks, and malignant mammary tumors were found in 6/60 (10%), 
6/30 (20%), 4/30 (13%), 9/30 (30%), 12/30 (40%) and 9/30 (30%) respectively. 
Total incidences of mammary tumors at these exposure levels were respectively 
34/60 (57%), 24/30 (80%), 21/30 (70%), 23/30 (77%), 24/30 (80%) and 25/30 
(83%) (33). 
70 
Table 9. Styrene carcinogenicity studies with rats. 
 
Exposure Strain Result Ref. 
 
Gavage: 500 mg/kg b.w.,  
1 day/week, 120 weeks 
BDIV Negative. 126 
Inhalation: 600 or 1000 ppm, 
6 hours/day, 5 days/week,  
18.3 months (males), 
20.7 months (females) 
Sprague-
Dawley 
Positive for mammary tumors 
(adenocarcinomas) in low-
dose group. 
31* 
Gavage: 500 mg/kg b.w.,  
5 days/week, 103 weeks; 
1000 or 2000 mg/kg b.w.,  
5 days/week, 78 weeks 
F344/N Negative. 118 
Gavage: 30% β-nitrostyrene, 70% styrene, 
175, 350 or 700 mg/kg b.w.,  
3 days/week, 79 weeks 
F344/N Negative.  119 
In drinking water: 
125 or 250 ppm, 104 weeks 
Sprague-
Dawley 
Negative.  7 
Gavage: 50 or 250 mg/kg b.w.,  
4 or 5 days/week, 52 weeks 
Sprague-
Dawley 
Negative.  33 
Inhalation: 25, 50, 100, 200 or 300 ppm,  
4 hours/day, 5 days/week, 52 weeks 
Sprague-
Dawley 
Positive for both total and 
malignant mammary tumors.  
33 
Inhalation: 50, 200, 500 or 1000 ppm,  
6 hours/day, 5 days/week, 104 weeks 
Sprague-
Dawley 
Positive in the two highest 
dose groups for benign tumors 
in interstitial cells in testes. 
36 
 
* Jersey et al., Dow Chemicals, 1978; cited in Reference 31. 
 
 
Regarding the positive results for mammary tumors reported in the inhalation 
study by Conti et al. (33), the assessments of the IARC (71) and HCRA (31) both 
point out that exposure time was short, that the reporting was incomplete, and that 
the frequency of spontaneous tumors was high; both mention also that in the well-
reported study by Cruzan et al. (36) a dose-dependent reduction of mammary 
tumors was seen in females. In this study rats were exposed to 0, 50, 200, 500 or 
1000 ppm styrene for 104 weeks, and mammary adenocarcinomas were observed 
in 20/61 (33%), 13/60 (22%), 9/60 (15%), 5/60 (8%) and 2/60 (3%); fibroade-
nomas, including epithelial hyperplasias, were observed in 27/61 (44%), 22/60 
(37%), 18/60 (30%), 21/60 (35%) and 19/60 (32%) respectively. 
Three of five studies with mice have provided evidence that styrene causes lung 
tumors, but no evidence of tumors of other types (Table 10). In one study, groups 
of 50 male and 50 female CD-1 mice were exposed to 0, 20, 40, 80 or 160 ppm 
styrene for 98 weeks (females) or 104 weeks (males). Elevated occurrences of 
benign lung tumors were reported in mice exposed to styrene levels as low as 20 – 
40 ppm, and malignant tumors at 160 ppm. Bronchoalveolar adenomas were 
found in 15/50 (30%), 21/50 (42%), 35/50 (70%), 30/50 (60%) and 33/50 (66%) 
males, and in 6/50 (12%), 16/50 (32%), 16/50 (32%), 11/50 (22%) and 24/50 
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Table 10. Styrene carcinogenicity studies with mice. 
 
Exposure Strain Result Ref. 
 
Gavage: 1350 mg/kg b.w.,  
1 day/week, lifelong 
O20 Positive for lung tumors in both sexes. 
 
126 
Gavage: 300 mg/kg b.w.,  
1 day/week, lifelong 
C57B1 Negative. 126 
Gavage: 150 or 300 mg/kg b.w.,  
5 days/week, 78 weeks 
B6C3F1 Significantly higher occurrence of broncho- 
alveolar adenomas and carcinomas in males 
in the high-dose group. 
118 
Gavage: 30% β-nitrostyrene,  
70% styrene, 200 or 400 mg/kg b.w.,  
3 days/week, 78 weeks 
B6C3F1 Negative.  119 
Inhalation: 20, 40, 80 or 160 ppm,  
6 hours/day, 5 days/week,  
98 weeks (females),  
104 weeks (males) 
CD-1 Positive for late lung tumors. Elevated 
occurrence of lung adenomas at all exposure 
levels. Significant increase of lung 
carcinomas only in females at 160 ppm. 
37 
 
 
 
(48%) females exposed to 0, 20, 40, 80 and 160 ppm respectively. Malignant 
bronchoalveolar carcinomas were reported in 0/50 (0%), 0/50 (0%), 2/50 (4%), 
0/50 (0%) and 7/50 (14%) females at these exposure levels. There was no in- 
crease of malignant lung tumors in the males (37).  
Administration of SO by gavage has been shown to increase the incidence  
of tumors in the forestomachs of both rats (33, 96, 127) and mice (96). In its 
evaluation, the IARC states that there is “sufficient evidence” that SO causes 
tumors in experimentally exposed animals (70). 
In summary, the assessments made by the IARC (71), HCRA (31) and ATSDR 
(5) all conclude that styrene causes lung tumors in mice. There is no reliable evi-
dence that styrene causes tumors in rats. 
Human data 
This section does not contain detailed reviews of the numerous published studies 
of potentially carcinogenic effects on humans, but rather provides a survey of the 
principal findings that are described in more detail in the risk assessments made 
by the IARC (71), HCRA (31), EU (68), and ATSDR (5). A few recent follow-ups 
of earlier studies are also reviewed. The IARC assessed 13 retrospective cohort 
studies, five of which drew their material from industries producing fiberglass-
reinforced plastic. The others were from styrene monomer and styrene polymer 
production and from production of styrene-butadiene rubber (71). As previously 
mentioned, the highest exposure levels occur in production of fiberglass-rein-
forced plastic, where also mixed exposures are less common. A problem here is 
that short-term employment is widespread in this industry, and epidemiological 
studies are consequently quite difficult.  
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Studies of styrene-exposed mice have indicated that there may be a risk of lung 
cancer associated with styrene exposure (37). Most of the epidemiological studies, 
however, have reported no elevation in risk for lung cancer in any of the three dif-
ferent types of industry where styrene occurs (15, 66, 88, 123, 131). In a cohort of 
15,826 men and women employed in production of fiberglass-reinforced plastic, 
however, there were 162 cases of lung cancer vs. 115.2 expected (SMR 1.41; 95% 
CI: 1.20 - 1.64) (168). The elevation in risk was seen only at low cumulative 
exposures and in persons with brief employment.  
An early study of workers making styrene-based products reports a significant 
increase of lymphatic leukemia (124). Follow-up studies, however, have yielded 
equivocal results for lymphatic and hematopoietic cancers (15, 88, 89, 103, 107, 
169). A multinational European study of nearly 41,000 employees working with 
fiberglass-reinforced plastic at 660 different companies, which included eight sub-
cohorts from Denmark, Finland, Italy, Norway, Sweden and the UK, reported  
no increase in either overall mortality or mortality due to malignant neoplastic 
diseases (88). Mortality from neoplastic diseases in lymphatic and hematopoietic 
tissues increased with time elapsed from initial exposure and with increasing 
average exposure, but not with cumulative exposure. 
No increase in mortality due to leukemia or lymphoma is reported in the study 
by Ruder et al. (see above under “Ischemic heart disease”), which is an update of  
a cohort study of 5204 persons who made fiberglass boats in two companies in the 
USA between 1959 and 1978 and who were followed until 1998 (129). Elevated 
mortalities due to cancers of the esophagus (n = 12, SMR 2.30; 95% CI: 1.19 – 
4.02) and prostate (n = 24, SMR 1.71; 95% CI: 1.09 – 2.54) were reported, and 
among 2062 highly exposed workers there was also an elevated incidence of 
urinary tract cancer (n = 6, SMR 3.44; 95% CI: 1.26 – 7.50). 
Other studies of laminators have also reported elevated mortalities due to 
various forms of cancer, including cancers of the esophagus (88, 169), pancreas 
(88), urinary tract (88, 123, 168), male sex organs (123, 168) and female sex 
organs (168). Most of these increases were small, not statistically proven, and not 
seen in groups with the highest exposures, and have therefore been considered to 
be unrelated to styrene exposure (31). 
There are thus a number of epidemiological studies in which possible increases 
in mortality due to various forms of cancer have been observed among people 
exposed to styrene. The IARC pointed out in its assessment of the epidemiological 
data that the risk increases were generally low and statistically uncertain and were 
often based on analyses of sub-groups. The findings were rather weak, and the 
possibility that they were due to chance, bias or simultaneous exposure to other 
substances could not be ruled out. 
Inter-species differences in sensitivity 
The local metabolism in the lungs – particularly in Clara cells – that leads to 
formation of toxic metabolites has been put forth as an explanation for the 
differences between mice and rats in sensitivity to lung tumors. The hypothesis 
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that the greater sensitivity of mice may be explained by higher levels of SO in 
terminal bronchioles still has some support, but the observation that, at the same 
exposure levels, blood levels of styrene and SO are the same in mice and rats 
argues against a causal role for SO (37). 
Metabolic transformation of styrene to SO in lung tissue from mice, rats and 
humans has been compared in several studies (summarized in Reference 31). 
These studies have shown that cytochrome P450-dependent transformation to  
SO is less effective in human lung than in rat lung, and much less effective  
than in mouse lung.  
Both physiologically based pharmacokinetic models and measurements of  
SO in in situ ventilated lungs show higher local concentrations of SO in mouse 
lung, but this difference does not seem large enough to provide a complete ex-
planation for the difference between rats and mice in sensitivity to lung cancer 
(42, 67). Protection against toxic effects in Clara cells with P450 inhibitors, lower 
levels of SO in the blood of mice at levels of styrene that cause lung tumors (160 
ppm) than in rats at higher levels of styrene that do not cause lung tumors (1000 
ppm), as well as lack of SO-DNA adducts in lungs, also argue against the blood 
level of SO as a major factor in the appearance of lung cancer (37, 38, 83). 
Current research suggests rather that mice have a greater sensitivity to local 
formation of reactive styrene metabolites and GSH depletion, which leads to local 
toxicity and compensatory cell proliferation (42, 130). This greater sensitivity in 
mice, together with the higher activity of the enzymes CYP2E1 and CYP2F2 and 
the somewhat higher formation of the more reactive and more toxic R-enantiomer 
of SO in mouse lung, has been put forward as possible explanation for their 
greater sensitivity to lung tumors (31, 42, 51, 67, 69, 83). It has also been pro-
posed, on the basis of new data, that 4-vinylphenol and its metabolites are more 
important than SO in the appearance of lung cancer (38, 39, 167). CYP2F2, the 
enzyme that has been most strongly associated to formation of 4-vinylphenol,  
has lower activity in lungs of humans and rats than in lungs of mice (17, 58). 
Remarkably high concentrations of styrene and SO are needed to cause DNA 
strand breaks/genotoxicity under in vitro conditions. There also seems to be a 
considerable difference in sensitivity to chromosome damage, including micro-
nuclei, between occupationally exposed people and the animal species exposed  
in laboratories. In humans, micronuclei have been identified in lymphocytes at 
exposure levels of about 20 ppm and lower. In animal experiments, on the other 
hand, only a few studies have reported elevated levels of micronuclei and then at 
exposures above 300 ppm. In animal exposures, however, microneuclei in bone 
marrow have been studied rather than micronuclei in peripheral lymphocytes. This 
may partially explain why experimental animals seem to be less sensitive. 
The well-made genotoxicity studies of occupationally exposed humans made in 
the past few years should be given greater weight than the earlier studies on which 
the IARC based its assessments (70, 71). More refined methods of detecting 
exposure markers and biomarkers for genotoxicity have been used in the newer 
studies, and clear correlations between genotoxic effects and various exposure 
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markers have been shown. It has also been clearly shown that gender and age are 
factors having a large effect on biomarkers for genotoxicity, and the recent studies 
that include larger numbers of subjects have had better control over these con-
founding factors. 
Effects on reproduction 
There are only a few studies of styrene's toxic effects on reproductive function, 
and most of them do not meet present standards. A Dutch hazard evaluation (64) 
of human and animal studies of styrene published in 1966 – 1999 found no sup-
port for classification and labeling of styrene with regard to effects on fertility, 
developmental toxicity, or effects during lactation. However, the committee 
strongly emphasized that several of the assessed human studies give reason to fear 
toxic effects on reproduction even though it is not clear in these studies whether 
exposure was to pure styrene or to a mixture of solvents including styrene (64). 
Studies published since this assessment are reviewed below under Human data 
and Animal data. 
Human data 
From 1560 Danish, Italian and Dutch men who worked or had worked with 
fiberglass-reinforced plastic were chosen 220 styrene-exposed and 382 unex- 
posed (at time of conception) men who already had at least one child. The men 
were divided into four groups (high, medium, low and no exposure) on the basis 
of exposure estimates derived from historical styrene measurements and styrene 
metabolites in urine. Fertility was estimated by reported time to conception. A  
not-significant reduction in fertility was seen in the exposed men (fertility ratio 
0.79; 95% CI: 0.59 – 1.05), but there was no observed reduction with increasing 
estimated exposure. The men with the highest exposure had a fertility ratio of 1.09 
(95% CI: 0.69 – 1.72). The authors concluded that styrene exposure probably has 
little effect on male fertility (90).  
Luderer et al. (100) examined correlations between prolactin levels in serum 
and occupational exposure to styrene in 259 men and 43 women. The subjects 
were recruited from 17 companies in the plastics industry. Exposure, styrene  
in blood and prolactin in serum were measured on 1 to 3 occasions about a year 
apart. On each sampling day, the subject was interviewed and observed working 
and the blood samples were taken at the end of the workshift. The exposure 
measurements, made with personal monitors, covered an entire workshift (8 
hours) and were made 1 to 5 times (average 3) during the month the samples  
were taken (median exposure 9 ppm, range <1 – 142 ppm). Adjustments were 
made for a number of confounding factors, including gender, age, smoking habits, 
use of alcohol and other drugs, acetone exposure and use of protective equipment. 
Styrene in blood was more closely correlated to prolactin levels in serum than to 
styrene levels in air. Persons with exposures above 20 ppm were more likely (OR 
= 3.69; 95% CI: 1.39 – 9.97) to have an elevated prolactin level in serum (above 
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the reference values of 15 ng/ml for men and 20 ng/ml for women) than persons 
with lower exposure. Modeling was used to calculate prolactin levels as a function 
of acute, subacute or chronic air or blood levels of styrene with linear multiple 
regression analysis. The correlation to elevated prolactin levels was significant in 
the acute exposure model, but not in the sub-chronic or chronic model. According 
to the authors, their results confirm that styrene exposure elevates prolactin levels 
in serum and provide support for regarding this as an acute effect (100). This study 
confirms earlier studies reporting that prolactin levels in serum of both men and 
women occupationally exposed to styrene were higher than in unexposed controls 
(4, 9, 10, 114). The clinical relevance of elevated prolactin levels as a response to 
styrene exposure is not clear. 
Cho et al. (28) examined the occurrence of oligomenorrhea (defined as a 
menstrual cycle longer than 35 days, including amenorrhea) during the previous 
year among women exposed to solvents (benzene, toluene, xylene and styrene)  
in the petrochemical industry. The women were recruited from a government 
industrial area in China via their applications for permission to marry or become 
pregnant. Data were collected for 1408 women. A qualitative occupational 
hygiene estimate of solvent exposure was made for workplaces and jobs, i.e. 
whether exposure to benzene, toluene, xylene and/or styrene occurred or not. 
Averages were reported to be low for benzene: 0.017 ppm (rubber industry) to 
0.191 ppm (chemical industry). Average levels of toluene, xylene and styrene 
were reported to be below 1 ppm. A total of 440 women were judged to have  
been exposed to one or more solvents, and 276 exposed to styrene (3 to styrene 
only). Oligomenorrhea was reported on a questionnaire by 8.5% of the unexposed 
women, 12.7% of women exposed to one or more solvents, and 14.5% of women 
whose exposure included styrene. After adjustment for factors including age,  
body mass index (BMI), passive smoking and exposure to other chemicals, the 
odds ratio was 1.34 (95% CI: 0.90 – 1.99) for exposure to one or more solvents 
and 1.65 (95% CI: 1.05 – 2.55) for exposure that included styrene. The authors 
concluded that exposure to solvents is associated with a trend toward greater 
frequency of oligomenorrhea (28).  
Animal data 
In a two-generation reproduction study (40) rats (25 animals of each sex per 
exposure group) were exposed by inhalation to styrene concentrations of 0,  
50, 150 or 500 ppm, 6 hours/day for at least 70 days prior to mating (F0 and F1 
generations), and exposure of the females was continued throughout gestation  
and from day 5 of lactation. On the first 4 days of the lactation period the mothers 
were given by gavage 66, 117 or 300 mg styrene/kg b.w./day, divided into 3 equal 
doses 2 hours apart. Indications of systemic toxicity prior to mating, in the form  
of lower body weights compared to the control group, were seen in F0 males and 
females in the 500 ppm group and in the F1 generation in the 500 and 150 ppm 
groups (but not significant for females at 150 ppm). Body weights during gestation 
were significantly lower only in females in the F1 generation in the 500 ppm 
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group. No effects were observed in either the F0 or F1 generation on mating  
and fertility index for males or females, pre-coital interval, spermatogenesis, 
reproductive organ weights, estrous cycle, length of gestation, litter size and sex 
ratio, and postnatal survival. Further, the numbers of ovarian follicles and corpora 
lutea in the F1 generation in the 500 ppm group were the same as in controls. The 
authors give a no observed adverse effect level (NOAEL) of 50 ppm for systemic 
toxicity to the parents and 500 ppm or more for effects on reproductive ability 
(40). Pups (F2) born to the F1 generation in the 150 and 500 ppm groups had lower 
body weights 21 days after birth (not significant for females at 150 ppm). At the 
higher exposure the lower body weights persisted (not significant) until 70 days 
after birth and a slight retardation in physical development was noted. Pups in  
the high-dose group had poorer swimming ability on day 24 after birth, and grip 
strength was reduced in both sexes on days 45 and 60 after birth. No effects were 
seen in the acoustic startle response, learning and memory tests, motor activity, 
brain morphology and histology, or brain weight. No exposure-related effects  
were seen in the 50 ppm group, and no indications of teratogenicity were seen  
in any of the exposed groups. The authors give a NOAEL of 50 ppm for growth 
and 500 ppm for neurological development in the F2 generation (40, 41). 
Rats (10 – 14 per group) were exposed to 0 (controls), 50 or 300 ppm styrene 
for 6 hours/day on days 6 – 20 of gestation (82). No significant differences in 
weight gain were seen in the mothers during the exposure period, although a 
significant reduction (about 20%) of feed intake was seen in the group exposed to 
300 ppm. An extra control group was introduced with a corresponding reduction 
in feed availability (pair-fed control) and the same feed restriction was made for 
the group exposed to 50 ppm. No significant effects were observed in the group 
exposed to 50 ppm when they were compared with the pair-fed controls. In the 
group exposed to 300 ppm there was a significant increase in neonatal mortality, 
and 21 days after birth the male pups had lower body weights than pair-fed con-
trols. There were also delays in eye opening, tooth eruption and development of 
the air righting reflex. 
In a study with rats, hormone-disturbing effects of styrene, styrene dimer  
and styrene trimer were examined in vivo and in vitro (43). In vitro there was  
no observed binding of any of these substances to receptors for estrogen, androgen 
or thyroxin (tested up to 10 µM). In vivo there was no observed effect on uterus 
weight in either sexually immature (n = 5) or ovariectomized (n = 5) female rats 
after subcutaneous injection of up to 200 mg/kg b.w./day for 3 days. Nor was  
there any anti-androgenic effect seen in testosterone-treated, castrated, sexually 
immature male rats (n = 5) given up to 200 mg/kg b.w./day by gavage for 7 days. 
Subcutaneous injections of 20 mg/kg b.w./day given to ovariectomized rats for  
3 days had no effect on prolactin levels in blood.  
Male rats (10 animals/group) were exposed to 0 (controls), 150, 500 or 1500 
ppm styrene 6 hours/day for 5 days. When compared with controls, exposed rats 
showed no significant effect on prolactin or dopamine levels in serum or on the 
levels of catecholamines and their metabolites in striatum or hypothalamus in  
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the brain, at any dose level. No difference was seen if the rats were given a day to 
recover after the exposure. According to the authors, these negative results suggest 
that styrene probably has no neuroendocrine effects on humans (75). In male rats 
(10 animals/group) exposed on the same schedule there was a small but significant 
increase of luteinizing hormone (LH) in serum from the two highest exposure 
groups immediately after the exposure (76). Another study (152) reports a small 
but significant increase of prolactin in plasma of female rats, but not male rats, ex- 
posed to 150 ppm styrene (8 animals/group) 8 hours/day, 5 days/week for 2 weeks. 
The female rats had about twice as much styrene in their blood as the males. 
Dose-effect/dose-response relationships 
Several studies (8, 77, 149) report effects on psychological performance tests after 
less than 10 years of occupational exposure to styrene levels of 20 – 30 ppm. 
In two studies (57, 87), effects on color vision were shown at exposure levels 
around 10 ppm, and three other studies (46, 52, 53) showed effects on color vision 
at exposures of 20 ppm or lower. In three of these five studies, subjects had been 
exposed for six to seven years.  
Some studies have shown effects on hearing at low styrene levels, even when 
noise levels are factored in. In one study, hearing loss was noted at air levels of  
18 ppm (career average), 3.8 ppm (current air levels) and a level of MA in urine 
corresponding to an air level of >9 ppm. Only age, current noise exposure and MA 
in urine had a significant effect on hearing in the final multiple logistic regression 
analysis (112). Another study reports an odds ratio of 3.9 (95% CI: 2.4 – 6.2) for 
hearing loss with styrene exposure, after adjustment for age, sex, and current and 
previous noise exposure, and also a significant positive linear correlation between 
average career exposure to styrene (14.5 ± 12.2 ppm, range 0.8 – 72.5 ppm) and 
elevated hearing thresholds at 6 and 8 kHz (141, 142). A conference proceedings 
contains a report of significantly higher hearing thresholds in a small group ex-
posed to about 7.5 ppm styrene (calculated from MA+PGA in urine) than in  
a control group (106). Deriving an effect level for hearing damage caused by 
styrene from the information in these studies is problematic, since there are large 
uncertainties in estimates of previous exposure levels for both styrene and noise, 
and the occurrence and effect of exposure peaks and impulse sound are unclear. 
Considered together, however, the studies indicate an effect level of about 10 
ppm. Performance on balance tests is affected at higher levels (19, 146). 
In the IARC evaluation published in 2002, the evidence for mutagenic effects in 
people occupationally exposed to styrene was judged to be weak. Well designed 
and well made studies published since then contain analyses of chromosome 
damage in large groups of exposed subjects, and have now shown that exposure-
related chromosome damage occurs in people occupationally exposed to styrene. 
Both chromosome aberrations and micronuclei in peripheral lymphocytes have 
been reported. At an exposure level of 8.7 ± 0.9 ppm, Migliore et al. (111) 
reported significant correlations between chromosome aberrations and levels  
of styrene in air and 4-vinylphenol in urine of 45 Italian laminators. There was 
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also a significant correlation between micronuclei in lymphocytes and level of  
4-vinylphenol in urine. Significantly elevated levels of micronuclei were observed 
in two other studies at average exposure levels of 9.5 ppm (55) and 16.8, 17.5 and 
19.3 ppm (data from three monitoring sessions) (92). 
Electrophilic effects on macromolecules, in the form of hemoglobin adducts, 
DNA adducts and DNA strand breaks, have been reported at occupational expo-
sure to styrene levels below 20 ppm (55, 92, 155). 
Styrene causes lung cancer in mice. Benign lung tumors have been reported in 
mice after exposures as low as 20 to 40 ppm, and malignant tumors at 160 ppm 
(37). 
The differences between rats, mice and humans with regard to measured and 
simulated levels of SO, sensitivity to glutathione depletion, and metabolic capacity 
in the lungs indicate that people are considerably less sensitive than mice to dam-
age to pulmonary epithelium. 
With occupational exposure to styrene levels above 20 ppm there was a sig-
nificantly greater risk for elevated prolactin levels in serum (100). The clinical 
significance of this is not clear, however. In a multi-generation study with rats, 
exposure to 150 ppm resulted in lower body weights prior to weaning in the F2 
generation. No effects were seen at 50 ppm (40, 41). At 150 ppm there was some 
maternal (F1) toxicity in the form of a not significant weight loss prior to mating. 
Conclusions 
The critical effects of occupational exposure to styrene are genotoxicity, hearing 
loss and effects on color vision. Styrene is probably genotoxic to humans and 
possibly also carcinogenic. Genotoxic effects have been observed at occupational 
exposures down to about 10 ppm. Effects on color perception have also been 
documented at occupational exposures around 10 ppm, and hearing loss is 
presumed to occur at approximately the same levels. 
Skin exposure to styrene in liquid form can result in significant uptake. 
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Appendix 1  
Abbreviations 
ALAT Alanine aminotransferase 
ALP Alkaline phosphatase 
ASAT Aspartate aminotransferase 
ATSDR  Agency for Toxic Substances and Disease Registry 
BAT-value Biological tolerance value 
CC16 Clara cell protein 
CI Confidence interval 
CYP Cytochrome P450 
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals 
GSD Geometric standard deviation 
GSH Glutathione 
GST Glutathione transferase  
HCRA  Howard Center for Risk Analysis 
IARC International Agency for Research on Cancer 
IHD Ischemic heart disease  
LDH Lactate dehydrogenase 
M1  N-acetyl-S-(1-phenyl-2-hydroxyethyl)-L-cysteine 
M2 N-acetyl-S-(2-phenyl-2-hydroxyethyl)-L-cysteine 
MA Mandelic acid 
PGA Phenylglyoxylic acid  
SD Standard deviation 
SMR Standardized Mortality Ratio 
SO Styrene 7,8-oxide 
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Consensus Report for Sulfuric, 
Hydrochloric, Nitric and Phosphoric Acid 
June 3, 2009 
This Consensus Report is based primarily on the Criteria Document compiled by 
the Nordic Expert Group (NEG) (85). A final literature search of PubMed and 
Toxline was made on October 29, 2008. 
Chemical and physical data. Occurrence 
Identification, 
description 
Sulfuric acid Hydrochloric acid Nitric acid Phosphoric acid 
CAS No.: 7664-93-9 7647-01-0 7697-37-2 7664-38-2 
Synonyms: dihydrogen 
sulfate 
hydrogen chloride 
(liquid), 
chlorohydric acid 
hydrogen 
nitrate, nitroso 
nitric acid 
orthophosphoric 
acid 
Formula: H2SO4 HCl HNO3 H3PO4 
Mol weight: 98.08 36.46 63.02 98.00 
Boiling point (°C): 338 (98%)a 110 (20%) 
- 85 (gas) 
121 (70%) 
86 (100%)b 
158 (85%) 
Melting point (°C):  10 (100%) - 85 (25%) 
- 114 (gas) 
- 42 (70%) 26 (100%) 
Density (g/ml):  1.84 (100%) 1.19 (38%) 1.41 (70%) 1.71 (85%) 
1.86 (100%) 
pKa: - 3.0; 1.99 - 8.0 - 1.3 2.12; 7.21; 
12.32 
Distribution coefficientc : - 2.20 0.54 0.21 - 0.77 
Odor threshold (mg/m3): > 1 1 – 50 0.75 – 2.50 Odorless 
Conversion factors: 
   (25 °C, 101.3 kPa) 
    
 
   1 mg/m3 = 0.25 ppm 0.7 ppm 0.4 ppm 0.25 ppm 
   1 ppm = 4.0 mg/m3 1.4 mg/m3 2.5 mg/m3 4.1 mg/m3 
a
 Percent by weight in aqueous solution. 
b Disintegrates. 
c
 Octanol/water (log Pow), estimated values. 
 
 
Sulfuric acid, hydrochloric acid and nitric acid are strong acids that dissociate 
completely in water at low to moderate concentrations; phosphoric acid is weaker. 
All four of these acids are hygroscopic (attract water) and corrosive. Nitric acid 
and relatively concentrated sulfuric acid are also oxidizing. 
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Aqueous solutions of these acids are not flammable per se, but on contact with 
metals may release highly flammable and explosive hydrogen gas (for nitric acid, 
on contact with only a few metals). 
All four acids are important industrial chemicals with broad areas of use, e.g.  
in production of chemicals, fertilizers, and paper pulp; for surface treatment of 
metals; and as pH regulators. Sulfuric acid is also used in batteries and as a drying 
agent, hydrochloric acid as a disinfectant, and nitric acid in the production of 
explosives. 
Sulfuric acid was previously used in Sweden for pickling steel (cleaning prior  
to electroplating), but in the late 1980s and early 1990s this use was almost 
completely phased out in favor of hydrochloric acid or – with production of 
stainless steel – hydrofluoric acid, either alone or mixed with nitric acid (personal 
communication, Cecilia Andersson, Swedish Industrial and Chemical Employers 
Association.  
Sulfuric acid and phosphoric acid, which are less volatile than the other two 
acids, occur in workplace air primarily as aerosols, whereas hydrochloric acid and 
nitric acid occur more often as vapors. Various types of sorbent tubes and filter 
cassettes are used for sampling. Analysis is usually made with ion chromatog-
raphy, but the presence of the acid’s salts may cause some interference. Analysis 
of sulfuric acid is subject to interference from sulfur dioxide, sulfites and organic 
sulfur compounds as well; moreover, different analysis methods have often led  
to considerable differences in measured concentrations (14, 36, 37).  
The most sensitive analysis methods for sulfuric acid have detection limits of 
0.003 and 0.01 mg/m3 with 8 hours of sampling time (69). 
According to the CAREX database, in 1990 – 1993 about 7,900 persons in 
Sweden were exposed to “aerosols of strong inorganic acids containing sulfuric 
acid” (16).  
Sulfuric acid 
Sulfuric acid is a colorless (if pure) to dark brown, oily liquid. It is odorless unless 
heated, when it releases pungent fumes. It produces heat on reaction with water. 
On reaction with many organic substances the main residue is carbon. 
Concentrated sulfuric acid is 96 – 98% (by weight, 18 M), and battery acid is 
33.5%. “Fuming” sulfuric acid, also called oleum, is a solution of sulfur trioxide 
in anhydrous sulfuric acid. 
Production of concentrated sulfuric acid is a closed process until discharging, 
when some exposure may occur. Few exposure measurements have been made 
during this stage of the process, however. The most recent measurements with 
personal monitors are from 2007 and showed levels below 0.04 mg/m3, which  
is near the detection limit. On this occasion the charge was somewhat lower  
than usual. In production of copper, the temperature in the electrolysis bath is  
67 – 68 °C and the content of sulfuric acid is 17.5%. Exposure occurs primarily 
when the electrolyte tanks are being emptied (personal communication, Cecilia 
Andersson, Swedish Industrial and Chemical Employers Association. 
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Exposure measurements (n = 134) made in Norway in the 2000 – 2006 period 
showed average levels of 0.003 – 0.14 mg/m3 in most industries: levels were 
higher with production of iron, steel and iron alloys, where the average level for  
3 measurements was 3.5 mg/m3 and the highest value was 10.2 mg/m3 (85). 
Further information on occupational exposure levels is contained in the Nordic 
Criteria Document (85). 
Hydrochloric acid 
The term “hydrochloric acid” refers to an aqueous solution of hydrogen  
chloride gas. This acid, which is colorless and has a sharp odor, is produced in 
concentrations up to about 38% (by weight, 12 M). A mixture of concentrated 
hydrochloric acid and a strong oxidant, e.g. a 3:1 mixture of concentrated 
hydrochloric acid and nitric acid (aqua regia), dissolves gold. 
Exposure measurements (n = 33) made during 2000 – 2006 in various industries 
in Norway showed average levels of 0.0033 – 0.23 mg/m3, with the highest level 
(1.1 mg/m3) in science/technology research and development (85). In a Dutch 
study published in 1982, it was estimated that workers at a zinc galvanizing plant 
(pickling) were exposed to air levels above 7 mg/m3 for 27% of the time (64). 
Nitric acid 
Pure nitric acid is a clear liquid with a characteristic suffocating odor, and in damp 
air it becomes a white, fuming liquid. Nitric acid is difficult to produce in pure 
form, since it readily decomposes into water, nitrous oxides and oxygen. Vapors 
of nitric acid are therefore always a mixture of the acid and its decomposition 
products. Nitrogen dioxide colors the liquid yellow, shading to red as the 
concentration rises. 
Concentrated nitric acid is about 70% (by weight, 16 M). White fuming nitric 
acid is extremely concentrated, usually >90%, and contains very little nitrogen 
dioxide (0.1 – 0.4%). Red fuming nitric acid contains more nitrogen dioxide. 
Concentrated nitric acid is a strong oxidizer that reacts, often explosively,  
with combustible, organic and easily oxidized materials. 
Exposure data are sparse. Measurements (n = 36) made in various industries  
in Norway in 2000 – 2006 showed average levels of 0.013 – 0.061 mg/m3. The 
highest measured value was 0.17 mg/m3 (85). Individual air levels compiled by 
the IARC, dating mostly from 1975 – 1983, were in the range 0.01 – 2.8 mg/m3 
(38). 
Phosphoric acid 
“Phosphoric acid” in this document refers to aqueous solutions of the pure acid, 
which is a solid substance at room temperature and normal atmospheric pressure. 
An 85% aqueous solution of phosphoric acid is a clear, viscous liquid with neither 
color nor odor. 
93 
Exposure measurements (n = 13) made in various industries in Norway in  
2000 – 2006 showed average levels of 0.0003 – 0.74 mg/m3. The few measure-
ments compiled by the IARC were below 0.67 mg/m3 (38). 
Uptake, distribution, biotransformation, excretion 
This section is based on the Nordic Criteria Document (85). Because of their high 
affinity for water, vapors of hydrochloric acid or nitric acid can be transformed to 
aerosols in the damp air of the respiratory passages. Aerosols of the four acids are 
deposited in the respiratory passages as droplets. 
The droplet size of an acid aerosol is usually the factor that determines where  
in the respiratory passages it is deposited, but respiratory rate and way of breathing 
are also relevant. The particle size of an aerosol is usually given as the diameter of 
the spherical particle representing the median in the aerosol. The median is based 
either on the mass of the particle (Mass Median Diameter, MMD) or on the mass 
of a particle with the density of 1 which has the same sedimentation rate in air as 
the particle in question (Mass Median Aerodynamic Diameter, MMAD). The 
median can also be based on the volume (Volume Median Diameter, VMD). 
Inert particles with an aerodynamic diameter of 5 – 30 µm are deposited mostly 
in the nose and throat (nasopharynx) by impaction. Smaller particles sediment in 
the tracheobronchial region (1 – 5 µm) or are deposited by diffusion in the alveoli 
(<1 µm). 
Hygroscopic droplets attract water and increase in size on their way through  
the respiratory passages. The growth of sulfuric acid droplets tends to increase 
retention in the respiratory passages, compared to inert particles of the same  
size as either the original or the enlarged acid droplets. Sulfuric acid aerosols  
are deposited mostly in the upper respiratory passages. An important area of 
deposition is the larynx. 
Nitric acid vapor is generally deposited in the upper respiratory passages 
because of its high solubility in water and high reactivity. If other particles  
act as vectors, however, the vapor can reach the lower respiratory passages. 
Inhaled acid aerosols are neutralized in the upper respiratory passages by  
the body’s own ammonia in the mouth cavity.  
The acids are protolyzed, but unless exposure is extremely high the contribution 
of the protons and anions to the body’s total pool is negligible. Locally, however, 
the concentrations of protons and anions can be high. 
There are no data on skin uptake, but the polarity indicates that absorption via 
intact skin should be low. 
Toxic effects 
The inhalation toxicity of the four acids seems to be mostly due to the protons 
liberated by their dissociation. Low pH is believed to be an important factor in  
the development of tooth erosion, for example. As mentioned previously, nitric 
acid and relatively concentrated sulfuric acid are oxidizing. All four acids are 
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classified as corrosive in the European legislation on classification and labeling: 
hydrochloric acid and phosphoric acid in solutions of 25% or higher, sulfuric  
acid 15% or higher, and nitric acid as low as 5% (lower limits for classification). 
Severe reactions, with chemical burns that may cause sores, blindness and even 
death, are described after contact with skin, eyes and mucous membranes. Acute 
pulmonary edema has been reported after inhalation of high concentrations, as 
well as potentially fatal “acute respiratory distress syndrome” (ARDS) and chronic 
“reactive airways dysfunction syndrome” (RADS). Repeated or prolonged skin 
exposure to dilute solutions can cause contact eczema (85). 
There are no reports of sensitization after exposure to any of these acids (85). 
Because of the pronounced dehydrating ability of sulfuric acid and the heat 
produced on its reaction with water, sulfuric acid causes more tissue damage  
than might be expected from the strength of the acid (85). 
The published LC50 values in mmol/m3 (mg/m3) are 0.2 – 5.2 (18 – 510) for 
sulfuric acid, 2.1 – 4.1 (130 – 260) for nitric acid, >8.7 (>850) for phosphoric  
acid and 21 – 329 (780 – 12,000) for hydrochloric acid (85). 
Aside from the cancer studies (see below under Carcinogenicity), there are only 
a few studies reporting effects of long-term occupational exposure to these acids. 
Most of the reports are about erosion damage to teeth (85). A survey article con-
cludes (on the basis of prevalence studies with control groups) that workers 
occupied in the battery industry and with galvanizing/pickling, and who were 
exposed to sulfuric acid or hydrochloric acid, and to a lesser degree to phosphoric 
acid, nitric acid and hydrogen fluoride, had an elevated risk of tooth erosion. 
There was considerable variation in prevalence for both exposed subjects and 
controls, however: 26 – 100% vs. 0 – 80% (86). The prevalence of tooth erosion 
varies with age, diet and eating habits, and is not particularly well known in the 
general population. A survey article reports prevalence figures of 4 – 82% for 
adults aged 18 to 88 (41). 
The toxicological literature for each of these acids is summarized in the follow-
ing sections. More detailed descriptions of individual studies and information on 
effects at higher exposure levels are presented in the Nordic Expert Group’s 
Criteria Document (85). 
Sulfuric acid: Experimental studies with human subjects 
Several studies have been made with volunteers, both healthy and asthmatic.  
The studies differ with regard to exposure method (chamber, mouthpieces or  
nasal masks), exposure levels (0.01 – 3 mg/m3), droplet size (0.1 – 10 µm MD), 
relative humidity (<10 – 100%), exposure time (10 minutes – 6.5 hours), degree  
of physical activity, and control of levels of endogenous ammonia in the mouth 
cavity. The subjects served as their own controls. The control conditions were 
usually pure air or an aerosol of a physiological saline solution. Some of these 
studies are described below. The results from combined exposures are included 
only in exceptional cases. 
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Lung function: Mucociliary clearance and other pulmonary defense mechanisms 
The effect of sulfuric acid aerosols on mucociliary clearance has been examined  
in several studies. In the usual experimental design, the subjects inhaled a radio-
actively labeled inert aerosol (e.g. 99mTc-labeled Fe2O3 or 85Sr-labeled latex 
particles) for a few minutes prior to their exposure to the sulfuric acid. The 
emitted γ-radiation was then monitored with a series of measurements made  
over a number of hours, sometimes with a final measurement 24 hours after the 
exposure. In several studies, an effect on bronchial mucociliary clearance (either 
stimulation or inhibition ) was seen in healthy volunteers after 1 hour of exposure 
to 0.1 – 0.47 mg/m3 or 1 mg/m3 (48 – 50, 60, 74, 75). An effect at 0.1 mg/m3 was 
demonstrated in three studies (49, 50, 75). An effect on tracheal mucociliary 
clearance in healthy volunteers was shown in only one study with exposure to 
larger droplets (MMAD 10.3 µm) at 0.47 mg/m3 (48). The mechanism behind  
the effect on mucociliary clearance is not clear, but changes in pH and viscosity, 
for example, have been shown and may be relevant (84). 
The effect on clearance can be either stimulating or inhibiting, and seems to 
depend on the acid concentration and the size of both the sulfuric acid droplets 
and the inert test particles that the clearance is calculated from. The proposed 
explanation for the apparently contradictory effects attributes them to differences 
in dosimetry; i.e. that short-term exposures to low concentrations have a stimu-
lating effect, whereas high exposure or prolonged exposure to low levels can 
damage the epithelium and inhibit clearance. 
Accordingly, in a study with 10 healthy volunteers, bronchial clearance of iron 
oxide particles (MMAD 7.5 µm) was faster after 1 hour of exposure to 0.1 mg/m3 
(MMAD 0.5 µm) than after the control exposure. With exposure to 0.3 mg/m3 the 
responses of the subjects ranged from marked acceleration to marked retardation, 
and at 1 mg/m3 clearance was reduced (49). In a follow-up study with the same 
experimental design (8 subjects), but with smaller iron oxide particles (MMAD 
4.2 µm), clearance was reduced after all exposures. The authors’ explanation for 
this was that the deposition pattern of the smaller iron oxide particles more closely 
resembles that of the acid (50). In another study, reduced clearance (iron oxide, 
MMAD 5.2 µm) was observed in healthy subjects (n = 10) after exposure to  
0.1 mg/m3 (MMAD 0.5 µm) for 1 or 2 hours (75). 
Reduced superoxide anion production and reduced adhesion ability were seen 
ex vivo in pulmonary macrophages from bronchoalveolar lavage of 12 healthy 
subjects after exposure to 1 mg/m3 (MMAD 0.9 µm) for 3 hours. There was no 
observed effect on viability or phagocytosis (89). In another study with similar 
design and exposure level, there were no observed effects on function of alveolar 
macrophages or antimicrobial defense and no indications of inflammation in 
bronchoalveolar lavage fluid (26). 
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Lung function: other effects 
Hyperreactivity in respiratory passages after provocation with carbachol was 
demonstrated in 14 healthy subjects after 16 minutes of exposure to 1 mg sulfuric 
acid/m3 (MMAD 0.6 – 1 µm). The subjects inhaled carbachol (1%) with or with-
out previous exposure (16 minutes) to sulfuric acid or to a saline aerosol (1%). 
Lung function was measured both before and after exposure. After the exposure  
to sulfuric acid, specific airway conductance was reduced by about 24% (read 
from the figure), compared with about 9 – 10% after inhalation of carbachol alone 
as well as after inhalation of the saline aerosol followed by the carbachol. Maxi-
mum expiratory flow at 60% of total lung capacity was also lower (p <0.05) after 
exposure to the sulfuric acid than it was after the other exposures. The effect was 
not seen after exposure to 0.1 mg/m3 sulfuric acid (82). In other studies, single 
exposures to sulfuric acid in concentrations of 0.1 – 0.47 mg/m3 and 1 – 2 mg/m3 
had no effect on lung function of healthy volunteers (3, 7 – 9, 26, 48 – 51, 66, 74, 
75, 80). However, some studies (described below) indicate that asthmatics and 
perhaps especially young people are more sensitive. A small (reversible) but 
significant reduction in FEV1 (forced expiratory volume during one second) was 
seen in 14 young asthmatics (aged 13 – 18) after 45 minutes of exposure to 0.035 
mg/m3 (MMAD 0.6 µm) compared with the change after exposure to air. A ten-
dency to lower FEV1 was also observed after exposure to 0.07 mg/m3 for the same 
amount of time, but the effect was not observed after 90 minutes of exposure at 
these levels (46). In another study by the same research team, small (reversible) 
but significant reductions are reported in FEV1, total respiratory resistance and 
forced expiratory flow at 50% of forced vital capacity (FEF50) in 10 young asth-
matics (aged 12 – 17) exposed for 40 minutes to 0.1 mg/m3 (MD 0.6 µm) (45). 
Adult asthmatics had poorer lung function (lower FEV1) after exposure during 
exercise to 0.35 mg/m3 (MMAD 0.8 µm) sulfuric acid in combination with low 
levels of ammonia in the mouth (obtained by gargling with a lemon concentrate 
and impedes neutralization of the acid) (83). The same research team also reported 
increased bronchoconstriction (reduced specific airway conductance) and bron-
chial hyperreactivity on provocation with carbachol in adult asthmatics after 16 
minutes of exposure during rest to 0.45 mg/m3. Exposure to 1 mg/m3 (MMAD  
0.6 – 1 µm) caused reduction in FEV1 as well (81, 82). Other studies report no 
observed effect on lung function of adult asthmatics exposed to up to 1 mg/m3  
or higher (4, 66, 80). 
 
Symptoms 
Single exposures to 0.1 – 0.47 mg/m3 (MMAD 0.1 – 10 µm) had no effect on 
subjective symptom assessments made by healthy volunteers (3, 7, 8, 26, 45, 48, 
51, 80). However, a dose-dependent increase was seen in subjective assessments 
of respiratory symptoms made after one hour of exposure to larger droplets (VMD 
10 µm) at 0.5 – 1.5 mg/m3 (9), although exposure to smaller droplets (MMAD 0.9 
µm) at 1 – 1.5 mg/m3 had no effect on the subjective symptom assessments (8). 
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In the above study, asthmatics reported no increase in symptoms at 0.5 mg/m3 
(large droplets, VMD 10 µm), but reported an increase at exposure to 1 mg/m3 
(MD 0.9 and 10 µm) (8, 9).  
Other studies with healthy and asthmatic subjects report no effects at 2 –  
3 mg/m3 (4, 80). 
Sulfuric acid: Studies of occupationally exposed subjects 
Exposures are poorly described in the epidemiological studies. Further, the 
measurements are of questionable validity since results vary with sampling 
method and are subject to interference from the presence of both inorganic and 
organic sulfur compounds. Information on droplet size in industrial aerosols is 
usually lacking, but the median diameter (MD) can be up to 14 µm. In a study 
made at five lead acid battery plants the MD ranged from 2.6 to 10 µm (43). 
A conference proceedings from Australia reports irritation of eyes and respire-
tory passages in workers exposed to 0.1 – 0.5 mg/m3. Significant differences were 
seen in symptom reports (self-administered questionnaires) when workers exposed 
to levels up to 0.15 mg/m3 (n = 37) were compared to a group exposed to 0.15 – 
0.50 mg/m3 (n = 45). One or more symptoms were reported by 54% and 93%  
in the two exposed groups, compared to 25% of controls. The symptoms most 
commonly reported by all the workers were sneezing, coughing, nasal irritation 
and runny noses. Workers below the age of 40 reported more symptoms than  
older workers (25). 
A cross-sectional study of 225 workers at five battery plants reports that acute 
work-related symptoms involving e.g. skin, eyes or respiratory passages were  
no more common in the group with highest exposure (above 0.3 mg/m3) than in 
the group with lowest exposure (below 0.07 mg/m3). Changes in lung function 
during the day showed no correlation to air levels of sulfuric acid (27). The same 
population (n = 248) was also examined for effects of long-term exposure. No 
correlation between respiratory symptoms (cough, mucus, breathlessness, wheez-
ing) and exposure to sulfuric acid was observed. However, forced vital capacity 
(FVC) was lower in the group with cumulative exposures above 15 mg/m3 x 
months (average 0.21 mg/m3) than in a group with cumulative exposures below  
7 mg/m3 x months (average 0.10 mg/m3). Tooth erosion was observed in 38% of 
the workers in the group with highest exposure, compared to 8% in the group with 
lowest exposure (p<0.005 after correction for age and smoking). The earliest cases 
of “etching” and tooth erosion were seen after 4 and 30 months, respectively, of 
exposure to an average level of 0.23 mg/m3 (28). Other studies have also 
mentioned tooth erosion after high or unknown exposures (85).  
Nasal symptoms and changes in the cells of nasal mucosa were examined in  
52 workers (in 5 factories) with an average exposure time of 6 years. Five days  
of measurements with stationary monitors showed average air levels of 0.035 – 
2.1 mg/m3. Pale areas and sores were seen only in workers with exposures above 
0.2 mg/m3. Histopathological examination of nasal mucosa revealed that changes 
such as squamous cell metaplasia, squamous atypia and slight dysplasia were 
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more common among exposed workers than among controls (29). This study has 
shortcomings in both design and reporting (description of the control group, data 
processing, statistical analysis etc.). 
 
Sulfuric acid: Animal studies 
In general, the results of animal studies support the results of the human studies. 
Irritation and effects on lung function and pulmonary defense mechanisms (clear-
ance, phagocytosis, production or release of superoxide anions, hydrogen peroxide 
and mediators such as TNFα). The effects on lungs appear at about the same ex-
posure levels in animals as in humans. Changes in cells of the respiratory epithe-
lium (hyperplasia) have been reported after repeated exposure to 0.125 mg/m3 
(rabbits) and 0.38 mg/m3 (monkeys) (85).  
Proliferative changes were observed in cells in rat larynx after exposure to  
1.38 and 5.52 mg/m3 for 5 or 28 days. At 0.3 mg/m3, minimal squamous cell 
metaplasia was observed in the larynx after 28 days. No histopathological changes 
related to sulfuric acid were observed in lungs or nose at any of the exposures 
(44). The response to 0.3 mg/m3 can be regarded as adaptive, and implies that  
with prolonged exposure there is a risk of cell changes in respiratory epithelium.  
Hydrochloric acid 
Ten asthmatics (aged 18 to 25) showed no more airway irritation, effect on  
lung function, fatigue, headache or dizziness after 45 minutes of exposure via 
half-face mask to 1.1 or 2.5 mg/m3 than they did after exposure to air alone (78). 
The authors also compiled information from older human studies and case reports, 
which indicated that the odor threshold for hydrochloric acid is in the interval 1.5 
– 7.5 mg/m3; that work can be done unhindered at 15 mg/m3, is difficult at 15 –  
75 mg/m3, and unbearable at 75 – 150 mg/m3; and that 1,950 – 3,000 mg/m3  
are lethal concentrations (78). 
Workers (number not given) in a steel pickling plant showed no evidence of 
mucous membrane irritation at 3 – 4.5 mg/m3. Initial, mild and brief irritation  
of respiratory passages was observed at about 5 mg/m3, slight irritation at 7 –  
11 mg/m3 and breathing difficulty at 26 – 34 mg/m3. Chronic bronchitis was also 
reported after several years of exposure at the latter levels. It was also noted that 
no effects on the teeth appeared at average concentrations of 4.5 – 7.7 mg/m3 (53). 
This study is based on many years of observation, but does not meet modern stan-
dards for scientific documentation. 
A high prevalence of tooth erosion was seen in a study of industrial workers 
exposed to hydrochloric acid, but the study reports no air levels (79). In another 
study, the prevalence of tooth erosion was 90% among 38 workers in a zinc gal-
vanizing plant, but since there was no control group this result is difficult to 
interpret. Exposure measurements made during 6 workshifts showed average 
levels of 1.8 – 12.4 mg/m3 (geometric means) (64). 
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Guinea pigs exposed to 15 mg/m3 2 hours/day, 5 days/week for 7 weeks  
showed no effects on lung function and no histological changes in lungs or res-
piratory passages (61). The RD50 (the exposure level at which respiratory rate is 
lowered by 50%) for mice is reported to be 309 ppm (432 mg/m3) with exposure  
6 hours/day. After three exposures all the animals were dead or dying (15). 
In a 90-day study with mice and rats, no systemic effects could be seen at  
30 mg/m3, although at 15 mg/m3 – the lowest exposure level – nasal irritation  
was observed in the rats (industry report cited in the MAK documentation, 
Reference 22). 
No nasal cancer was observed in rats after lifetime exposure to 14 mg/m3 (the 
only dose level tested), but there were elevated incidences of hyperplasia in larynx 
and trachea (22% and 26%, vs. 2% and 6% in controls) (70). The purpose of this 
study was to examine the effect of combined exposure to formaldehyde and 
hydrochloric acid, not to investigate the carcinogenicity of hydrochloric acid. 
In an eye irritation study with rabbits, made in accordance with OECD 
guidelines, 10% hydrochloric acid was placed in the category “risk of serious 
damage to eyes” (40). 
Nitric acid 
No effects on pulmonary function were observed in 28 young asthmatics (aged  
12 – 19) after 90 minutes of inhaling a combination of 0.05 ppm (0.125 mg/m3) 
nitric acid, 0.12 ppm ozone and 0.30 ppm nitrogen dioxide (47). 
Exposure of 9 healthy subjects to 0.2 mg/m3 for 2 hours, 100 minutes of which 
was during exercise, had no discernible effects on lung function (FEV1, FVC, 
specific airway resistance) or subjective symptom assessments, and there were  
no effects on indicators of damage or inflammation in the respiratory passages 
(bronchoalveolar lavage 18 hours after the exposure) when compared to the 
effects of exposure to air alone. Alveolar macrophages in the lavage fluid (ex  
vivo) showed more phagocytic activity and greater resistance to infection by  
RS virus, whereas superoxide anion production dropped (12). 
No effects on subjective symptom assessments or inflammatory response  
and no indications of lung damage (examined with lung function measurements, 
lavage and bronchial biopsy) were observed in 10 healthy subjects after 4 hours  
of exposure to 0.5 mg/m3 (vapor). The subjects were their own controls (6). In a 
previous study by the same research group, in which 10 healthy volunteers were 
exposed for 2 hours to nitric acid fog (0.4 mg/m3, VMD 6 µm), lung function and 
symptom assessments were the same as after exposure to fog (water aerosol) or 
ordinary air (5). 
In an older study based on 1 or 2 subjects, exposure to 11 – 12 ppm (27 – 30 
mg/m3) for more than one hour was reported to be unbearable and hazardous to 
human health. Exposure to 84 ppm (210 mg/m3) could be endured for only two or 
three minutes (thesis from 1907, cited in the MAK documentation, Reference 21). 
The lowest effect levels reported in animal studies pertain to effects on pulmo-
nary defense mechanisms. When rabbits were exposed to vapor of nitric acid 
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(0.05, 0.15 or 0.45 mg/m3, 4 weeks) there were effects on alveolar macrophages  
ex vivo (reduced production of superoxide anions) at all tested concentrations, and 
reduced bronchial reactivity on provocation with acetylcholine and histamine at 
0.15 and 0.45 mg/m3. A dose-related reduction of TNFα release/activity, signifi-
cant at the two higher exposures, was also reported (68). 
In another study, rats were exposed to 0.25 mg/m3 (vapor) 4 hours/day for 4 
days, or to 1 mg/m3 for 4 hours (same total dose). At both exposures, ability to 
inhibit elastase activity was enhanced in bronchial lavage ex vivo, and the repeated 
exposure also reduced production of superoxide anions (59). 
Chronic exposure of rats to low levels of nitric acid vapor (0.05 mg/m3, 40 
weeks) had no effect on body weight, polyamine levels in lungs, or lung clear- 
ance. However, there were elevated levels of a stress protein in the lungs (stress-
inducible heat-shock protein 70) (52, 73, 87). 
No bronchoconstriction (reduced specific pulmonary flow resistance) was 
observed in either normal or sensitized sheep (bronchospasm on provocation with 
roundworm extract) after 4 hours of exposure to nitric acid vapor (4.1 mg/m3). 
However, after the exposure the sensitized animals had greater hyperreactivity  
in respiratory passages on provocation with carbachol in aerosol form (1). 
Phosphoric acid 
This section takes up only studies in which the effects of exposure to phosphoric 
acid alone were examined: studies of phosphorus compounds such as phosphorus 
pentoxide and red phosphorus, which can be transformed to phosphoric acid, are 
excluded. 
Phosphoric acid is a mild irritant to eyes, upper respiratory passages and skin. 
The dust is more irritating to skin in the presence of moisture (85). 
Case reports describe severe effects such as RADS, hyperphosphatemia, hypo-
calcemia, systemic metabolic acidosis and even death, after massive exposure to 
phosphoric acid (85). 
The LC50 for rats was above 850 mg/m3 with one hour of exposure. No other 
toxic effects were reported (65). 
No other peer-reviewed studies of phosphoric acid were found. 
Genotoxicity 
Low pH had no effect on the frequency of point mutations in various strains of 
bacteria and yeast (38), but other genotoxic effects of low pH have been reported 
in several in vitro studies. DNA damage (strand breaks) and effects on chromo-
somes have been shown in studies of mammalian and eukaryotic cells (13, 17, 38, 
42, 54 – 57, 88). The mechanism is not clear, but it has been proposed that low pH 
causes oxidative stress (42) or induces DNA damage mediated by an inhibition of 
the enzyme topoisomerase II (TOP 2) (88), which may have a co-initiating effect 
(32). In cell cultures, low pH has been shown to enhance the expression of genes 
involved in inflammation, proliferation, differentation, and response to DNA 
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damage (23), and has also been shown to affect cell proliferation (90). It has  
been proposed that these effects are important to the development of cancer in  
the esophagus. Reduced pH functioned as a promotor in a classical skin-tumor 
promotion test with mice in which DMBA was used as the initiator (88). 
Inhalation of the air levels that occur in work environments may cause a local 
lowering of pH in the respiratory passages, but is hardly likely to affect systemic 
pH. 
Carcinogenicity 
In 1992, the IARC classified “aerosols of strong inorganic acids containig sulfuric 
acid” as carcinogenic to humans (Group 1) (38). The classification is based 
primarily on cohort and case-control studies showing correlations between long-
term exposure and cancer in respiratory passages, especially the larynx. The 
exposed subjects in these studies worked in the metal industry (pickling) or 
petrochemical industry, or in production of isopropanol, soap or fertilizer. Expo-
sure in these studies is generally not well described, but there are exposure data 
for a cohort of steelworkers. The cohort consisted of persons who had worked 
with pickling for at least 6 months in the 1940 – 1965 period (average start of 
employment was 1949). Sulfuric acid was the predominant acid in the pickling 
process until the mid-1960s. According to a classification made by occupational 
hygienists, 62% of the workers had been exposed to sulfuric acid only, 22% to 
sulfuric acid and other acids, and 16% to other acids only. Exposure to sulfuric 
acid had stopped by the time the study began. Exposure data from two of the three 
plants, covering the 1975 – 1979 period, showed average sulfuric acid exposure 
levels of 0.19 mg/m3 (personal monitors, n = 15) and 0.29 mg/m3 (stationary 
monitors, n = 34). The authors pointed out that, although the production process 
had not been changed, it was still possible that exposures were higher prior to1975 
due to a lower awareness of the risks (11, 76, 77). The cohort (n = 1,065) was first 
studied for mortality due to lung cancer (11). Later, 77% of the study population 
was examined for incidence of laryngeal cancer (76). After the IARC assessment, 
the incidence cohort was followed up (77). The length of exposure for this group 
on the two study occasions was on average 9.2 – 9.5 years. In the follow-up 14 
exposed cases were found, 7 of which were exposed to sulfuric acid only, 4 to 
sulfuric acid and other acids, and 3 to other acids only. The relative risk of laryn-
geal cancer for all the exposed subjects was 2.2 (95% Confidence Interval: 1.2 – 
3.7) compared with the national average and after correction for use of tobacco 
and alcohol. 
In a cohort (n = 2,678) of battery manufacturers and steelworkers, exposed 
primarily to sulfuric acid but also to hydrochloric acid, mortalities (SMR) due  
to all cancers and to cancers of the larynx or lungs were lower than the national 
averages. A case-control study (n = 15) based on the same cohort yielded no 
definite information on “upper aerodigestive” cancers, including lip cancer, 
because there were too few cases (OR 2.0; 95% CI: 0.4 – 10 for cases with at  
least 5 years of exposure) (20). There is no information on use of tobacco or 
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alcohol. Hathaway later pointed out other shortcomings in the study, such as that 
the odds ratio would be close to 1 if the four cases of lip cancer were excluded 
from the analysis (31). 
No increases in mortality due to laryngeal cancer (4 cases vs. 3.1 expected) or 
lung cancer (27 vs. 32.8) were observed in a cohort of 1,409 workers in a plant  
for production of sulfuric acid. Nearly half (46%) of the workers had previously 
worked in mines. An elevation in mortality due to myeloid leukemia could not  
be explained by the exposure (63). 
There are reports of one case of laryngeal cancer and three cases of naso-
pharyngeal cancer attributed to sulfuric acid exposure (34, 35). 
A population-based case-control study (included in the IARC monograph) 
indicated an elevated risk of esophageal cancer after exposure to sulfuric acid  
(p <0.10) (72, also published in Reference 62). 
In a recently published case-control study of workers at a nickel refinery  
who were exposed to low levels of sulfuric acid (usually below 0.5 mg/m3),  
no elevation in risk of lung cancer caused by the acid was seen (30). 
Cocco et al. made a case-control study of stomach cancer based on death certifi-
cates from 24 states in the U.S. No elevation in risk was correlated to occupational 
exposure to sulfuric acid (19). In another case-control study (n = 1,056) based on 
death certificates, the same research group evaluated the risk of gastric cardia can-
cer in various jobs and industries. Exposure was divided in-to three categories 
according to intensity but was not numerically quantified. Among white males 
there was a significant increase in risk with increased exposure to sulfuric acid 
(18). 
Historical exposure levels (prior to 1970) of sulfuric acid are described in a 
survey article. Exposures (8-hour averages) were estimated to have been above  
1 mg/m3 in production of sulfuric acid and isopropanol and around pickling of 
metals, 0.1 – 1 mg/m3 in e.g. soap production, and below 0.1 mg/m3 in refining 
copper and zinc and in production of phosphate fertilizers and lead acid batteries. 
Beginning in the early 1970s various measures have been introduced which have 
lowered exposure levels considerably (67). Measurements of sulfuric acid made 
(without reference to cancer occurrence) in pickling plants in the 1970s and 1980s 
and compiled by the IARC showed that the average level in most cases was 0.l – 
0.3 mg/m3, with a highest average of 3 mg/m3 (38). 
In summary, the uncertainty of exposure data for sulfuric acid in the epidemio-
logical studies, in combination with the analytic difficulties previously encoun-
tered in monitoring sulfuric acid, make it impossible to correlate an increase in 
cancer incidence to an exposure level (69). The occurrence of cancer is apparently 
secondary to the severe, chronic local irritation and the damage to respiratory epi-
thelium due to the lower pH caused by the acid. SCOEL and DECOS present the 
hypothesis that there is a threshold for the genotoxic effect (33, 69). 
In its 1992 assessment, the IARC placed hydrochloric acid in Group 3: “not 
classifiable with regard to carcinogenicity to humans” (39). The assessment was 
based on about 10 studies. 
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A recently published case-control study of workers exposed to inorganic acid 
aerosols (mostly hydrochloric acid but also nitric acid, phosphoric acid, sulfuric 
acid, hydrogen fluoride and chromic acid) reports no elevation in risk for laryngeal 
or hypopharyngeal (lower throat) cancer. A significant elevation in risk for cancer 
in the hypopharynx (4 exposed cases) was observed with exposures exceeding 15 
years, but no correlation was seen between cumulative exposure and cancer inci-
dence (71). 
The population-based case-control study mentioned above (72) indicated 
elevated risk (p <0.10) for cancer in the pancreas (n = 5), prostate (n = 9) and 
kidneys (n = 4) after exposure to nitric acid. For phosphoric acid, the analyses 
showed elevated risks for renal cancer (n = 6) and lung cancer (n = 14) (72). 
Effects on reproduction 
In the only available study on reproduction effects, no embryotoxic, fetotoxic or 
teratogenic effects were observed in mice and white rabbits exposed to sulfuric 
acid during the organogenesis period of gestation (0, 5 or 20 mg/m3, 7 hours/day). 
Slight maternal toxicity was observed in both species at the higher exposure level 
(58). 
It is unlikely that occupational exposure to any of these four acids has toxic 
effects on reproduction because their contribution of protons and anions to  
the body’s pool is negligible, but secondary effects due to lung damage are  
a possibility.  
Dose-effect/dose-response relationships 
Dose-effect relationships observed with inhalation exposure to sulfuric acid, 
hydrochloric acid and nitric acid are summarized in Tables 1 – 3. There are no 
relevant studies of phosphoric acid. The tables list the lowest exposure level 
having a particular effect (LOAEL, lowest observed adverse effect level) and  
the highest level that did not have an effect (NOAEL, no observed adverse effect 
level). There are no data on skin uptake for any of these four acids, but their 
polarity suggests that absorption is minimal if the skin barrier is intact. 
Sulfuric acid 
The toxicological data from short-term and long-term studies of animals and 
humans are relatively consistent. In many studies the effects have appeared at the 
lowest tested exposure level. With present analysis methods, it is possible to make 
reliable measurements of sulfuric acid at the lowest effect levels with 8-hour 
samples, provided there are no interfering substances in the air, but shorter 
sampling times are still problematical (69). 
The effects observed at the lowest exposure levels are effects on lung function 
and pulmonary defense mechanisms, as well as irritation. Effects on bronchial 
mucociliary clearance have been reported in studies of healthy subjects exposed  
to 0.1 mg/m3 (49, 50, 75). One study of occupationally exposed subjects indicated 
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that irritation of eyes and respiratory passages begins to appear at about 0.1 mg/m3 
(25), although another field study reports no irritation at somewhat higher levels 
(27). Healthy volunteers did not report irritation at levels below 0.5 mg/m3 (9).  
In one study, hyperreactivity in respiratory passages (carbachol) was observed in 
healthy volunteers exposed to 1 mg/m3 (82), whereas other studies report no effect 
on lung function at that level. Some studies indicate, however, that asthmatics – 
especially young asthmatics – may be more sensitive. Small declines in lung 
function have been reported in young asthmatics exposed during exercise to 0.1 
mg/m3 or even lower concentrations (45, 46). The lowest exposure level having 
effect on lung function of adult asthmatics is 0.35 mg/m3 in combination with low 
levels of endogenous ammonia in the mouth cavity (83). Tooth erosion, declines 
in lung function and cell changes in nasal mucous membranes have been reported 
at occupational exposures of about 0.2 mg/m3 (28, 29).  
The results from animal experiments support the evidence from human studies. 
Irritation, effects on clearance and other pulmonary defense mechanisms and on 
lung function, and cell changes in respiratory epithelium have been observed. 
Effects in animals have been reported at about the same exposure levels as in 
humans. 
Occupational exposure to aerosols of strong inorganic acids containing sulfuric 
acid has been shown to cause cancer in respiratory passages. Exposures in the 
epidemiological studies are in general poorly described, but elevated cancer 
incidence was observed in a cohort with a reported average exposure level of  
0.2 mg/m3 (11, 76, 77). However, exposure began long before measurements  
were made and it is probable that levels were previously higher. The analytical 
problems encountered with measuring sulfuric acid further increase the uncer-
tainty in the exposure estimates. It is therefore not possible to identify a level  
that yields an increase in cancer risk. Available data indicate that development  
of cancer may involve indirect DNA damage, oxidative stress and cytotoxicity.  
It is reasonable to assume that DNA damage does not appear below the threshold 
dose at which the cell’s buffering capacity is exceeded. 
Hydrochloric acid 
Toxicological data are sparse. There were no changes in lung function, no 
respiratory symptoms, and no fatigue, headaches or dizziness in asthmatic adults 
exposed to up to 2.5 mg/m3 for 45 minites (78). 
In a study of occupationally exposed workers, it was noted that no effects on 
teeth appeared at average concentrations of 4.5 – 7.7 mg/m3 (no further informa-
tion is given). No irritation was observed at 3 – 4.5 mg/m3; slight, brief respiratory 
irritation at about 5 mg/m3; slight irritation at 7 – 11 mg/m3; and breathing diffi-
culty at 26 – 34 mg/m3. Chronic bronchitis was also reported after several years  
of exposure at the latter levels (53). This study was based on several years of 
observations, but the study design and documentation do not meet modern re-
quirements. 
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An elevated incidence of hyperplasia in larynx and trachea was observed in rats 
after lifetime exposure to 14 mg/m3 (the only exposure level tested) (70). At about 
the same level (15 mg/m3, 90 days) nasal irritation has been reported in rats (in-
dustry report cited in the MAK documentation, Reference 22). 
Nitric acid 
Healthy subjects were exposed to 0.2 mg/m3 for 2 hours, 100 minutes of which 
was during exercise: the exposure had no effect on lung function, subjective 
symptom assessments, or markers for inflammation or damage in respiratory 
passages. Pulmonary defense was stimulated in alveolar macrophages (increased 
phagocyte activity and greater resistance to infection), but superoxide anion pro-
duction dropped (12).  
No effects were reported in healthy subjects after 4 hours of exposure to 0.5 
mg/m3 (no symptoms, effects on lung function or damage to respiratory passages) 
or 2 hours of exposure to 0.4 mg/m3 (no symptoms or effects on lung function) (5, 
6). 
The lowest effect levels reported in animal studies refer to effects on pulmonary 
defense mechanisms. At 0.05 – 0.25 mg/m3 there was an increased ability to in-
hibit elastase activity in lung lavage ex vivo, a reduced level or production of 
superoxide anions (59), reduced release/activity of TNFα by stimulated macro-
phages, reduced bronchial reactivity on provocation with acetylcholine and 
histamine (68), and elevated levels of stress protein in lungs (stress-inducible  
heat-shock protein 70) (52, 73, 87). 
No bronchoconstriction was observed in either normal or sensitized sheep after 
4 hours of exposure to nitric acid vapor (4.1 mg/m3). However, after the exposure 
the respiratory passages of the sensitized animals showed greater hyperreactivity 
on provocation with a carbachol aerosol (1). 
Judging from animal data on acute toxicity, nitric acid seems to have about the 
same potency as sulfuric acid. 
Phosphoric acid 
Phosphoric acid has an LC50 above 850 mg/m3 (>8.7 mmol/m3). There is no  
other available information on dose-effect or dose-response relationships. 
According to a criteria document published in 1992 by the European Commis-
sion, aerosols of phosphorus pentoxide are probably not irritating at concentra-
tions in the range 0.8 – 5.4 mg/m3 (based on unpublished data contained in the 
ACGIH documentation, Reference 2). It was also observed that phosphorus 
pentoxide is a powerful dehydrating agent that reacts with moisture in the air in 
respiratory passages, forming phosphoric acid and generating heat. Phosphorus 
pentoxide therefore probably causes more tissue damage than phosphoric acid 
alone. Exposure limits based on data for phosphorus pentoxide should therefore 
provide an adequate margin of safety (24). 
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Conclusions 
Sulfuric acid 
The critical effects of occupational exposure to sulfuric acid are judged to be 
effects on bronchial mucociliary clearance and lung function, as well as irritation 
of eyes and respiratory passages. These effects are seen at about 0.1 mg/m3. At 
somewhat higher levels (about 0.2 mg/m3) tooth erosion and pathological changes 
in nasal mucosa have been reported in exposed workers. 
Damage to respiratory epithelium and cancer (see below) probably do not occur 
below the levels that affect mucociliary clearance and cause irritation. 
Hydrochloric acid 
There are no data from which to derive a critical effect of occupational exposure. 
No respiratory tract irritation was seen in asthmatics exposed to 2.5 mg/m3 for 45 
minutes. A report that is based on many years of observations of occupationally 
exposed workers but does not meet modern requirements for a scientific study 
indicated slight, brief irritation at 5 mg/m3. Rats exposed to 14 mg/m3 showed 
hyperplasia (increase in number of cells) in trachea and larynx. 
Nitric acid 
In general, there are no data on which to base a critical effect of occupational 
exposure to nitric acid. Single exposures of healthy volunteers to 0.4 and 0.5 
mg/m3 had no effects on self-reported symptom assessments or lung function, and 
yielded no indication of inflammatory response in lungs. With a similar exposure 
to 0.2 mg/m3 both stimulation and inhibition of activity was observed in alveolar 
macrophages. 
Phosphoric acid 
There are no data from which to derive a critical effect for occupational exposure 
to phosphoric acid. 
Carcinogenicity 
Epidemiological studies have shown that aerosols of strong inorganic acids con-
taining sulfuric acid cause cancer in respiratory passages. It is not possible, on  
the basis of these studies, to determine an exposure level at which cancer appears. 
Development of cancer seems to occur via indirect DNA damage, oxidative stress 
and cytotoxicity. It is reasonable to assume, however, that DNA damage does not 
occur until the cell’s buffering capacity has been exceeded. 
Data on the other acids are not sufficient to support any conclusions regarding 
their carcinogenic potential. 
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Table 1. No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse 
Effect Level (LOAEL) in humans subjects exposed by inhalation to low concentrations 
of sulfuric acid. 
 
NOAEL 
(mg/m3) 
LOAEL 
(mg/m3) 
Subjectsa Exposure 
time 
Effects Ref. 
 
 – 0.035 and 
0.07 
Asthmatic 
adolescents  
45 and 90 
minutes 
Marginal reduction in FEV1 
immediately after 45-minute 
exposure, but not after 90 
minutes. Values normalized  
20 minutes after exposure. 
46 
 – 
 
0.1 Asthmatic 
adolescents 
40 minutes 
including 
exercise 
Decline in lung function 
(reversible reductions in FEF50, 
FEV1 and total respiratory 
resistance). 
45 
 – 0.1 Healthy 
volunteers 
1 hour Increase in bronchial mucociliary 
clearance of larger test particles 
(MMAD 7.5 µm). 
49 
 – 0.1 Healthy 
volunteers 
1 - 2 hours Decline in bronchial mucociliary 
clearance of smaller test particles 
(MMAD 4-5 µm). 
50, 
75 
 – ~0.1 Exposed 
workers 
 Irritation of eyes and respiratory 
passages.  
25 
 – ~0.2 Exposed 
workers 
10 years 
(mean)  
Tooth erosion, reduced FVC. 28 
 – >0.2 Exposed 
workers 
6 years 
(mean)  
Cell changes in nasal mucosa. 29 
0.35 (high 
oral level 
of NH3) 
0.35 (low 
oral level 
of NH3) 
Asthmatics 
 
20 minutes 
rest +  
10 minutes 
exercise 
Decline in lung function (reduced 
FEV1 and maximum expiratory 
flow at 60% of total lung 
capacity). 
83 
0.1 0.45 Asthmatics 16 minutes Bronchoconstriction (lower 
specific airway conductance) and 
bronchial hyperreactivity 
(carbachol). 
81, 
82 
 – 0.47 Healthy 
volunteers 
1 hour 
including 
exercise 
Accelerated mucociliary clearance 
in trachea and small airways. 
48 
0.47 
(MMAD 
10 µm) 
0.5 (VMD 
10 µm) 
Healthy 
volunteers 
1 hour 
including 
exercise 
Small increase of upper and lower 
respiratory symptoms. 
9, 
48 
0.38 
(MMAD 
0.9 µm) 
1 (MMAD 
0.9 µm) 
Asthmatics 1 hour 
including 
exercise 
Increase in reported symptoms 
(lower respiratory passages, 
headache, fatigue, eye irritation). 
8 
0.5 (VMD 
10 µm) 
1 (VMD 
10 µm) 
Asthmatics 1 hour 
including 
exercise 
Increase in reported symptoms 
(upper and lower respiratory 
passages). 
9 
0.3 1 Asthmatics 1 hour Decline in bronchial mucociliary 
clearance. 
74 
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Table 1. Continued. 
 
NOAEL 
(mg/m3) 
LOAEL 
(mg/m3) 
Subjectsa Exposure 
time 
Effects Ref. 
 
0.1 1 Healthy 
volunteers 
16 minutes Hyperreactivity in airways on 
provocation with carbachol. 
82 
 – 1 Healthy 
volunteers 
3 hours 
including 
exercise 
Lower superoxide anion 
production by pulmonary 
macrophages and lower ability  
to adhere to a substrate. 
89 
 
FEV1 = forced expiratory volume during one second; FEF50 = forced expiratory flow at 50% of 
FVC; FVC = forced vital capacity; MMAD = mass median aerodynamic diameter; VMD = volume 
median diameter.  
a
 The subjects were adults unless otherwise described. 
 
 
Table 2. NOAELs and LOAELs reported in inhalation studies with low levels of hydro-
chloric acid. 
 
NOAEL 
(mg/m3) 
LOAEL 
(mg/m3) 
Subjects/  
Species 
Exposure time Effect Ref. 
 
Human studies     
4.5-7.7a 1.8-12.4 Exposed 
workers 
 Tooth erosion (no controls). 53, 
64 
2.5  Asthmatics 45 minutes No airway irritation, fatigue, 
headache, dizziness; no 
effect on lung function. 
78 
3-4.5a 5.2a Exposed 
workers 
 Brief initial airway irritation. 53 
 – 26-34a Exposed 
workers 
 Breathing difficulty, chronic 
bronchitis. 
53 
Animal studies     
2.8b 14 Rat 6 hrs/day, 
5 days/week 
lifelong 
Elevated incidence of 
hyperplasia in larynx and 
trachea. 
70 
 – 15 Rat 6 hrs/day, 
5 days/week 
90 days 
Nasal irritation. 22c 
 – 56 Mouse 10 minutes 10% reduction in respiratory 
rate. RD50 = 432 mg/m3. 
10 
15 – Guinea pig 2 hrs/day, 
5 days/week 
7 weeks 
No histological changes in 
lungs or airways. No effect 
on lung function. 
61 
 
RD50 = The exposure level at which respiratory rate is reduced by 50%.  
a
 No details are given. 
b
 Calculated by the German MAK committee using linear interpolation between the incidence at 0  
  and at 14 mg/m3. 
c
 Chemical Industry Institute of Toxicology. 90-day inhalation study of hydrogen chloride gas in  
  B6C3F1 mice, Sprague-Dawley rats and Fischer-344 rats. ToxiGenics, Inc. for CIIT, Research 
  Triangle Park NC, CIIT Docket No. 20915. Cited in the MAK documentation, Reference 22. 
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Table 3. NOAELs and LOAELs reported with inhalation exposure to low levels of nitric acid. 
 
NOAEL 
(mg/m3) 
LOAEL 
(mg/m3) 
Subjects/ 
Species 
Exposure 
time 
Effect Ref. 
 
Human studies     
0.125 – Asthmatic 
adolescents 
40 minutes No effect on lung function. 47 
 – 0.2 Healthy 
volunteers 
2 hours 
including 
exercise 
Effect on alveolar 
macrophages (higher 
phagocytosis and resistance to 
infection, lower superoxide 
anion production). 
12 
0.4 – Healthy 
volunteers 
2 hours No effects on reported 
symptoms or lung function. 
5 
0.5 – Healthy 
volunteers 
4 hours No effects on reported 
symptoms. No damage to 
respiratory passages measured 
with lung function tests, 
lavage and bronchial biopsy. 
6 
Animal studies     
– 0.05 Rat 40 weeks Higher levels of stress-
inducible heat shock protein 
70 in lungs. 
52,  
73,  
87 
– 0.05 Rabbit 4 weeks Reduced production of 
superoxide anions in alveolar 
macrophages. 
68 
0.05 0.15 Rabbit 4 weeks Reduced bronchial reactivity 
in vitro on provocation with 
acetylcholine and histamine. 
Lower TNFα activity in 
alveolar macrophages. 
68 
– 0.25a Rat 4 hrs/day 
4 days 
Lower superoxide anion 
production in isolated lung 
macrophages. Higher ability in 
lung lavage to inhibit elastase 
activity. 
59 
4.1 b, c – Sheep 4 hours No bronchoconstriction 
(specific pulmonary flow 
resistance). 
1 
4.1 b 4.1 c Sheep 4 hours Hyperreactivity in respiratory 
passages (carbachol). 
1 
 
TNF = Tumor Necrosis Factor 
a
 A 4-hour exposure to 1 mg/m3 (same total dose) also increased ability to inhibit elastase activity. 
b
 Not sensitized. 
c
 Sensitized. 
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Summary 
 
Montelius J (ed). Swedish Criteria Group for Occupational Standards. Scientific 
Basis for Swedish Occupational Standards. XXX. Arbete och Hälsa 2010;44(5):1-
124. University of Gothenburg, Sweden. 
 
Critical review and evaluation of those scientific data which are relevant as a 
background for discussion of Swedish occupational exposure limits. This volume 
consists of the consensus reports given by the Criteria Group at the Swedish Work 
Environmental Authority from July, 2008 through June, 2009. 
 
Key Words; Grain dust, Hydrochloric acid, Molybdenum, Molybdenum 
compounds, Nitric acid, Occupational exposure limit (OEL), 
Phosphoric acid, Risk assessment, Scientific basis, Styrene, Sulfuric 
acid, Toxicology. 
 
 
 
Sammanfattning 
 
Montelius J (ed). Kriteriegruppen för hygieniska gränsvärden. Vetenskapligt 
underlag för hygieniska gränsvärden. XXX. Arbete och Hälsa 2010;44;(5):1-124. 
Göteborgs Universitet. 
 
Sammanställningar baserade på kritisk genomgång och värdering av de 
vetenskapliga fakta, vilka är relevanta som underlag för fastställande av hygieniskt 
gränsvärde. Volymen omfattar de underlag som avgivits från Kriteriegruppen för 
hygieniska gränsvärden under perioden juli 2008 – juni 2009. 
 
Nyckelord; Fosforsyra, Hygieniskt gränsvärde, Molybden, Molybdenföreningar, 
Riskvärdering, Salpetersyra, Saltsyra, Spannmålsdamm, Styren, 
Svavelsyra, Toxikologi, Vetenskapligt underlag. 
 
 
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och 
Hälsa 2010;44(2):1-123. 
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APPENDIX 
 
Consensus reports in this and previous volumes 
 
 
Substance Consensus  
date 
Published in  
Arbete och Hälsa 
year;volume(No) 
No. in series  
of Consensus 
Reports 
 
Acetaldehyde February 17, 1987 1987;39 VIII 
Acetamide December 11, 1991 1992;47 XIII 
Acetic acid June15, 1988 1988;32 IX 
Acetone October 20, 1987 1988;32 IX 
Acetonitrile September 12, 1989 1991;8 XI 
Acrylamide April 17, 1991 1992;6 XII 
Acrylates December 9, 1984 1985;32 VI 
Acrylonitrile April 28, 1987 1987;39 VIII 
Aliphatic amines August 25, 1982 1983;36 IV 
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983;36 IV 
Aliphatic monoketons September 5, 1990 1992;6 XII 
Allyl alcohol September 9, 1986 1987;39 VIII 
Allylamine August 25, 1982 1983;36 IV 
Allyl chloride June 6, 1989 1989;32 X 
Aluminum April 21, 1982 1982;24 III 
      revised September 14, 1994 1995;19 XVI 
Aluminum trifluoride September 15, 2004 2005;17 XXVI 
p-Aminoazobenzene February 29, 1980 1981;21 I 
Ammonia April 28, 1987 1987;39 VIII 
      revised October 24, 2005 2006;11 XXVII 
Ammonium fluoride September 15, 2004 2005;17 XXVI 
Amylacetate March 23, 1983 1983;36 IV 
      revised June 14, 2000 2000;22 XXI 
Aniline October 26, 1988 1989;32 X 
Anthraquinone November 26, 1987 1988;32 IX 
Antimony + compounds December 8, 1999 2000;22 XXI 
Arsenic, inorganic December 9, 1980 1982;9 II 
      revised February 15, 1984 1984;44 V 
Arsine October 20, 1987 1988;32 IX 
Asbestos October 21, 1981 1982;24 III 
    
Barium June 16, 1987 1987;39 VIII 
      revised January 26, 1994 1994;30 XV 
Benzene March 4, 1981 1982;9 II 
      revised February 24, 1988 1988;32 IX 
Benzoyl peroxide February 13, 1985 1985;32 VI 
Beryllium April 25, 1984 1984;44 V 
Borax October 6, 1982 1983;36 IV 
Boric acid October 6, 1982 1983;36 IV 
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Boron Nitride January 27, 1993 1993;37 XIV 
Butadiene October 23, 1985 1986;35 VII 
1-Butanol June 17, 1981 1982;24 III 
Butanols June 6, 1984 1984;44 V 
Butyl acetate June 6, 1984 1984;44 V 
Butyl acetates February 11, 1998 1998;25 XIX 
Butylamine August 25, 1982 1983;36 IV 
Butyl glycol October 6, 1982 1983;36 IV 
γ-Butyrolactone June 2, 2004 2005;7 XXV 
    
Cadmium January 18, 1980 1981;21 I 
      revised February 15, 1984 1984;44 V 
      revised May 13, 1992 1992;47 XIII 
      revised February 5, 2003 2003;16 XXIV 
Calcium fluorid September 15, 2004 2005;17 XXVI 
Calcium hydroxide February 24, 1999 1999;26 XX 
Calcium nitride January 27, 1993 1993;37 XIV 
Calcium oxide February 24, 1999 1999;26 XX 
Caprolactam October 31, 1989 1991;8 XI 
Carbon monoxide December 9, 1981 1982;24 III 
Cathecol September 4, 1991 1992;47 XIII 
Chlorine December 9, 1980 1982;9 II 
Chlorine dioxide December 9, 1980 1982;9 II 
Chlorobenzene September 16, 1992 1993;37 XIV 
      revised April 2, 2003 2003;16 XXIV 
o-Chlorobenzylidene malononitrile June 1, 1994 1994;30 XV 
Chlorocresol December 12, 1990 1992;6 XII 
Chlorodifluoromethane June 2, 1982 1982; 24 III 
Chlorophenols September 4, 1985 1986;35 VII 
Chloroprene April 16, 1986 1986;35 VII 
Chromium December 14, 1979 1981;21 I 
      revised May 26, 1993 1993;37 XIV 
      revised May 24, 2000 2000;22 XXI 
Chromium trioxide May 24, 2000 2000;22 XXI 
Coal dust September 9, 1986 1987;39 VIII 
Cobalt October 27, 1982 1983;36 IV 
Cobalt and cobalt compounds October 22, 2003 2005;7 XXV 
Copper October 21, 1981 1982;24  III 
Cotton dust February14, 1986 1986;35 VII 
Creosote October 26, 1988 1989;32 X 
      revised December 5, 2007 2009;43(4) XXIX 
Cresols February 11, 1998 1998;25 XIX 
Cumene June 2, 1982 1982;24 III 
Cyanamid September 30, 1998 1999;26 XX 
Cyanoacrylates March 5, 1997 1997;25 XVIII 
Cycloalkanes, C5-C15 April 25, 1984 1984;44 V 
Cyclohexanone March 10, 1982 1982;24 III 
      revised February 24, 1999 1999;26 XX 
Cyclohexanone peroxide February 13, 1985 1985;32 VI 
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Cyclohexylamine February 7, 1990 1991;8 XI 
    
Desflurane May 27, 1998 1998;25 XIX 
Diacetone alcohol December 14, 1988 1989;32 X 
Dichlorobenzenes February 11, 1998 1998;25 XIX 
1,2-Dibromo-3-chloropropane May 30, 1979 1981;21 I 
Dichlorodifluoromethane June 2, 1982 1982;24 III 
1,2-Dichloroethane February 29, 1980 1981;21 I 
Dichloromethane February 29, 1980 1981;21 I 
Dicumyl peroxide February 13, 1985 1985;32 VI 
Dicyclopentadiene March 23, 1994 1994;30 XV 
Diesel exhaust December 4, 2002 2003;16 XXIV 
Diethanolamine September 4, 1991 1992;47 XIII 
Diethylamine August 25, 1982 1983;36 IV 
2-Diethylaminoethanol January 25, 1995 1995;19 XVI 
Diethylene glycol September 16, 1992 1993;37 XIV 
Diethyleneglycol ethylether + acetate December 11, 1996 1997;25 XVIII 
Diethyleneglycol methylether + acetate March 13, 1996 1996;25 XVII 
Diethyleneglycol monobutylether January 25, 1995 1995;19 XVI 
Diethylenetriamine August 25, 1982 1983;36 IV 
      revised January 25, 1995 1995;19 XVI 
Diisocyanates April 8, 1981 1982;9 II 
      revised April 27, 1988 1988;32 IX 
      revised May 30, 2001 2001;20 XXII 
Diisopropylamine February 7, 1990 1991;8 XI 
N,N-Dimethylacetamide March 23, 1994 1994;30 XV 
Dimethyl adipate December 9, 1998 1999;26 XX 
Dimethylamine December 10, 1997 1998;25 XIX 
N,N-Dimethylaniline December 12, 1989 1991;8 XI 
Dimethyldisulfide September 9, 1986 1987;39 VIII 
Dimethylether September 14, 1994 1995;19 XVI 
Dimethylethylamine June 12, 1991 1992;6 XII 
Dimethylformamide March 23, 1983 1983;36 IV 
Dimethyl glutarate December 9, 1998 1999;26 XX 
Dimethylhydrazine January 27, 1993 1993;37 XIV 
Dimethyl succinate December 9, 1998 1999;26 XX 
Dimethylsulfide September 9, 1986 1987;39 VIII 
Dimethylsulfoxide, DMSO December 11, 1991 1992;47 XIII 
Dioxane August 25, 1982 1983;36 IV 
      revised March 4, 1992 1992;47 XIII 
Diphenylamine January 25, 1995 1995;19 XVI 
4,4'-Diphenylmethanediisocyanate (MDI) April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Dipropylene glycol May 26, 1993 1993;37 XIV 
Dipropyleneglycol monomethylether December 12, 1990 1992;6 XII 
Disulfiram October 31, 1989 1991;8 XI 
    
Enzymes, industrial June 5, 1996 1996;25 XVII 
Ethanol May 30, 1990 1991;8 XI 
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Ethanolamine September 4, 1991 1992;47 XIII 
Ethylacetate March 28, 1990 1991;8 XI 
Ethylamine August 25, 1982 1983;36 IV 
Ethylamylketone September 5, 1990 1992;6 XII 
Ethylbenzene December 16, 1986 1987;39 VIII 
Ethylchloride December 11, 1991 1992;47 XIII 
Ethylene December 11, 1996 1997;25 XVIII 
Ethylene chloride February 29, 1980 1981;21 I 
Ethylene diamine August 25, 1982 1983;36 IV 
Ethylene glycol October 21, 1981 1982;24 III 
Ethylene glycol ethylether + acetate February 6 2009;43(4) XXIX 
Ethylene glycol methylether + acetate June 2, 1999 1999;26 XX 
Ethyleneglycol monoisopropylether November 16, 1994 1995;19 XVI 
Ethyleneglycol monopropylether + acetate September 15, 1993 1994;30 XV 
Ethylene oxide December 9, 1981 1982;24 III 
Ethylenethiourea September 27, 2000 2001;20 XXII 
Ethylether January 27, 1993 1993;37 XIV 
Ethylglycol October 6, 1982 1983;36 IV 
    
Ferbam September 12, 1989 1991;8 XI 
Ferric dimethyldithiocarbamate September 12, 1989 1991;8 XI 
Flour dust December 10, 1997 1998;25 XIX 
Fluorides September 15, 2004 2005;17 XXVI 
Formaldehyde June 30, 1979 1981;21 I 
      revised August 25, 1982 1983;36 IV 
Formamide December 12, 1989 1991;8 XI 
Formic acid June 15, 1988 1988;32 IX 
Furfural April 25, 1984 1984;44 V 
Furfuryl alcohol February 13, 1985 1985;32 VI 
    
Gallium + Gallium compounds January 25, 1995 1995;19 XVI 
Glutaraldehyde September 30, 1998 1999;26 XX 
Glycol ethers October 6, 1982 1983;36 IV 
Glyoxal September 13, 1996 1996;25 XVII 
Grain dust December 14, 1988 1989;32 X 
      revised February 4, 2009 2010;44(5) XXX 
Graphite December 10, 1997 1998;25 XIX 
    
Halothane April 25, 1985 1985;32 VI 
2-Heptanone September 5, 1990 1992;6 XII 
3-Heptanone September 5, 1990 1992;6 XII 
Hexachloroethane September 15, 1993 1994;30 XV 
Hexamethylenediisocyanate (HDI) April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Hexamethylenetetramine August 25, 1982 1983;36 IV 
n-Hexanal March 29, 2006 2006;11 XXVII 
n-Hexane January 27, 1982 1982;24 III 
2-Hexanone September 5, 1990 1992;6 XII 
Hexyleneglycol November 17, 1993 1994;30 XV 
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Hydrazine May 13, 1992 1992;47 XIII 
Hydrochloric acid June 3, 2009 2010;44(5) XXX 
Hydrogen bromide February 11, 1998 1998;25 XIX 
Hydrogen cyanide February 7, 2001 2001;20 XXII 
Hydrogen fluoride April 25, 1984 1984;44 V 
      revised September 15, 2004 2005;17 XXVI 
Hydrogen peroxide April 4, 1989 1989;32 X 
Hydrogen sulfide May 4, 1983 1983;36 IV 
Hydroquinone October 21, 1989 1991;8 XI 
    
Indium March 23, 1994 1994;30 XV 
Industrial enzymes June 5, 1996 1996;25 XVII 
Isocyanic Acid (ICA) December 5, 2001 2002;19 XXIII 
Isophorone February 20, 1991 1992;6 XII 
Isopropanol December 9, 1981 1982;24 III 
Isopropylamine February 7, 1990 1991;8 XI 
Isopropylbenzene June 2, 1982 1982;24 III 
    
Lactates March 29, 1995 1995;19 XVI 
Lactate esters June 2, 1999 1999;26 XX 
Laughing gas June 7, 2006 2006;11 XXVII 
Lead, inorganic February 29, 1980 1981;21 I 
      revised September 5, 1990 1992;6 XII 
      revised December 8, 2004 2005;17 XXVI 
Lithium and lithium compounds June 4, 2003 2003;16 XXIV 
Lithium boron nitride January 27, 1993 1993;37 XIV 
Lithium nitride January 27, 1993 1993;37 XIV 
    
Maleic anhydride September 12, 1989 1991;8 XI 
Manganese February 15, 1983 1983;36 IV 
      revised April 17, 1991 1992;6 XII 
      revised June 4, 1997 1997;25 XVIII 
Man made mineral fibers March 4, 1981 1982;9 II 
      revised December 1, 1987 1988;32 IX 
Mercury, inorganic April 25, 1984 1984;44 V 
Mesityl oxide May 4, 1983 1983;36 IV 
Metal stearates, some September 15, 1993 1994;30 XV 
Methacrylates September 12, 1984 1985;32 VI 
Methanol April 25, 1985 1985;32 VI 
Methyl acetate March 28, 1990 1991;8 XI 
Methylamine August 25, 1982 1983;36 IV 
Methylamyl alcohol March 17, 1993 1993;37 XIV 
Methyl bromide April 27, 1988 1988;32 IX 
Methyl chloride March 4, 1992 1992;47 XIII 
Methyl chloroform March 4, 1981 1982;9 II 
4,4´-methylene-bis-(2-chloroaniline) February 4, 2004 2005;7 XXV 
Methylene chloride February 29, 1980 1981;21 I 
4,4'-Methylene dianiline June 16, 1987 1987;39 VIII 
      revised October 3, 2001 2002;19 XXIII 
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Methyl ethyl ketone February 13, 1985 1985;32 VI 
Methyl ethyl ketone peroxide February 13, 1985 1985;32 VI 
Methyl formate December 12, 1989 1991;8 XI 
Methyl glycol October 6, 1982 1983;36 IV 
Methyl iodide June 30, 1979 1981;21 I 
Methylisoamylamine September 5, 1990 1992;6 XII 
Methylisoamylketone February 6, 2002 2002;19 XXIII 
Methylisocyanate (MIC) December 5, 2001 2002;19 XXIII 
Methyl mercaptane September 9, 1986 1987;39 VIII 
Methyl methacrylate March 17, 1993 1993;37 XIV 
Methyl pyrrolidone June 16, 1987 1987;39 VIII 
α-Methylstyrene November 1, 2000 2001;20 XXII 
Methyl-t-butyl ether November 26, 1987 1988;32 IX 
      revised September 30, 1998 1999;26 XX 
Mixed solvents, neurotoxicity April 25, 1985 1985;32 VI 
MOCA February 4, 2004 2005;7 XXV 
Molybdenum October 27, 1982 1983;36 IV 
      revised Februari 4, 2009 2010;44(5) XXX 
Monochloroacetic acid February 20, 1991 1992;6 XII 
Monochlorobenzene September 16, 1993 1993;37 XIV 
Monomethylhydrazine March 4, 1992 1992;47 XIII 
Mononitrotoluene February 20, 1991 1992;6 XII 
Monoterpenes February 17, 1987 1987;39 VIII 
Morpholine December 8, 1982 1983;36 IV 
      revised June 5, 1996 1996;25 XVII 
    
Naphthalene May 27, 1998 1998;25 XIX 
Natural crystallinic fibers, except asbestos June 12, 1991 1992;6 XII 
Nickel April 21, 1982 1982;24 III 
Nicotine June 2, 2004 2005;7 XXV 
Nitric acid June 3, 2009 2010;44(5) XXX 
Nitric oxide December 11, 1985 1986;35 VII 
      revised June 13, 2007 2008;42(6) XXVIII 
Nitroethane April 4, 1989 1989;32 X 
Nitrogen dioxide December 11, 1985 1986;35 VII 
      revised September 12, 2007 2008;42(6) XXVIII 
Nitrogen oxides December 11, 1985 1986;35 VII 
Nitroglycerin February 13, 1985 1985;32 VI 
Nitroglycol February 13, 1985 1985;32 VI 
Nitromethane January 6, 1989 1989;32 X 
Nitropropane October 28, 1986 1987;39 VIII 
2-Nitropropane March 29, 1995 1995;19 XVI 
Nitroso compounds December 12, 1990 1992;6 XII 
Nitrosomorpholine December 8, 1982 1983;36 IV 
Nitrotoluene February 20, 1991 1992;6 XII 
Nitrous oxide December 9, 1981 1982;24 III 
      revised June 7, 2006 2006;11 XXVII 
    
Oil mist April 8, 1981 1982;9 II 
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Organic acid anhydrides, some September 12, 1989 1991;8 XI 
      revised June 4, 2008 2009;43(4) XXIX 
Oxalic acid February 24, 1988 1988;32 IX 
Ozone April 28, 1987 1987;39 VIII 
      revised February 7, 2007 2008;42(6) XXVIII 
    
Paper dust February 7, 1990 1991;8 XI 
Penicillins November 23, 2005 2006;11 XXVII 
Pentaerythritol November 16, 1994 1995;19 XVI 
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999;26 XX 
Pentyl acetate June 14, 2000 2000;22 XXI 
Peroxides, organic February 13, 1985 1985;32 VI 
Phenol February 13, 1985 1985;32 VI 
Phosphoric acid June 3, 2009 2010;44(5) XXX 
Phosphorous chlorides September 30, 1998 1999;26 XX 
Phosphorous oxides February 11, 1998 1998;25 XIX 
Phthalates December 8, 1982 1983;36 IV 
Phthalic anhydride September 12, 1989 1991;8 XI 
Piperazine September 12, 1984 1985;32 VI 
Plastic dusts December 16, 1986 1987;39 VIII 
Platinum June 4, 1997 1997;25 XVIII 
Polyaromatic hydrocarbons February 15, 1984 1984;44 V 
Polyisocyanates April 27, 1988 1988;32 IX 
Potassium aluminium fluoride June 4, 1997 1997;25 XVIII 
Potassium cyanide February 7, 2001 2001;20 XXII 
Potassium dichromate May 24, 2000 2000;22 XXI 
Potassium Fluoride September 15, 2004 2005;17 XXVI 
Potassium hydroxide Marsh 15, 2000 2000;22 XXI 
2-Propanol December 9, 1981 1982;24 III 
Propene September 13, 1996 1996;25 XVII 
Propionic acid November 26, 1987 1988;32 IX 
Propylacetate September 14, 1994 1995;19 XVI 
Propylene glycol June 6, 1984 1984;44 V 
Propylene glycol-1,2-dinitrate May 4, 1983 1983;36 IV 
Propylene glycol monomethylether October 28, 1986 1987;39 VIII 
Propylene oxide June 11, 1986 1986;35 VII 
Pyridine May 13, 1992 1992;47 XIII 
    
Quartz March 13, 1996 1996;25 XVII 
    
Resorcinol September 4, 1991 1992;47 XIII 
    
Selenium December 11, 1985 1986;35 VII 
      revised February 22, 1993 1993;37 XIV 
Sevoflurane May 27, 1998 1998;25 XIX 
Silica March 13, 1996 1996;25 XVII 
Silver October 28, 1986 1987;39 VIII 
Sodium cyanide February 7, 2001 2001;20 XXII 
Sodium Fluoride September 15, 2004 2005;17 XXVI 
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Sodium hydroxide August 24, 2000 2000;22 XXI 
Stearates, metallic, some September 15, 1993 1994;30 XV 
Stearates, non-metallic, some November 17, 1993 1994;30 XV 
Strontium January 26, 1994 1994;30 XV 
Styrene February 29, 1980 1981;21 I 
      revised October 31, 1989 1991;8 XI 
      revised April 1, 2009 2010;44(5) XXX 
Sulfur dioxide April 25, 1985 1985;32 VI 
Sulfur fluorides March 28, 1990 1991;8 XI 
Sulfuric acid June 3, 2009 2010;44(5) XXX 
Synthetic inorganic fibers March 4, 1981 1982;9 II 
      revised December 1, 1987 1988;32 IX 
      revised December 3, 2003 2005;7 XXV 
Synthetic organic and inorganic fibers May 30, 1990 1991;8 XI 
    
Talc dust June 12, 1991 1992;6 XII 
Terpenes, mono- February 17, 1987 1987;39 VIII 
Tetrabromoethane May 30, 1990 1991;8 XI 
Tetrachloroethane June 4, 1997 1997;25 XVIII 
Tetrachloroethylene February 29, 1980 1981;21 I 
1,1,1,2-Tetrafluoroethane March 29, 1995 1995;19 XVI 
Tetrahydrofuran October 31, 1989 1991;8 XI 
Tetranitromethane April 4, 1989 1989;32 X 
Thioglycolic acid June 1, 1994 1994;30 XV 
Thiourea December 1, 1987 1988;32 IX 
      revised June 2, 1999 1999;26 XX 
Thiram October 31, 1989 1991;8 XI 
Thiurams, some October 31, 1989 1991;8 XI 
Tin and inorganic tin compounds October 22, 2003 2005;7 XXV 
Titanium dioxide February 21, 1989 1989;32 X 
Toluene February 29, 1980 1981;21 I 
      revised February 6, 2002 2002;19 XXIII 
Toluene-2,4-diamine November 1, 2000 2001;20 XXII 
Toluene-2,6-diamine November 1, 2000 2001;20 XXII 
Toluene-2,4-diisocyanate April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
Toluene-2,6-diisocyanate April 8, 1981 1982;9 II 
      revised May 30, 2001 2001;20 XXII 
1,1,1-Trifluoroethane February 24, 1999 1999;26 XX 
Trichlorobenzene September 16, 1993 1993;37 XIV 
1,1,1-Trichloroethane March 4, 1981 1982;9 II 
Trichloroethylene December 14, 1979 1981;21 I 
Trichlorofluoromethane June 2, 1982 1982;24 III 
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982;24 III 
Triethanolamine August 25, 1982 1983;36 IV 
      revised October 23, 2002 2003;16 XXIV 
Triethylamine December 5, 1984 1985;32 VI 
Trimellitic anhydride September 12, 1989 1991;8 XI 
Trimethylolpropane November 16, 1994 1995;19 XVI 
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Trinitrotoluene April 17, 1991 1992;6 XII 
    
Vanadium March 15, 1983 1983;36 IV 
Vinyl acetate June 6, 1989 1989;32 X 
Vinyl toluene December 12, 1990 1992;6 XII 
    
White spirit December 16, 1986 1987;39 VIII 
      revised November 13, 2006 2008;42(6) XXVIII 
Wood dust June 17, 1981 1982;9 II 
      revised June 25, 2000 2000;22 XXI 
    
Xylene February 29, 1980 1981;21 I 
      revised September 14, 2005 2005;17 XXVI 
    
Zinc April 21, 1982 1982;24 III 
Zinc chromate May 24, 2000 2000;22 XXI 
Zinc dimethyl dithiocarbamate September 12, 1989 1991;8 XI 
Ziram September 12, 1989 1991;8 XI 
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